Methods for treating cysteamine-sensitive disorders

By adding reducing agents and panthenylethylamine inducers to oral cysteamine oral preparations, specific dosage regimens and dosage form designs, the sensory characteristics, pharmacology and toxicological problems of existing cysteamine preparations have been solved. Achieved treatment with longer-lasting blood levels and fewer side effects.

CN118924717APending Publication Date: 2024-11-12THIOGENESIS THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410743384.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-09-20
Filing Date
2018-09-20
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing oral cysteamine preparations have sensory properties (bitter, bad smell) and pharmacology (subtherapeutic blood levels in most dose intervals), toxicology (gastrointestinal and other side effects), resulting in poor treatment effects. , and frequent administration is required.

Method used

Using compounds at doses of 50 to 150 mg/kg body weight, combined with reducing agents and panthiothionase inducers, improve cysts through specific dosage regimens and dosage form designs such as immediate release, delayed release or sustained release The blood level of amines decreases peak concentration and reduces side effects.

Benefits of technology

A longer lasting cysteamine blood levels are achieved, reducing side effects, improving treatment effects, and providing individualized dosing regimens to suit the needs of different patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention provides methods of treating cystine disease and other cysteamine-sensitive conditions in an individual comprising administering a disulfide that can be converted to cysteamine in vivo. The methods may include administering a reducing agent alone to the individual to increase the bioavailability of the cysteamine produced after administration of the disulfide and to extend the plasma pharmacokinetic profile of the cysteamine. The methods permit sustained cysteamine plasma concentrations in an individual.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of an invention application filed on September 20, 2018, with Chinese national application number 201880074778.3 and invention name “Method for treating cysteamine-sensitive disorders”. Technical Field

[0002] The present invention provides compositions and methods for treating cysteamine-sensitive symptoms, syndromes and diseases. Background Art

[0003] Cysteamine is a naturally occurring aminothiol that is produced in vivo through the catabolism of pantetheine. Preclinical and early clinical studies have suggested that cysteamine may have therapeutic activity in a variety of diseases, but widespread clinical development has been hampered by a lack of convenient dosing regimens and poor toxicology.

[0004] Cysteamine has several mechanisms of action, most of which are related to the reducing ability of its thiol moiety. Cysteamine was first used in the 1950s as a radioprotectant for cancer patients undergoing radiotherapy and as a treatment for radiation poisoning. The thiol group of cysteamine can reduce free radicals and other oxidative compounds that may be harmful to cells, thereby contributing to redox homeostasis. Cysteamine can also indirectly neutralize harmful oxidants by increasing the content of other antioxidant thiols (such as glutathione and cysteine). For example, cysteamine can participate in the exchange of thiol-disulfides with cystine (the dimeric oxidized form of cysteine) to form cysteamine-cysteine ​​disulfide and free cysteine. Cysteamine can also form disulfides with cysteine ​​residues of proteins, thereby affecting protein structure and function. Cysteamine can inhibit enzymes, including transglutaminases, caspases, matrix metalloproteinases, and glutaminyl cyclases. Cysteamine is a chelating agent with a special affinity for copper. Cysteamine also blocks the secretion of certain peptide hormones, including somatostatin.

[0005] Diseases for which there is preclinical or clinical evidence of therapeutic benefit with cysteamine include neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, and Parkinson's disease; inflammatory and fibrotic diseases of the kidney, liver, and lung; metabolic diseases, including diabetes, metabolic syndrome, and the fatty liver disease spectrum; infectious diseases, including viral, bacterial, and parasitic infections; hypercholesterolemia; ischemic diseases, including ischemic heart disease or stroke; sickle cell anemia; inherited mitochondrial diseases; inherited diseases caused by mutations of arginine to cysteine; and cancer.

[0006] Unfortunately, cysteamine has very unpleasant organoleptic properties (smell and bitterness) and produces body and breath odor when ingested in therapeutically effective amounts (more than 1 gram per day for adolescents and adults). Most patients also experience gastrointestinal side effects, including anorexia, nausea, vomiting, and / or stomach pain. Bad breath, body odor, and gastrointestinal side effects are all associated with peak cysteamine blood levels (typically 50 times higher than endogenous cysteamine levels in healthy subjects). In addition, the elimination half-life of cysteamine is only about 25 minutes, which requires frequent dosing. In summary, existing oral formulations of cysteamine have problems with organoleptic properties (bitter, bad odor), pharmacology (subtherapeutic blood levels at most dose intervals), toxicology (gastrointestinal and other side effects), and stability (short shelf life due to oxidation). Many of these problems are inherent to the drug, a volatile thiol compound. As a result, many cystinosis patients do not fully comply with cysteamine therapy and therefore suffer from disease progression.

[0007] Clinical development has been hampered by the inability of cysteamine formulations to deliver therapeutic levels of the drug over a sustained period of time with acceptable toxicology. Thus, there is a need for improved treatment regimens, including improved cysteamine producing compounds, improved formulations, and improved dosing regimens that can produce sustained elevated blood levels of cysteamine while reducing peak concentrations and increasing trough concentrations, thereby providing improved efficacy while minimizing side effects. Furthermore, given the known inter-patient variability in cysteamine pharmacokinetics, there is a need for compositions that enable individualized dosing regimens to improve efficacy and reduce toxicity. Summary of the invention

[0008] In a first aspect, the present invention provides a method of treating a cysteamine-sensitive disorder in a subject, comprising administering to the subject a dose of 50 to 150 milligrams per kilogram of body weight (mg / kg) (e.g., 60±10, 70±10, 80±10, 90±10, 100±25, 110±20, 120±10, 130±10, or 140±10 mg / kg) of Compound 1:

[0009]

[0010] Or its pharmaceutically acceptable salt, once or multiple times a day (for example, once, twice or three times a day). In a specific embodiment, within 2 hours of the dose (for example, within 30 minutes, 1 hour, 90 minutes or 2 hours), the reducing agent is not administered to the individual. In a specific embodiment, the reducing agent is administered to the individual 2 hours to 8 hours after the dose is administered. In a specific embodiment, the reducing agent is administered 3 ± 1 hours, 4 ± 1 hours, 5 ± 1 hours, 6 ± 1 hours, 7 ± 1 hours or 4 ± 2 hours after the dose of compound 1 or a pharmaceutically acceptable salt is administered. In one embodiment, the reducing agent is selected from glutathione, glutathione diethyl ester, gamma glutamylcysteine, dihydrolipoic acid, N-acetylcysteine, homocysteine, pantetheine, 4-phosphopantetheine, dephosphorylated coenzyme A, coenzyme A, vitamin E and ascorbic acid. In a specific embodiment, wherein compound 1 or its pharmaceutically acceptable salt is formulated for immediate release. In a specific embodiment, compound 1 or a pharmaceutically acceptable salt thereof is formulated as a powder and the dosage form is a sachet. In a specific embodiment, a pantetheine enzyme inducer selected from the group including: a PPARα agonist, a PPARγ agonist, or an Nrf2 inducer is administered to an individual. In one embodiment, the pantetheine enzyme inducer is an isothiocyanate present in cruciferous vegetables, sulforaphane, S-allylcysteine, diallyl trisulfide, oxidized fat, ω-3 fatty acid, or octadecene ethanolamide. In a specific embodiment, within 30 minutes (e.g., 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, or 30 minutes) of administering compound 1 or a pharmaceutically acceptable salt thereof, 10 to 50 mg / kg (e.g., 15±5, 20±5, 25±5, 30±5, 35±5, 40±5, or 45±5 mg / kg) of cystamine or a pharmaceutically acceptable salt thereof is administered to an individual. In one embodiment, cystamine or a pharmaceutically acceptable salt thereof is formulated for immediate release. In certain embodiments, cystamine or a pharmaceutically acceptable salt thereof is administered simultaneously with the administration of Compound 1 or a pharmaceutically acceptable salt thereof.

[0011] In certain embodiments, a dose of 10 to 50 mg / kg (e.g., 15±5, 20±5, 25±5, 30±5, 35±5, 40±5, or 45±5 mg / kg) of Compound 3 is administered to a subject within 30 minutes (e.g., 5 minutes, 10 minutes, 15 minutes, 20 minutes, 20 minutes, or 25 minutes) of administering Compound 1, or a pharmaceutically acceptable salt thereof:

[0012]

[0013] Or a pharmaceutically acceptable salt thereof. Optionally, Compound 3 or a pharmaceutically acceptable salt thereof is formulated for immediate release. In a specific embodiment, Compound 3 or a pharmaceutically acceptable salt thereof is administered simultaneously with Compound 1 or a pharmaceutically acceptable salt thereof.

[0014] In any of the above methods, the cysteamine-sensitive disorder can be selected from cystinosis; neurodegenerative diseases; neurodevelopmental diseases; neuropsychiatric diseases; mitochondrial diseases; fibrotic diseases of the kidney, liver or lung; parasitic infections; sickle cell anemia; cancer; ischemic diseases, including ischemic heart disease or stroke; chronic obstructive pulmonary disease (COPD); cystic fibrosis (CF); bacterial infections; viral infections; non-alcoholic steatohepatitis (NASH); alcoholic steatohepatitis; and non-alcoholic fatty liver disease (NAFLD), or any other cysteamine-sensitive disorder described herein.

[0015] In a related aspect, the present invention provides a kit comprising: (i) a first pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof; (ii) a second pharmaceutical composition comprising a reducing agent; and (iii) instructions for administering the second pharmaceutical composition at least two hours after administering the first pharmaceutical composition to a subject to treat a cysteamine-sensitive disorder.

[0016] In another aspect, the present invention provides a kit comprising: (i) a first pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof; (ii) a second pharmaceutical composition comprising a pantetheinease inducer; and (iii) instructions for administering the first pharmaceutical composition and the second pharmaceutical composition to an individual to treat a cysteamine-sensitive disorder.

[0017] In another related aspect, the present invention provides a kit comprising: (i) a first pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof; (ii) a second pharmaceutical composition comprising cystamine or a pharmaceutically acceptable salt thereof; and (iii) instructions for administering the second pharmaceutical composition within 30 minutes of administering the first pharmaceutical composition to a subject to treat a cysteamine-sensitive disorder.

[0018] In another aspect, the present invention provides a kit comprising: (i) a first pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof; (ii) a second pharmaceutical composition comprising Compound 3 or a pharmaceutically acceptable salt thereof; and (iii) instructions for administering the second pharmaceutical composition within 30 minutes of administering the first pharmaceutical composition to a subject to treat a cysteamine-sensitive disorder.

[0019] In any of the above kits, the instructions may include instructions for performing the method of administering Compound 1 described above.

[0020] In another aspect, the invention provides a method for treating a cysteamine-sensitive disorder in a subject, comprising administering to the subject a dose of 50 to 150 milligrams per kilogram of body weight (mg / kg) (e.g., 60±10, 70±10, 80±10, 90±10, 100±25, 110±20, 120±10, 130±10, or 140±10 mg / kg) of Compound 2:

[0021]

[0022] Or its pharmaceutically acceptable salt, once or multiple times a day (for example, once, twice or three times a day). In a specific embodiment, within 2 hours of the dose (for example, within 30 minutes, 1 hour, 90 minutes or 2 hours), the reducing agent is not applied to the individual. In a specific embodiment, the reducing agent is applied to the individual 2 hours to 8 hours after the dose is applied. In a specific embodiment, the reducing agent is applied 3 ± 1 hours, 4 ± 1 hours, 5 ± 1 hours, 6 ± 1 hours, 7 ± 1 hours or 4 ± 2 hours after the dose of compound 2 or a pharmaceutically acceptable salt is applied. In one embodiment, the reducing agent is selected from glutathione, glutathione diethyl ester, γ-glutamylcysteine, dihydrolipoic acid, N-acetylcysteine, homocysteine, pantetheine, 4-phosphopantetheine, dephosphorylated coenzyme A, coenzyme A, vitamin E and ascorbic acid. In a specific embodiment, wherein compound 2 or its pharmaceutically acceptable salt is formulated for immediate release. In a specific embodiment, compound 2 or a pharmaceutically acceptable salt thereof is formulated as a powder and the dosage form is a sachet. In a specific embodiment, a pantetheine enzyme inducer selected from the group including: a PPARα agonist, a PPARγ agonist, or an Nrf2 inducer is administered to an individual. In one embodiment, the pantetheine enzyme inducer is an isothiocyanate present in cruciferous vegetables, sulforaphane, S-allylcysteine, diallyl trisulfide, oxidized fat, ω-3 fatty acid, or octadecene ethanolamide. In a specific embodiment, within 30 minutes (e.g., 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, or 30 minutes) of administering compound 2 or a pharmaceutically acceptable salt thereof, 10 to 50 mg / kg (e.g., 15±5, 20±5, 25±5, 30±5, 35±5, 40±5, or 45±5 mg / kg) of cystamine or a pharmaceutically acceptable salt thereof is administered to an individual. In one embodiment, cystamine or a pharmaceutically acceptable salt thereof is formulated for immediate release. In certain embodiments, cystamine or a pharmaceutically acceptable salt thereof is administered simultaneously with the administration of Compound 2 or a pharmaceutically acceptable salt thereof.

[0023] In certain embodiments, 10 to 50 mg / kg (e.g., 15±5, 20±5, 25±5, 30±5, 35±5, 40±5, or 45±5 mg / kg) of Compound 3 is administered to a subject within 30 minutes (e.g., 5 minutes, 10 minutes, 15 minutes, 20 minutes, 20 minutes, or 25 minutes) of administering Compound 2, or a pharmaceutically acceptable salt thereof:

[0024]

[0025] Or a pharmaceutically acceptable salt thereof. Optionally, compound 3 or a pharmaceutically acceptable salt thereof is formulated for immediate release. In a specific embodiment, compound 3 or a pharmaceutically acceptable salt thereof is administered simultaneously with compound 2 or a pharmaceutically acceptable salt thereof.

[0026] In any of the above methods, the cysteamine-sensitive disorder can be selected from cystinosis; neurodegenerative diseases; neurodevelopmental diseases; neuropsychiatric diseases; mitochondrial diseases; fibrotic diseases of the kidney, liver or lung; parasitic infections; sickle cell anemia; cancer; ischemic diseases, including ischemic heart disease or stroke; chronic obstructive pulmonary disease (COPD); cystic fibrosis (CF); bacterial infections; viral infections; non-alcoholic steatohepatitis (NASH); alcoholic steatohepatitis; and non-alcoholic fatty liver disease (NAFLD), or any other cysteamine-sensitive disorder described herein.

[0027] In a related aspect, the present invention provides a kit comprising: (i) a first pharmaceutical composition comprising Compound 2 or a pharmaceutically acceptable salt thereof; (ii) a second pharmaceutical composition comprising a reducing agent; and (iii) instructions for administering the second pharmaceutical composition at least two hours after administering the first pharmaceutical composition to a subject to treat a cysteamine-sensitive disorder.

[0028] In another aspect, the present invention provides a kit comprising: (i) a first pharmaceutical composition comprising Compound 2 or a pharmaceutically acceptable salt thereof; (ii) a second pharmaceutical composition comprising a pantetheinease inducer; and (iii) instructions for administering the first pharmaceutical composition and the second pharmaceutical composition to an individual to treat a cysteamine-sensitive disorder.

[0029] In another aspect, the present invention provides a kit comprising: (i) a first pharmaceutical composition comprising Compound 2 or a pharmaceutically acceptable salt thereof; (ii) a second pharmaceutical composition comprising cystamine or a pharmaceutically acceptable salt thereof; and (iii) instructions for administering the second pharmaceutical composition within 30 minutes of administering the first pharmaceutical composition to a subject to treat a cysteamine-sensitive disorder.

[0030] In another aspect, the present invention provides a kit comprising: (i) a first pharmaceutical composition comprising Compound 2 or a pharmaceutically acceptable salt thereof; (ii) a second pharmaceutical composition comprising Compound 3 or a pharmaceutically acceptable salt thereof; and (iii) instructions for administering the second pharmaceutical composition within 30 minutes of administering the first pharmaceutical composition to a subject to treat a cysteamine-sensitive disorder.

[0031] In any of the above kits, the instructions may include instructions for performing the method of administering Compound 2 described above.

[0032] The present invention provides a pharmaceutical composition comprising compound 3:

[0033]

[0034] Or a pharmaceutically acceptable salt thereof. The pharmaceutical composition may include Compound 3 or a pharmaceutically acceptable salt thereof, formulated for immediate release, formulated for delayed release, or formulated for sustained release. In a particular embodiment, the pharmaceutical composition further includes a second active ingredient, which includes a cysteamine precursor or a pharmaceutically acceptable salt thereof. Optionally, the second active ingredient is formulated for immediate release. In a particular embodiment, the second active ingredient is formulated for delayed release or is formulated for sustained release. In a particular embodiment, Compound 3 or a pharmaceutically acceptable salt thereof is formulated for immediate release and the second active ingredient is formulated for delayed release.

[0035] In a related aspect, the present invention provides a method of treating a cysteamine-sensitive disorder in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising Compound 3 or a pharmaceutically acceptable salt thereof. The cysteamine-sensitive disorder may be selected from cystinosis; neurodegenerative diseases; neurodevelopmental diseases; neuropsychiatric diseases; mitochondrial diseases; fibrotic diseases of the kidney, liver or lung; parasitic infections; sickle cell anemia; cancer; ischemic diseases, including ischemic heart disease or stroke; chronic obstructive pulmonary disease (COPD); cystic fibrosis (CF); bacterial infections; viral infections; nonalcoholic steatohepatitis (NASH); alcoholic steatohepatitis; and nonalcoholic fatty liver disease (NAFLD), or any other cysteamine-sensitive disorder described herein.

[0036] In another aspect, the present invention provides a method of treating a cysteamine-sensitive disorder in a subject, comprising administering to the subject a dose of 50 to 150 milligrams per kilogram of body weight (mg / kg) (e.g., 60±10, 70±10, 80±10, 90±10, 100±25, 110±20, 120±10, 130±10, or 140±10 mg / kg) of Compound 3:

[0037]

[0038] Or its pharmaceutically acceptable salt, once or multiple times a day (for example, once, twice or three times a day). In a specific embodiment, within 2 hours of the dose (for example, within 30 minutes, 1 hour, 90 minutes or 2 hours), the reducing agent is not applied to the individual. In a specific embodiment, the reducing agent is applied to the individual 2 hours to 8 hours after the dose is applied. In a specific embodiment, the reducing agent is applied 3 ± 1 hours, 4 ± 1 hours, 5 ± 1 hours, 6 ± 1 hours, 7 ± 1 hours or 4 ± 2 hours after the dose of compound 3 or a pharmaceutically acceptable salt is applied. In one embodiment, the reducing agent is selected from glutathione, glutathione diethyl ester, γ-glutamylcysteine, dihydrolipoic acid, N-acetylcysteine, homocysteine, pantetheine, 4-phosphopantetheine, dephosphorylated coenzyme A, coenzyme A, vitamin E and ascorbic acid. In a specific embodiment, wherein compound 3 or its pharmaceutically acceptable salt is formulated for immediate release. In a specific embodiment, compound 3 or a pharmaceutically acceptable salt thereof is formulated as a powder and the dosage form is a sachet. In a specific embodiment, a pantetheine enzyme inducer selected from the group including: a PPARα agonist, a PPARγ agonist or an Nrf2 inducer is administered to an individual. In one embodiment, the pantetheine enzyme inducer is an isothiocyanate present in cruciferous vegetables, sulforaphane, S-allylcysteine, diallyl trisulfide, oxidized fat, ω-3 fatty acid or octadecene ethanolamide. In a specific embodiment, within 30 minutes (e.g., 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes or 30 minutes) of administering compound 3 or a pharmaceutically acceptable salt thereof, 10 to 50 mg / kg (e.g., 15±5, 20±5, 25±5, 30±5, 35±5, 40±5 or 45±5 mg / kg) of cystamine or a pharmaceutically acceptable salt thereof is administered to an individual. In one embodiment, cystamine or a pharmaceutically acceptable salt thereof is formulated for immediate release. In certain embodiments, cystamine or a pharmaceutically acceptable salt thereof is administered simultaneously with the administration of Compound 3 or a pharmaceutically acceptable salt thereof.

[0039] In any of the above methods, the cysteamine-sensitive disorder can be selected from cystinosis; neurodegenerative diseases; neurodevelopmental diseases; neuropsychiatric diseases; mitochondrial diseases; fibrotic diseases of the kidney, liver or lung; parasitic infections; sickle cell anemia; cancer; ischemic diseases, including ischemic heart disease or stroke; chronic obstructive pulmonary disease (COPD); cystic fibrosis (CF); bacterial infections; viral infections; non-alcoholic steatohepatitis (NASH); alcoholic steatohepatitis; and non-alcoholic fatty liver disease (NAFLD), or any other cysteamine-sensitive disorder described herein.

[0040] In a related aspect, the present invention provides a kit comprising: (i) a first pharmaceutical composition comprising Compound 3 or a pharmaceutically acceptable salt thereof; (ii) a second pharmaceutical composition comprising a reducing agent; and (iii) instructions for administering the second pharmaceutical composition at least two hours after administering the first pharmaceutical composition to a subject to treat a cysteamine-sensitive disorder.

[0041] In another aspect, the present invention provides a kit comprising: (i) a first pharmaceutical composition comprising Compound 3 or a pharmaceutically acceptable salt thereof; (ii) a second pharmaceutical composition comprising a pantetheinease inducer; and (iii) instructions for administering the first pharmaceutical composition and the second pharmaceutical composition to an individual to treat a cysteamine-sensitive disorder.

[0042] In another aspect, the present invention provides a kit comprising: (i) a first pharmaceutical composition comprising Compound 3 or a pharmaceutically acceptable salt thereof; (ii) a second pharmaceutical composition comprising cystamine or a pharmaceutically acceptable salt thereof; and (iii) instructions for administering the second pharmaceutical composition within 30 minutes of administering the first pharmaceutical composition to a subject to treat a cysteamine-sensitive disorder.

[0043] In any of the above kits, the instructions may include instructions for performing the method of administering Compound 3 described above.

[0044] In another aspect, the present invention provides an acid addition salt of compound 1, wherein the acid is hydrochloric acid, acetic acid, trifluoroacetic acid or tartaric acid. In a specific embodiment, the acid is acetic acid or tartaric acid. In a specific embodiment, the acid is acetic acid.

[0045] In one embodiment, the acid addition salt has the formula:

[0046]

[0047] In some embodiments, the acid addition salt has the formula:

[0048]

[0049] In particular embodiments, the acid is tartaric acid.

[0050] In one embodiment, the acid addition salt has the formula:

[0051]

[0052] In one embodiment, the acid addition salt has the formula:

[0053]

[0054] In one embodiment, the acid addition salt has the formula:

[0055]

[0056] In another aspect, the present invention provides a method of treating a cysteamine-sensitive disorder in a subject, comprising administering to the subject an effective amount of any one of the aforementioned acid addition salts.

[0057] In a particular embodiment, within 2 hours of the administration of the dose (e.g., within 30 minutes, 1 hour, 90 minutes, or 2 hours), the reducing agent is not administered to the individual. In a particular embodiment, the reducing agent is administered to the individual 2 hours to 8 hours after the administration of the dose. In a particular embodiment, the reducing agent is administered 3 ± 1 hours, 4 ± 1 hours, 5 ± 1 hours, 6 ± 1 hours, 7 ± 1 hours, or 4 ± 2 hours after the administration of the dose of Compound 1 or a pharmaceutically acceptable salt. In one embodiment, the reducing agent is selected from glutathione, glutathione diethyl ester, gamma glutamylcysteine, dihydrolipoic acid, N-acetylcysteine, homocysteine, pantetheine, 4-phosphopantetheine, dephosphorylated coenzyme A, coenzyme A, vitamin E, and ascorbic acid.

[0058] In certain embodiments, any of the aforementioned acid addition salts is formulated for immediate release. In certain embodiments, any of the aforementioned acid addition salts is formulated as a powder and the dosage form is a sachet, or formulated in a bottle to be resuspended in an aqueous solution suitable for drinking. In certain embodiments, a pantetheine enzyme inducer selected from the group consisting of a PPARα agonist, a PPARγ agonist, or an Nrf2 inducer is administered to the individual. In one embodiment, the pantetheine enzyme inducer is an isothiocyanate present in cruciferous vegetables, sulforaphane, S-allylcysteine, diallyl trisulfide, oxidized fats, omega-3 fatty acids, or octadecene ethanolamide. In certain embodiments, 10 to 50 mg / kg (e.g., 15±5, 20±5, 25±5, 30±5, 35±5, 40±5, or 45±5 mg / kg) of cystamine or a pharmaceutically acceptable salt thereof is administered to the subject within 30 minutes (e.g., 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, or 30 minutes) of administering any of the aforementioned acid addition salts. In one embodiment, cystamine or a pharmaceutically acceptable salt thereof is formulated for immediate release. In certain embodiments, cystamine or a pharmaceutically acceptable salt thereof is administered simultaneously with the administration of any of the aforementioned acid addition salts.

[0059] In certain embodiments, a dose of 10 to 50 mg / kg (e.g., 15±5, 20±5, 25±5, 30±5, 35±5, 40±5, or 45±5 mg / kg) of Compound 3 is administered to a subject within 30 minutes (e.g., 5 minutes, 10 minutes, 15 minutes, 20 minutes, 20 minutes, or 25 minutes) of administering Compound 1, or a pharmaceutically acceptable salt thereof:

[0060]

[0061] Or a pharmaceutically acceptable salt thereof. Optionally, Compound 3 or a pharmaceutically acceptable salt thereof is formulated for immediate release. In a specific embodiment, Compound 3 or a pharmaceutically acceptable salt thereof is administered simultaneously with Compound 1 or a pharmaceutically acceptable salt thereof.

[0062] In any of the above methods, the cysteamine-sensitive disorder can be selected from cystinosis; neurodegenerative diseases; neurodevelopmental diseases; neuropsychiatric diseases; mitochondrial diseases; fibrotic diseases of the kidney, liver or lung; parasitic infections; sickle cell anemia; cancer; ischemic diseases, including ischemic heart disease or stroke; chronic obstructive pulmonary disease (COPD); cystic fibrosis (CF); bacterial infections; viral infections; non-alcoholic steatohepatitis (NASH); alcoholic steatohepatitis; and non-alcoholic fatty liver disease (NAFLD), or any other cysteamine-sensitive disorder described herein.

[0063] In another aspect, the present invention provides a method for synthesizing an asymmetric disulfide, the method comprising combining: (a) 1 molar equivalent of an organic carboxylic acid or a salt thereof; (b) 2 to 4 molar equivalents (e.g., 2, 2.5, 3, 3.5, or 4 molar equivalents) of cystamine or a salt thereof; and (c) an amide coupling reagent to form a mixture comprising greater than 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5%) of the organic carboxylic acid or a salt thereof converted to an asymmetric disulfide of formula (A), and less than 10% (e.g., 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.5%) of the organic carboxylic acid that remains unreacted or is converted to a symmetric disulfide of formula (B):

[0064]

[0065] wherein R is an organic group. In certain embodiments, the group RC(O)- is a moiety of less than 1,000 Daltons, 700 Daltons, 400 Daltons, or 200 Daltons. In some embodiments, RC(O)- is a natural or synthetic amino acid, or an ester or amide thereof.

[0066] In some embodiments, the organic carboxylic acid or its salt is selected from pantothenic acid, 4-phosphopantothenic acid, acetic acid or its salt. In a specific embodiment, the organic carboxylic acid or its salt is pantothenic acid or its salt. In some embodiments, the amide coupling reagent is hydroxybenzotriazole. In some embodiments, the amide coupling reagent is N, N'-dicyclohexylcarbodiimide. In some embodiments, the combination is in one or more solvents selected from the following: dichloromethane, tetrahydrofuran, acetonitrile dimethylformamide, water and combinations thereof.

[0067] In another aspect, the present invention provides a method for synthesizing an asymmetric disulfide, the method comprising combining in an organic solvent:

[0068] (a) 2 to 4 molar equivalents (e.g., 2 to 2.3, 2.2 to 3, 2.7 to 3.3, or 3.1 to 4 molar equivalents) of a thiol selected from cysteamine, N-acetylcysteamine, cysteine, N-acetylcysteine, N-acetylcysteine ​​amide, or a salt thereof; and

[0069] (b) 1 molar equivalent of a disulfide selected from cystamine, pantethine or a salt thereof.

[0070] In some embodiments, the molar ratio of thiol to disulfide is from about 2:1 to about 4:1 (e.g., from about 2:1 to about 2.5:1, from about 2.5:1 to 3.5:1, from about 2.7:1 to about 3.3:1, from about 2.5:1 to about 3:1, from about 3:1 to about 3.5, or from about 3:1 to about 3.5, to about 4:1, from about 3.5:1 to about 4:1). In specific embodiments, the molar ratio of thiol to disulfide is from about 2.5:1 to about 3.5:1 (e.g., from about 2.5:1 to 2.7:1, from about 2.7:1 to about 3.3:1, or from about 3.3:1 to about 3.5:1). In other embodiments, the molar ratio of thiol to disulfide is from about 2.7:1 to about 3.3:1 (e.g., from about 2.7:1 to about 3.1:1, or from about 3.1 to about 3.3).

[0071] In some embodiments, the thiol is N-acetylcysteamine or a salt thereof.

[0072] In some embodiments, the disulfide is cystamine or a salt thereof.

[0073] In some embodiments, the organic solvent is methanol or ethanol. In a specific embodiment, the organic solvent is methanol.

[0074] definition

[0075] "Immediate release" refers to a pattern of release of an active agent (e.g., a cysteamine precursor or a pharmaceutically acceptable salt thereof) formulated in a unit dosage form having a dissolution release profile in simulated gastric medium wherein at least 55%, 65%, 75%, 85% or 95% of the agent is released within the first two hours of testing using USP compatible apparatus.

[0076] "Controlled release" means a pattern of releasing an active agent (e.g., a cysteamine precursor or a pharmaceutically acceptable salt thereof) from its formulation in a manner that allows for controlled anatomical sites of release or release rates, or both. In general, the purpose of a controlled release formulation is to extend the time period over which therapeutic drug levels are present in the body (e.g., relative to an immediate release formulation), and / or to optimize the delivery of the drug to the cysteamine absorption site, thereby reducing the dose that must be administered within a 24-hour period. Gastric retention, delayed release, sustained release, and colon targeted formulations are all examples of controlled release formulations. Controlled release formulations can also allow for a reduced peak drug concentration (Cmax) (i.e., a reduced cysteamine Cmax in the case of a cysteamine precursor of the present invention) relative to that observed for an immediate release formulation administered at the same dose level. Controlled release formulations of active agents can be achieved, for example, by embedding the active agent in a matrix material that dissolves or erodes slowly, such that the active ingredient slowly and regularly seeps out of the coating by diffusion, by diffusing out of the matrix or by eroding the matrix surface or both, or by forming a gel with a semi-permeable surface, wherein the drug slowly leaves the semipermeable layer.

[0077] "Delayed release" means a pharmaceutical formulation, such as an oral formulation, that passes substantially intact through the acidic environment of the stomach and dissolves in the more alkaline environment of the small intestine, such that an active agent (e.g., a cysteamine precursor or a pharmaceutically acceptable salt thereof) formulated in a unit dosage form has a dissolution release profile in simulated gastric fluid in which less than 25%, 20%, 15%, 10%, or 5% of the agent is released within the first hour of testing, and additionally has a dissolution release profile in simulated intestinal fluid at pH 6.0 or 6.3 or 6.5 in which at least 55%, 65%, 75%, 85%, or 95% of the agent is released within the first two hours of testing. In some embodiments, the delayed release of the active agent (e.g., a cysteamine precursor or a pharmaceutically acceptable salt thereof) is produced by the use of a pH-sensitive enteric coating of an oral dosage form. The enteric coating can be combined with, for example, a fast or slow (sustained) release formulation, or a combination of both, to extend the time of drug release.

[0078] The term "sustained release" (also referred to in the literature as "extended release") refers to a drug formulation that provides a gradual release of the drug over an extended period of time (e.g., 6-12 hours or longer) compared to an immediate release formulation of the same drug, such that the active agent (e.g., a cysteamine precursor or a pharmaceutically acceptable salt thereof) formulated in a unit dosage form has a dissolution release profile in simulated gastric or intestinal fluid, wherein when in simulated small intestinal fluid, at least 10-45% (i.e., 15-45%, 20-45%, 25-45%, 25-45%, 35-45%, 30-45%, or 40-45%) of the agent is released within three hours of testing and not less than 65%, 75%, 85%, 90%, 93%, 95%, or 97% of the agent is released within 8 hours. Preferably, although not necessarily, the sustained release results in a substantially constant blood level of the drug over an extended period of time that is within the therapeutic range for the disease being treated. Preferably, the sustained release formulation of cysteamine precursor produces plasma cysteamine levels falling within a concentration range of, for example, 5-50 μM, 5-40 μM, 5-35 μM, 5-30 μM, 5-25 μM, 5-20 μM, or 10-50 μM, 10-45 μM, 10-40 μM, 10-35 μM, 10-30 μM, 10-25 μM or 10-20 μM.

[0079] The term "colon targeting" refers to a formulation or composition that provides drug release in the colon (which has a much higher intestinal flora density than the small intestine), and optionally also in the terminal ileum (which tends to be the most alkaline region of the gastrointestinal tract). One method of targeting drug release to the distal ileum and colon is to use a pH-sensitive coating that dissolves at about pH 7 (e.g., pH 6.8, pH 6.9, pH 7.0), which is a typical pH in the ileum. Formulations designed for pH-dependent drug release in the ileum are likely to also release drugs in the colon (especially if the drug is embedded in a sustained release matrix), and / or some cysteamine precursors released in the ileum may still enter the colon in precursor form (i.e., not yet converted to cysteamine). Another type of colon-targeted formulation relies on enzymes made by intestinal bacteria to degrade drug encapsulation polymers that cannot be degraded by saliva, gastric or pancreatic enzymes, thereby affecting drug delivery in the colon. The density of intestinal flora is also high in the terminal ileum, so the intestinal flora may begin to digest the polymer and therefore release the drug in the terminal ileum. Ileum-targeted and colon-targeted formulations are collectively referred to herein as colon-targeted formulations.

[0080] The term "unit dosage form" refers to a physically discrete unit suitable as a unit dose, such as a pill, tablet, caplet, hard capsule or soft capsule, each unit containing a predetermined amount of cysteamine precursor or a pharmaceutically acceptable salt thereof. "Hard capsule" means a capsule comprising a membrane that forms a two-part capsule-shaped container capable of carrying a solid or liquid payload of a drug and excipient. "Soft capsule" means a capsule molded into a single container that carries a liquid or semi-solid or solid payload of a drug and excipient. Granules, powders and liquids can also be provided in "unit dosage form" by using appropriate packaging. For example, granules or powders can be administered in sachets or liquid forms in ampoules, vials or plastic containers.

[0081] As used herein, the term "microparticles" refers to microbeads, microspheres, micropellets, nanoparticles, nanobeads, nanospheres or other fine particles used in pharmaceutical preparations, wherein the average diameter of each microparticle is 0.05-999 microns. Tens, hundreds or thousands of such microparticles can be used in a single unit dosage form, for example, it can be filled in a capsule or formulated as a powder or suspended in a liquid.

[0082] As used herein, the term "effective amount" of an agent is an amount sufficient to produce a beneficial or desired result (e.g., disease alleviation) in a patient, and therefore, the "effective amount" depends on the circumstances in which the agent is used, including the age and weight of the patient; the nature of the disease, including the organ affected by the disease, the disease state or activity level; the patient's sensitivity to cysteamine and other factors.

[0083] As used herein, "pantetheine," "4-phosphopantetheine," "dephospho-CoA," and "CoA," as well as any analog or derivative that can be converted to one of those compounds in the gastrointestinal tract, refers to the D enantiomer (also occasionally referred to as the R enantiomer using newer nomenclature). Each of these compounds contains a chiral carbon in the panthenyl moiety that can exist in either the D (dextrorotatory) or L (levorotatory) form, also referred to as the (R) or (S) form, respectively. Only the D-pantetheine enantiomer is a substrate for the pantetheine enzyme, and therefore it is the only pantetheine enantiomer that is a precursor to cysteamine. Similarly, only the D-enantiomer of compounds that can be converted to pantetheine (e.g., 4-phosphopantetheine), dephospho-CoA, and CoA are suitable for use in the compositions and methods of the present invention.

[0084] As used herein, a "disulfide compound" is a compound containing a sulfur atom chemically bonded to a second sulfur atom in the form of: R1-SS-R2, wherein R1 and R2 are organic compounds. R1 and R2 may be the same or different. Disulfide compounds are generally formed by oxidation of two thiols (i.e., R1-SH plus R2-SH to produce R1-SS-R2 plus 2H +) and can be reversibly converted back to two thiols by reduction (i.e., R1-SS-R2 plus 2H + Disulfide compounds can also be formed by reacting one or two thiols with a dithiol (e.g., R1-SH plus R2-SH plus HS-R3-SH to produce R1-SS-R3-SS-R2 plus 4H + , wherein R1, R2 and R3 are organic compounds and H + The disulfide compounds of the present invention are sulfur-containing compounds with biological activity, which include: 1) a cysteamine mixed disulfide compound of the following formula: C2H6NS-S-R1, wherein R1 is an organic part, 2) a pantetheine disulfide compound of the following formula: C 11 H 21 N2O4S-S-R1, wherein R1 is an organic moiety, 3) a 4-phosphopantetheine disulfide compound of the following formula: C 11 H 22 N2O7PS-S-R1, wherein R1 is an organic moiety, 4) a dephosphorylated coenzyme A disulfide compound of the following formula: C 21 H 34 N7O 13 P2S-S-R1, wherein R1 is an organic moiety, 5) a coenzyme A disulfide compound of the following formula: 21 H 35 N7O 16 P3S-S-R1, wherein R1 is an organic moiety, or 6) an N-acetylcysteamine compound of the formula: C4H8NOS-S-R1, {2 wherein R1 is an organic moiety. A dithiol may be used to form an additional disulfide, and the dithiol compound may form two disulfide bonds. At least one and optionally both disulfide bonds are disulfide bonds with cysteamine or a compound that can be degraded to cysteamine in the gastrointestinal tract. Alternatively, the dithiol is disulfide bonded to only one such compound, the second thiol of the dithiol is still in the form of a thiol, or the second thiol may be disulfide bonded to any thiol, including, for example Fig.17The thiols listed in . Compounds that can be degraded to cysteamine in the gastrointestinal tract include, in addition to pantetheine, 4-phosphopantetheine, dephospho-coenzyme A, coenzyme A or N-acetylcysteamine, or any analog or derivative that can be converted into one of these five compounds in the gastrointestinal tract (e.g., by chemical or enzymatic processes). Any such analog or derivative referred to herein as "suitable analogs or derivatives" is a thiol of the present invention and can replace one of these five compounds. "Mixed disulfides" are disulfides formed by two different thiols. "Cysteamine mixed disulfide" means a disulfide that connects cysteamine to another (non-cysteamine) thiol; "pantetheine mixed disulfide" means a disulfide that connects pantetheine to another (non-pantetheine) thiol; and so on. In general, mixed disulfides are classified by simple two-component thiols (e.g., cysteamine-pantetheine is referred to as cysteamine mixed disulfide). Thiols that can be used to form disulfide cysteamine precursors include, for example, L-cysteine, N-acetylcysteine, glutathione, Fig.17 Any of the thiols listed in and other thiols described herein. Several exemplary mixed disulfides are described in Figures 2 to 10 middle. Figure 18-21 The table in Fig.17 How do the thiols in a compound efficiently combine to form a disulfide? For the sake of brevity and clarity, this article uses the name of the two thiols connected by the disulfide bond to name the disulfide, rather than the formal chemical name (such as using IUPAC nomenclature). Thus, cysteamine-pantetheine refers to the disulfide formed by these two compounds. There are three important exceptions to the rule: the disulfide formed by the reaction of two pantetheines is usually called pantethine, the disulfide formed by the reaction of two cysteines is usually called cystine, and the disulfide formed by the reaction of two cysteamines is usually called cystamine.

[0085] As used herein, the term "disulfide formed by reacting" or "compound formed by reacting" specifically refers to a disulfide formed between two named thiols. For example, the disulfide formed by reacting cysteamine with pantetheine (referred to as cysteamine-pantetheine) means a heterodimer formed between a cysteamine molecule and a pantetheine molecule. This definition does not reflect what may actually occur when two named thiols react. That is, when cysteamine reacts with pantetheine under oxidative conditions, three disulfides may be formed in different proportions depending on the chemical conditions: cysteamine-cysteamine (i.e., cystamine), cysteamine-pantetheine (i.e., pantetheine-cysteamine, which are the same for purposes of the present invention), and pantetheine-pantetheine (i.e., pantethine). When the actual reaction product (i.e., a mixture of the three disulfides) is intended, it is explicitly indicated herein.

[0086] "Cysteamine precursor" means a compound that can be converted into at least one cysteamine under physiological conditions. The conversion method includes reduction in the case of cysteamine-containing disulfides (i.e., cysteamine mixed disulfides), enzymatic hydrolysis in the case of pantetheine enzyme substrates (pantetheine and compounds that can be metabolically converted to pantetheine in the gastrointestinal tract, such as 4-phosphopantetheine, dephospho-CoA and CoA and suitable analogs or derivatives thereof), or both reduction and enzymatic cleavage. Examples of precursors include, but are not limited to, cysteamine mixed disulfides, pantetheine disulfide, 4-phosphopantetheine disulfide, dephospho-CoA disulfide, CoA disulfide and N-acetylcysteamine. Disulfides, as well as pantetheine, 4-phosphopantetheine, dephospho-CoA, CoA and N-acetylcysteamine. The chemical relationship between cysteamine, pantetheine, 4-phosphopantetheine, dephospho-CoA and CoA (the latter four compounds are cysteamine precursors) is shown below. A homodimer of two pantetheine molecules (i.e., pantetheine), or two 4-phosphopantetheine molecules, or two dephospho-CoA molecules or two CoA molecules or two N-acetylcysteamine molecules is also each a disulfide cysteamine precursor compound, because the component thiols are all cysteamine precursors.

[0087] By "suitable analogs or derivatives" with respect to the cysteamine precursors pantotheine, 4-phosphopantetheine, dephospho-CoA, Coenzyme A or N-acetylcysteamine, or disulfide-containing forms of any of these, is meant a compound that can be converted to pantetheine, 4-phosphopantetheine, dephospho-CoA, Coenzyme A or N-acetylcysteamine in the gastrointestinal tract, whether by chemical or enzymatic processes.

[0088] "Compounds convertible to pantetheine" means compounds that can be degraded to pantetheine in the gastrointestinal tract, such as 4-phosphopantetheine, dephospho-CoA and CoA, as well as analogs or derivatives of those compounds that can be converted to the parent compound in the gastrointestinal tract.

[0089] "Constituent thiol" as used with respect to a disulfide refers to the thiol (and optional dithiol) compound that reacts to form the disulfide.

[0090] "Cysteamine content" means the weight fraction of cysteamine precursors that can be converted to cysteamine in vivo upon chemical and / or enzymatic degradation.

[0091] As used herein, the term "pharmaceutically acceptable salt" means salts that are suitable for contact with human and animal tissues without excessive toxicity, irritation, allergic reaction, etc., and are commensurate with a reasonable benefit / risk ratio within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., Journal of Pharmaceutical Sciences (J. Pharmaceutical Sciences) 66: 1-19, 1977 and Pharmaceutical Salts: Properties, Selection, and Use, (PH Stahl and CG Wermuth eds.), Wiley-VCH, 2008. Salts can be prepared in situ during the final separation and purification of the compounds of the present invention, or prepared separately by reacting the free base with a suitable organic or inorganic acid. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, bitartrate, borate, butyrate, camphorsulfonate, camphorate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, dodecylsulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate, and the like. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.

[0092] "Gastroretentive", "gastric-retentive" and the like refer to pharmaceutical compositions that are able to remain in the stomach of a mammal, preferably a human, for a long period of time, preferably as long as food, more preferably longer than food. Thus, "gastric-retentive" is the maintenance of a pharmaceutical composition in the stomach for a longer period of time than when delivered in free form, e.g., in an oral delivery vehicle that is not considered gastroretentive. Gastric-retentive formulations may be characterized by being retained in the stomach for a period longer than the time it normally empties from the stomach, i.e., up to about 2 hours, particularly up to about 3 hours and typically more than about 4, 6, 8 or 10 hours. Gastric-retentive formulations typically remain in the stomach for about 3, 4, 6, 8, 10 hours or sometimes 18 hours or more after ingestion of a meal. However, it should be noted that according to the present invention, retention of a controlled release gastric-retentive drug delivery system is not observed after administration to a non-fasting stomach for more than 48 hours, and preferably after 24 hours. Gastric retentive formulations include floating or buoyant formulations, swelling or expandable formulations, bioadhesive or mucoadhesive formulations, unfolding formulations, and magnetic formulations, or any combination thereof. Combinations of two or more types of gastric retentive formulations are common, as it has proven difficult to maintain retention in the stomach using only one gastric retentive mechanism. Gastric retentive formulations are preferably administered with a meal.

[0093] "Floating", "flotation" and "buoyant" are used interchangeably to refer to a formulation that is capable of placing the composition of the present invention on or near the surface of gastric contents, which is chyme in the fed state (or gastric fluid in the fasted state or after gastric emptying). By floating on the gastric contents, the formulation is less likely to be pushed through the pylorus, which is located at the bottom of the stomach when in a sitting or standing position, into the duodenum during gastric muscle contractions. Floating formulations can be composed of small (e.g., micron-sized), medium (e.g., millimeter-sized), or large (e.g., centimeter-sized) particles. As described herein, large compositions can act simultaneously through a swellable / expandable mechanism. Formulations of any size can act simultaneously through a mucoadhesive mechanism.

[0094] "Swelling" and "expandable", which are used interchangeably, refer to the ability of a composition to increase its size when in contact with a fluid-containing medium such as gastric fluid or chyme. Preferably, "swelling" is characterized by increasing the size of the initial tablet to a size that will not be easily cleared from the stomach. Clearance from the stomach involves passage through the pylorus. The average resting diameter of the human pylorus varies in the fed and fasted states. In the fed state, it is about 1 cm or less, and in the fasted state it is about 1.28 cm, plus or minus 7 mm. Preferably, "swelling" entails increasing the size of the composition to more than 14 mm, more than 16 mm, more than 18 mm, more than 20 mm, or more than 22 mm in at least two dimensions, but alternatively in one dimension, wherein the second and third dimensions are both greater than 12 mm, 14 mm, or 16 mm.

[0095] "Mucoadhesion" means the ability of a composition to adhere to the mucus layer lining the gastrointestinal tract. In the case of gastroretentive formulations, "mucoadhesion" refers to adhesion to the mucus layer lining the stomach. Mucoadhesion is one of several techniques for extending gastric residence time, however the continuous turnover of the mucus layer of the stomach, albeit slowly, limits the duration of mucoadhesion. Therefore, mucoadhesion is often combined with other gastroretentive methods to achieve extended gastric residence time. "Biopause" means the ability of a composition to adhere to other molecules lining the gastrointestinal tract, including molecules on the surface of intestinal epithelial cells.

[0096] "Deployment" or "deformation" are used interchangeably and refer to the ability of a composition to expand, stretch, unwind, decompress or otherwise open in the stomach to transform into a composition having a size and / or geometry that does not easily pass through the pylorus and, therefore, remains in the stomach for a long time. The "deployed" or deformed formulation can be formulated within a capsule. Ideally, but not necessarily, the size of the expanded formulation in the expanded or opened state is greater than 16 mm, 18 mm, 20 mm or 22 mm in at least two dimensions, but may alternatively be only in one dimension, with the second and third dimensions exceeding 12 mm, 14 mm or 16 mm.

[0097] "Magnetic formulation" means a composition containing a magnet or dispersed magnetized material that is capable of interacting with an externally applied magnetic field generated by one or more magnets located outside the body, thereby achieving retention of the composition in the stomach or small intestine for a long period of time. The retention time of the stomach-targeted composition is preferably at least as long as the retention time of food in the stomach, and more preferably longer than the retention time of food. The small intestine-targeted composition is preferably retained until substantially complete drug dissolution, or until sufficient magnetic force is lost to keep the composition in place, whichever occurs first. The magnet or magnetic material used must be safe for human ingestion. External magnets can also be used to position the magnetic-containing pharmaceutical composition in other areas of the gastrointestinal tract, such as the colon, but in most cases, the magnetic formulation is a gastric retention or small intestine-targeted formulation.

[0098] As used herein, "therapeutically effective amount" refers to the amount that must be administered to a patient (human or non-human mammal) to ameliorate the disease or modulate a biomarker that serves as a surrogate for disease activity. Clinical endpoints for different diseases, including neurodegenerative, metabolic, fibrotic, ischemic, infectious, neoplastic, and genetic diseases vary widely, but are generally well known in the art. Specific biomarkers may include, for example: (i) white blood cell (WBC) cystine levels, which serve as a surrogate for disease control in patients with cystinosis; (ii) cognitive, motor or mood state indices may be used to measure treatment response in patients with neurodegenerative diseases, including instruments such as the following: Clinical Global Impression (CGI) score, Clinician Interview-Based Assessment of Change plus Caregiver Input (CIBIC-Plus) global score, Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change (ADCS-CCGIC) score, Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score, Modified Alzheimer's Disease Cooperative Study Activities of Daily Living Scale for Severe Dementia (ADCS-ADLsev) score, Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI) score, Unified Huntington's Disease Rating Scale (UDHRS), MATTIS test, Hopkins Trail Making Test (Hopkins Trail Making Test). gTest), categorization fluency, Unified Parkinson's Disease Rating Scale (UPDRS) score, or Parkinson's Disease Sleepiness Scale (PDSS-2) total score; (iii) biochemical measures of neurodegenerative disease activity including AD biomarkers (such as plasma β-amyloid) or brain-derived neurotrophic factor (BDNF) levels; (iv) indicators of metabolic and fibrotic liver disease including anatomical tests, such as liver biopsy-based measures of liver fibrosis, including the (NAFLD) Activity Score (NAS) and liver fibrosis score; (v) biochemical indices of liver health, including liver and adipose tissue insulin sensitivity as measured by the HOMA-IR and adipo-IR indices, respectively, serum transaminases and gamma-glutamyl transpeptidase (GGT) levels, and CK-18-derived fragments in the blood for NAFLD, NASH, ASH, or inherited liver diseases; (vi) disease state indices for mitochondrial disease, including the Newcastle Pediatric Mitochondrial Disease Scale (NMDS) as a clinical endpoint. Pediatric Mitochondrial Disease Scale; NPMDS) score, and (vii) biomarkers including glutathione, total serum thiols, acetoacetate, β-hydroxybutyrate, lactate or malondialdehyde (markers of oxidative stress). Other surrogate disease markers include modulation of immune response, modulation of gene or protein expression, or modulation of validated radiological disease measures (e.g., assessed by X-ray, CT scan, MRI scan or PET scan).Methods for determining therapeutically effective amounts of cysteamine precursors are highly disease specific and are well known to clinicians specializing in each of the above-mentioned diseases.

[0099] As used herein, "pharmaceutically acceptable excipients" are natural or synthetic substances contained (together with the active ingredient) in the formulation of the composition, which are suitable for use in humans and / or non-human mammals without undue side effects (such as toxicity, irritation or allergic reactions). Excipients may include, for example: anti-adherents, antioxidants, adhesives, coatings, compression aids, disintegrants, dyes (pigments), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavoring agents, fragrances, glidants (flow enhancers), lubricants, preservatives (including antioxidants), printing inks, adsorbents, suspending agents or dispersants, solvents, colloidal stabilizers, sweeteners and water. The U.S. FDA maintains an "inactive ingredient" database containing information on thousands of substances commonly used in the preparation of drugs. Excipients commonly used in controlled, delayed, sustained or extended release formulations can be searched in the database. Excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, carbomer, cross-linked carboxymethylcellulose, cross-linked polyvinyl pyrrolidone, citric acid, cross-linked povidone, cellulose derivatives including ethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose or hydroxypropyl methylcellulose, docusate sodium, gelatin, gelucire 43 / 01, lactose, magnesium stearate, maltitol, mannitol, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, poly(ethylene oxide), polyvinyl pyrrolidone, povidone, pregelatinized starch, propylparaben, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vegetable oils, waxes including white wax, yellow wax or beeswax, and xylitol. Excipients may also include diluents (e.g., saline and aqueous buffer solutions); aqueous carriers and non-aqueous carriers, such as water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof; vegetable oils, such as olive oil; and injectable organic esters, such as ethyl oleate. Excipients for preparing compositions having specific properties are described in more detail in the specific embodiments.

[0100] "Enteric coating" means an agent or compound added to a formulation described herein that protects the active ingredients described herein (e.g., cysteamine precursors and enhancers for degradation and absorption of cysteamine precursors) as they pass through the stomach. Enteric coatings can also protect the stomach from irritating drug ingredients (e.g., cysteamine). Examples of commercial enteric coating technologies include, but are not limited to, AcrylEZE, Opadry, Nutrateric, and Sureteric products (Colorcon, West Point PA), Advantia Performance Specialty Coatings (International Specialty Products, Wayne NJ), Kollicoat product lines (BASF Corporation, Ludwigshafen Germany), Aquacoat products (FMC BioPolymer), Eastman CAP (Eastman Chemical Co. Kingsman TN), Eudragit product lines (Evonik Industries), and AQOAT, HP-50, and HP-55 product lines (Shin Etsu Pharma). Ashland Specialty Ingredients, Encap Drug Delivery, and Sanyo Chemical Industries, Ltd. also market enteric coating systems.Examples of pH-sensitive film-forming polymers commonly used in enteric coating formulations include: (i) cellulose-based polymers, such as cellulose acetate phthalate (e.g., Aquacoat CPD, FMC; CAP, Eastman Chemical Co.), cellulose acetate succinate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate (e.g., AquaSolve, Ashland Specialty Ingredients, Wilmington DE); (ii) polymethacrylates, such as poly(methacrylic acid-ethyl acrylate) (e.g., Eudragit L30D-55 and Eudragit L100-55, Evonik Industries; AcrylEZE, Colorcon; Kollicoat MAE 30DP and Kollicoat MAE 100P, BASF Pharma Ingredients and Services; Polyquid PA-30, Sanyo Chemical Industries) and poly(methacrylic acid-methyl methacrylate) in ratios of 1:1 and 1:2; (iii) polyvinyl derivatives such as poly(vinyl acetate) phthalate (e.g. Sureteric, Colorcon); and (iv) other copolymers such as half esters of copolymers of styrene and maleic acid, half esters of copolymers of vinyl ether and maleic acid, and copolymers of vinyl acetate and crotonic acid. Enteric coatings are also prepared using shellac (e.g. PROTECT, Sensient Pharmaceutical Coating Systems) or sodium alginate and zein (EncapDrug Delivery). Hydroxypropyl methylcellulose is also known as hypromellose or HPMC. Examples of other excipients commonly used in enteric coating formulations include: wet microcrystalline cellulose, wet powdered cellulose, gellan gum, and stearic acid. Enteric coatings can be applied to a variety of formulations, including tablets, capsules, and microparticles.

[0101] As used herein, "combination therapy" means that in addition to the drugs disclosed herein, drugs not fully described herein, or drugs not contemplated in some cases, are administered to a patient (or non-human mammal) in need of treatment according to the present invention. Combination therapy can be performed consecutively (before or after) or simultaneously with the cysteamine precursor therapy of the present invention.

[0102] "Treatment" means subjecting a patient to a treatment regimen to treat a disease or disorder and to obtain a beneficial or desired result, such as an improvement in disease signs or symptoms or an improvement in biochemical, radiological, behavioral, or physical markers of disease activity or disease status. Examples of beneficial or desired results may include, but are not limited to, resolution of inflammation, resolution of biochemical imbalances, improvement in quality of life, improvement in cognitive and behavioral status, improvement in motor function, improvement in affect and emotional state, improvement in sleep, or more generally, alleviation or improvement of one or more symptoms or disorders; reduction in the extent of the disease; stabilization of the disease state; prevention of disease spread; delay or slowing of the progression of the disease; amelioration or alleviation of the disease, disorder, or condition; and partial or complete alleviation of significant disease manifestations.

[0103] The term "mammal" is intended to mean both human and non-human mammals.

[0104] "Delivery" means providing and / or administering the active ingredients described herein by oral administration of tablets, capsules, liquids, powders, granules, microparticles, sachets, suppositories, etc. (collectively referred to as "pharmaceutical compositions" or simply "compositions") containing the active ingredients and (optionally) one or more carriers and / or diluents and / or adjuvants or other excipients. The composition may be provided with delivery instructions, including an explanation of any color coding or alphanumeric text on the surface or packaging of the composition, and instructions as to whether the composition should be taken at a particular time of day or with food (e.g., a particular type or amount of food), liquids, meals (including details on the type of meal), or other medications, and whether the patient should remain upright or sit for a period of time after administration.

[0105] Several disease acronyms, gene names, and other medical terms are abbreviated. Disease acronyms include MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) and MERFF (myoclonic epilepsy with shaggy red fibers). Gene names include POLG, which encodes the catalytic subunit of DNA polymerase gamma, a mitochondrial DNA polymerase; OCT1, OCT2, and OCT3, which encode organic cation transporters 1, 2, and 3 (also known as SLC22A1, SLC22A2, and SLC22A3, respectively); PANK2, which encodes pantothenate kinase 2; VNN1, which encodes vanin 1, also known as pantetheinase; and VNN2, which encodes vanin 2, also known as GPI-80 and pantetheinase.

[0106] As used herein, "cysteamine-sensitive disease" means a disease for which there is evidence that cysteamine may be an effective treatment. The evidence may be derived from clinical or preclinical studies of the disease in mammals (e.g., humans, dogs, mice, rats, monkeys, rabbits), or from in vitro studies of the disease mechanism. Cysteamine-sensitive diseases constitute a broad, heterogeneous group of diseases with widely varying presentations and pathogenesis. Diseases and conditions for which there is evidence of cysteamine efficacy can be classified according to pathogenesis, with the important caveat that the mechanism of cysteamine efficacy is not always clear, and there may be unknown mechanisms of action. Important categories of cysteamine-sensitive diseases include (i) cystine transport disorders, of which cystinosis is the best known; (ii) diseases associated with oxidative damage, including neurodegenerative diseases and liver diseases; (iii) conditions associated with pathological enzyme activity (including neurodegenerative diseases), inherited mitochondrial diseases, diseases associated with mutant MECP2 and POLG; (iv) fibrotic conditions, including fibrosis of the kidney, liver, or lung; (v) metabolic disorders, including metabolic syndrome X, diabetes, and the nonalcoholic fatty liver disease spectrum, culminating in nonalcoholic steatohepatitis (NASH); (vi) infectious diseases, including certain viral infections (e.g., influenza), bacterial infections (e.g., Pseudomonas aeruginosa), and parasitic infections (e.g., malaria); (vii) ischemic diseases, including ischemia-reperfusion injury of the heart and other organs; (viii) diseases associated with abnormal adiponectin metabolism; and (ix) cancer and the amelioration of the deleterious effects of cancer therapy.

[0107] As used herein, the term "about" means ± 20% of the stated value. BRIEF DESCRIPTION OF THE DRAWINGS

[0108] Figure 1 The chemical structure of coenzyme A is depicted, from which a molecule of dephospho-coenzyme A, a molecule of 4-phosphopantetheine, a molecule of pantetheine, a molecule of pantothenic acid, or a molecule of cysteamine can be derived by an enzyme-catalyzed reaction (in Fig.11 ).

[0109] Figure 2 Two chemical structures of disulfides of the present invention are depicted. The top chemical structure depicts a mixed cysteamine disulfide molecule with cysteamine on the left and a second thiol on the right (RS-depicted). The bottom chemical structure depicts pantetheine disulfide with pantetheine on the left and a second thiol on the right (RS-depicted). Figure 3 , 4 5 and 6 show exemplary mixed cysteamine disulfides. Other mixed cysteamine disulfides can be used with Fig.17 The thiols listed in form together, such as Fig.18 and 21 As shown schematically in FIG.

[0110] Figure 3 Four chemical structures of exemplary cysteamine mixed disulfides are depicted. Specifically, as indicated in the labeling, mixed cysteamine disulfides are shown with partner thiols allyl mercaptan, L-cysteine, L-cysteine ​​ethyl ester, and N-acetylcysteine.

[0111] Figure 4 Depicted are two chemical structures of exemplary cysteamine mixed disulfides and one chemical structure of an exemplary N-acetylcysteamine mixed disulfide. Two cysteamine mixed disulfides are formed between cysteamine and N-acetylcysteamine and between cysteamine and N-acetylcysteine ​​amide. Also shown is a mixed disulfide formed between N-acetylcysteamine and N-acetylcysteine ​​amide (as indicated in the label).

[0112] Figure 5 Depicted are two chemical structures of exemplary cysteamine mixed disulfides formed between cysteamine and pantetheine and between cysteamine and glutathione as indicated in the labels.

[0113] Figure 6 The chemical structure of an exemplary cysteamine mixed disulfide formed between cysteamine and coenzyme A is depicted.

[0114] Figure 7 Two chemical structures are depicted. The top is an exemplary pantetheine mixed disulfide formed between pantetheine and cysteine. The bottom is an exemplary N-acetylcysteamine mixed disulfide formed with pantetheine.

[0115] Figure 8 Depicted are the chemical structures of two exemplary mixed disulfides, one formed between pantetheine and N-acetylcysteine ​​and the other formed between the dithiol dihydrolipoic acid and two cysteamines (one disulfide-bonded to each of the two thiols of dihydrolipoic acid), as indicated in the labels.

[0116] Fig. 9 Depicted is the chemical structure of an exemplary pantetheine mixed disulfide formed between pantetheine and glutathione.

[0117] Fig.10 Depicted is the chemical structure of an exemplary 4-phosphopantetheine mixed disulfide formed between 4-phosphopantetheine and Coenzyme A.

[0118] Fig.11Schematic diagram of partial CoA, pantetheine and cysteamine metabolic pathways, including intracellular metabolism (solid lines) and catabolic reactions (dashed lines) occurring in the gastrointestinal tract. Some reactions occur in two locations (e.g., phosphatases are present in the cytoplasm and the gastrointestinal lumen). Compounds are named in conventional type, enzymes in italics. Compounds and enzymes have various alternative names to those shown in the figure. This figure is not a complete presentation of CoA, pantetheine and cysteamine metabolism, but is intended only to convey that CoA, dephospho-CoA, 4-phosphopantetheine and pantetheine can be catabolized to cysteamine (and pantothenate) in the intestine.

[0119] Fig.12 The anatomical structure of the gastrointestinal (GI) tract is depicted in schematic form (top). Below is a table summarizing certain anatomical and physiological parameters related to the in vivo production and absorption of cysteamine from the cysteamine precursor of the present invention for each section of the GI tract. In particular, the table indicates the anatomical sites where cysteamine formation and absorption occur and the levels of physiological variables that affect the rate of in vivo production of cysteamine from the cysteamine precursor (e.g., by disulfide bond reduction and pantetheine enzyme cleavage), as well as the rate of cysteamine absorption along the GI tract (e.g., by organic cation transporters 1, 2, and 3). For example, pH affects disulfide exchange reactions. The level of glutathione (GSH) is representative of the redox environment, which affects the balance between oxidized and reduced forms of disulfides and mercaptans, including the reduction of disulfide cysteamine precursors. Absorption surface area and transit time, as well as the levels of pantetheine digestive enzymes and cysteamine transporters affect the cysteamine production rate from pantetheine and subsequent cysteamine absorption. Other physiological variables in the figure affect the performance of certain types of preparations. For example, some types of gastric retentive formulations swell to a size that prevents passage through the pylorus; some pH-sensitive drug coatings dissolve in the duodenum at around pH 5.5, pH 6, or pH 6.5, while other coatings dissolve around pH 7, which is more typical in the ileum; some types of colon-targeted formulations are composed in part of polymers that are difficult to digest by human (or mammalian) enzymes but can be degraded by enzymes produced by intestinal bacteria, thereby affecting the release of cysteamine precursors co-formulated with the polymers. The values ​​or ranges provided in the table are from literature data, but may not include the full range of normal human variation. Nevertheless, the degree of variation indicated can partially explain the wide inter-individual variation in cysteamine absorption and metabolism observed clinically.

[0120] Fig.13is a table showing the classification of cysteamine precursors and some of their salient pharmacological properties. On the left (lower) side of the table, the cysteamine precursors are classified as follows: according to (i) whether they are thiols or disulfides, (ii) if disulfides, whether they are mixed disulfides containing cysteamine (including cysteamine-pantetheine), disulfides containing pantetheine (other than cysteamine-pantetheine), or contain other thiols that can be degraded to pantetheine in the gastrointestinal tract, and (iii) how much cysteine ​​is produced upon chemical reduction and / or enzymatic degradation (under the # symbol). "Other thiols or dithiols" means any dithiol, as well as any thiol that is not cysteamine, pantetheine, 4-phosphopantetheine, dephospho-CoA, CoA, or N-acetylcysteamine. (For exemplary thiols and dithiols, see Fig.17). The number of cysteamines produced by the degradation of the disulfide cysteamine precursor containing "other thiols" is one, but the disulfide cysteamine precursor containing dithiols can produce one or two cysteamines when degraded, because one dithiol can bind, for example, two cysteamines (for an overview of how thiols and dithiols can be combined, see Table 21). The table further shows the chemical and / or enzymatic steps required to produce cysteamine from each type of cysteamine precursor under "Steps to Produce Cysteamine". For example, a cysteamine mixed disulfide containing cysteamine and another thiol (e.g., cysteine) requires only one step: disulfide bond reduction. Similarly, the thiol pantetheine requires only one step: pantetheine enzymatic cleavage. Other cysteamine precursors require two steps. For example, the pantetheine homodimer pantetheine requires disulfide bond reduction followed by pantetheine enzymatic cleavage. Other cysteamine precursors require three or more steps. For example, 4-phosphopantetheine homodimers require disulfide bond reduction, phosphatase cleavage, and pantetheine enzyme cleavage. Dephosphorylation of coenzyme A and coenzyme A containing disulfides requires additional steps. In some disulfide cysteamine precursors, the number of degradation steps of cysteamine is different between the two thiols produced by disulfide bond reduction, as shown in the table. The table further shows the classes of compounds that can be co-formulated or co-administered with cysteamine precursors to enhance the in vivo production of cysteamine, and shows which (some) types of enhancers can be used for various types of cysteamine precursors. For example, any disulfide cysteamine precursor can be co-formulated or co-administered with a reducing agent (abbreviated as RA in the table) to promote disulfide bond reduction. Cysteamine precursors that are or include pantetheine or any thiol that can be degraded to pantetheine can be co-formulated or co-administered with an inducer of the enzyme pantetheinease (abbreviated as PI in the table) to enhance the production of cysteamine. Pantethine disulfide can be effectively co-formulated or co-administered with reducing agents and pantethine enzyme inducers. Not shown in the table are enhancers of cysteamine absorption (e.g., inducers of cysteamine transporters, such as organic cation transporters), or inhibitors of cysteamine catabolism, because these compounds can be effectively co-formulated or co-administered with all classes of cysteamine precursors. On the far right (top), the table summarizes the salient pharmacological properties of different classes of cysteamine precursors, which may be affected by the number of degradation steps required to produce cysteamine, the yield of cysteine, or the presence of enhancers of cysteamine production in vivo. The very brief description provided is not complete and should not be construed as limiting.

[0121] Fig.14is a diagram of an exemplary pharmaceutical composition. Salient features of the exemplary composition are shown, including: (i) type of dosage form (e.g., tablet, capsule, powder, liquid), (ii) characteristics of the formulation with respect to anatomical localization of drug release (e.g., gastroretentive formulations are retained in the stomach; enteric-coated formulations may be designed to release the drug in the small intestine; colon-targeted formulations are designed to release the drug in the ileum or colon) and (iii) duration of drug release (immediate release: IR, or sustained release: SR), (iv) type of cysteamine precursor, (v) dosage (provided as a range), (vi) type of co-formulated enhancer of in vivo cysteamine production (if any), (vii) dosage of the enhancer compound (provided as a range), (viii) recommendations for administering the composition with food (e.g., applesauce or yogurt) or with a meal (e.g., dinner), or whether food is optional ("food OK"), (ix) site of cysteamine precursor release in the gastrointestinal tract, and (vii) site of in vivo cysteamine production (e.g., by disulfide bond reduction or pantetheine enzyme cleavage). Fig.13 The compositions in the drawings are each limited to a single type of formulation for the site and time of drug release. Such compositions (including many variations not shown in the drawings) can be administered in various combinations, providing flexibility for individualized dosing. Other exemplary compositions with more active ingredients and / or more complex formulations are shown in Fig.14 and 15 middle.

[0122] Fig.15 is an illustration of an exemplary pharmaceutical composition having (i) one or two drug release profiles - e.g., Composition G includes an immediate release and a sustained release component; (ii) at least two types of cysteamine precursors and up to two enhancers. Suggestions for administration with or without food are provided, as well as the site of drug release and the in vivo conversion of cysteamine precursors to cysteamine. The exemplary compositions and many other compositions not shown can be combined in various ratios.

[0123] Fig.16 is an illustration of an exemplary multiple-dose regimen, wherein two or more compositions are administered together or sequentially within a short time interval. Salient features of the exemplary compositions are as follows Fig.14 and 15 As shown. Examples of compositions that provide a cysteamine precursor degradation enhancer (e.g., a reducing agent) but do not contain a cysteamine precursor are included. A separate formulation of the enhancer allows it to be co-administered with a composition containing a cysteamine precursor in various ratios to optimize cysteamine production or absorption in vivo. A separate formulation of the enhancer further allows control of the site and timing of the enhancer release to optimize cysteamine production or absorption in vivo.

[0124] Fig.17is a list of exemplary thiols and dithiols that are thiol-type cysteamine precursors (compounds 2-6) or that can be combined to make disulfide-type cysteamine precursors. The chemical formula, Chemical Abstracts Service (CAS) registry number, and formula molecular weight of each thiol or dithiol are shown. In some cases, the CAS number is specific to a specific enantiomer. Each thiol is numbered ( Fig.17 ) for easy reference Figure 18-21 These thiols.

[0125] Fig.18 Contains two tables, which show Fig.17 How the thiols and dithiols in can be combined to prepare two types of disulfide cysteamine precursors: cysteamine mixed disulfides and pantetheine disulfide. The five columns in each of the two tables are listed starting from the left:

[0126] (i) two thiols that react to form a disulfide, which consists of Fig.17 The numbers in the leftmost column of the table refer to the compounds (thiols are numbered 1-29 and dithiols are numbered 30-35). Thus, for example, the notation: "1+28" represents the disulfide formed by reacting thiol 1 (cysteamine) with thiol 28 (tiopronin). All disulfides in the left table include cysteamine (compound 1) plus a second thiol (any one of compounds 2 to 35). All disulfides in the right table include pantetheine (compound 2) plus a second thiol (any one of compounds 2 to 35).

[0127] (ii) The formula molecular weight (MW) of the disulfide is indicated in the first column; for example, the MW of disulfide 1+28 is 238.35 Daltons (the sum of the masses of the two component thiols minus 2 to account for the two lost protons). It should be noted that in the case of thiols 13 and 14 (L-cysteine ​​ethyl ester HCl and L-cysteine ​​methyl ester HCl), the masses of the salt forms are used. The actual mass of the free disulfide is 36.46 Daltons less than the mass shown.

[0128] (iii) The amount of cysteamine that can be produced after degradation of the cysteamine precursor in vivo. The disulfides are sorted, with those that produce two cysteamines listed above the bold horizontal line and those that produce one cysteamine listed below.

[0129] (iv) The fraction of cysteamine precursors that can be converted to free cysteamine in vivo. For example, the fraction of 238.35 dalton disulfide 1+28 that can be converted to cysteamine is 32.4%. The disulfides that produce one type of cysteamine are arranged from high to low by the molecular weight fraction that can be converted to cysteamine.

[0130] (v) The number of degradation steps (chemical or enzymatic) required to produce cysteamine from the disulfide cysteamine precursor. For disulfides above the bold horizontal line (where both thiols can be degraded to cysteamine (or one of the two thiols is cysteamine itself)), two numbers are provided, showing the number of steps for each thiol component of the disulfide. The order of the two numbers corresponds to the order of the two thiols listed in the first column of the table. For disulfides where only one thiol can be degraded to cysteamine (below the bold horizontal line), only one number is shown, indicating the number of degradation steps for the thiol. For example, in the disulfide table 1B, the disulfide indicated as "2+5" represents pantetheine (thiol 2) disulfide-bonded to coenzyme A (thiol 5). The MW of this disulfide is 1,352.36. After degradation in the intestine, this disulfide produces two cysteamines. The two together weigh 154.3 Daltons, which is 11.4% of the mass of the disulfide, as shown in column 4. The degradation pathway from the disulfide to the two cysteamines includes two steps in the case of the pantetheine moiety (step 1: disulfide bond reduction, step 2: pantetheine enzymatic cleavage) and four or more steps (indicated as 4+) in the case of the coenzyme A moiety (step 1: disulfide bond reduction, step 2: nucleotide separation catalyzed by ectonucleotide diphosphatase (other catabolic pathways are possible), step 3: dephosphorylation to pantetheine, step 4: pantetheine enzymatic cleavage). Therefore, the numbers 2 / 4+ in column 5 represent the number of degradation steps from the disulfide to cysteamine for the pantetheine and coenzyme A moieties, respectively.

[0131] Fig.19 Contains two tables showing Fig.17 The five columns in each of the two tables provide information on how thiols and dithiols in the cysteamine precursors can be combined to make two types of disulfide cysteamine precursors: 4-phosphopantetheine disulfide and dephospho-CoA disulfide. Fig.18 Again, it should be noted that in the case of thiols 13 and 14 (L-cysteine ​​ethyl ester HCl and L-cysteine ​​methyl ester HCl), the masses of the salt forms are used. The actual masses of the free disulfides are 36.46 Daltons less than the masses shown.

[0132] Fig. 20 Contains two tables showing Fig.17 The five columns in each of the two tables provide information on how thiols and dithiols in the formula can be combined to make two types of disulfide cysteamine precursors: coenzyme A disulfide and N-acetylcysteamine disulfide. Fig.18 Again, it should be noted that in the case of thiols 13 and 14 (L-cysteine ​​ethyl ester HCl and L-cysteine ​​methyl ester HCl), the masses of the salt forms are used. The actual masses of the free disulfides are 36.46 Daltons less than the masses shown.

[0133] Fig.21 Two tables are included that show how a dithiol can be linked to two thiols to make a disulfide that can produce two cysteamines (upper table) or one cysteamine (lower table) when degraded in vivo. The thiols and dithiols are numbered as shown in Fig.17 In each table, for simplicity, the various possible dithiol-thiol-thiol combinations are grouped by the dithiol moiety (compounds 30-35), and the molecular weight and cysteamine yield of each group are provided as a range. The bottom of each table shows three exemplary dithiol-thiol-thiol combinations and includes the specific MW, the percentage of MW that can be converted to cysteamine, and the number of degradation steps for cysteamine (see above). Fig.18 Additional details are provided in the captions below the two tables.

[0134] Fig. 22 The initial thiol activation step used in the chemical synthesis of mixed (asymmetric) disulfides is described.

[0135] Fig.23 A synthetic scheme for preparing cysteamine-pantetheine disulfide (referred to as TTI-0102, where 01 refers to cysteamine, which is Fig.17 The thiol 1 in 0 refers to pantetheine, which is Fig.17 The thiol in 2). The primary amine of cysteamine is first protected with tert-butyloxycarbonyl (Boc), and then the -SH of cysteamine-Boc is activated with bis(5,5-dimethyl-2-thioxo-1,3,2-dioxaphosphorin-2-yl)disulfane (referred to by the abbreviation PDTA) in dichloromethane (DCM) in the presence of 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ). The Boc group is then removed with an acid, and the activated cysteamine is reacted with (R)-pantetheine.

[0136] Fig.24 A second synthetic scheme for preparing cysteamine-pantetheine disulfide (TTI-0102) is described. (R)-pantetheine is activated with bis(5,5-dimethyl-2-thioxo-1,3,2-dioxaphospholinane-2-yl)disulfane (referred to by the abbreviation PDTA) in dichloromethane (DCM) in the presence of 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ). The activated (R)-pantetheine is then reacted with cysteamine in sodium hydride (NaH) and tetrahydrofuran (THF).

[0137] Fig.25 A synthetic protocol for the preparation of N-acetylcysteamine-pantetheine disulfide (referred to as TTI-0602, where the numbers 6 and 2 refer to the two combined thiols, such as Fig.17N-acetylcysteamine is activated with bis(5,5-dimethyl-2-thioxo-1,3,2-dioxaphosphorin-2-yl)disulfane (PDTA) in dichloromethane (DCM) in the presence of 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ). The activated N-acetylcysteamine is then reacted with (R)-pantetheine in DCM containing triethanolamine (TEA).

[0138] Fig.26 A synthetic protocol for preparing N-acetylcysteine-pantetheine disulfide (referred to as TTI-1502, where the numbers 15 and 2 refer to the two combined thiols, such as Fig.17 N-acetylcysteine ​​is activated with bis(5,5-dimethyl-2-thioxo-1,3,2-dioxaphospholinane-2-yl)disulfane (PDTA) in dichloromethane (DCM) in the presence of 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ). The activated N-acetylcysteine ​​is then reacted with (R)-pantetheine in sodium hydride (NaH) and tetrahydrofuran (THF).

[0139] Fig. 27 Included is a nuclear magnetic resonance (NMR) spectrum of TTI-0102 obtained on a Varian INOVA 500. The inserted structure of TTI-0102 is labeled with letters a through i to indicate specific bonds, which are also highlighted on the NMR spectrum.

[0140] Fig.28 Contained is a nuclear magnetic resonance (NMR) spectrum of TTI-0602 obtained on a Varian INOVA 500. The inserted structure of TTI-0602 is annotated with letters a through g to indicate specific bonds, which are also highlighted on the NMR spectrum.

[0141] Fig.29 Included is a nuclear magnetic resonance (NMR) spectrum of TTI-1502 obtained on a Varian INOVA 500. The inserted structure of TTI-1502 is labeled with letters a through i to indicate specific bonds, which are also highlighted on the NMR spectrum.

[0142] Fig. 30A and Fig. 30B . Containing cysteamine hydrochloride (30 mg / kg; Fig. 30A ) or Compound 2 (also known as TTI-0602) (120 mg / kg; Fig. 30B ) after , the concentration-time curve of cysteamine in plasma, as described in Example 10. The values ​​in both curves are the average of three rats. The standard deviation is represented by the error bar.

[0143] Fig.31A and Fig.31B . Containing plasma cysteamine concentration-time curves after administration of 30 mg / kg, 60 mg / kg or 120 mg / kg doses of Compound 2 (also known as TTI-0602) to Sprague-Dawley rats (3 rats per dose) by gavage ( Fig.31A ), as described in Example 10, and the concentration-time curves of cysteamine, N-acetylcysteamine, and pantothenic acid in plasma after administration of 120 mg / kg of Compound 2 (also known as TTI-0602) to Sprague-Dawley rats by gavage ( Fig.31B ), also described in Example 10.

[0144] Fig.32 Contained is a graph illustrating the concentration of cysteamine (micromolar) in the liver and kidney 10.5 hours following administration of 120 mg / kg of Compound 2 (also known as TTI-0602) by gavage to Sprague-Dawley rats, as described in Example 10.

[0145] Fig.33 Depicted is the concentration-time profile of cysteamine in plasma following administration by gavage to male Sprague-Dawley rats of: (i) cysteamine hydrochloride (30 mg / kg) or cystamine dihydrochloride (30 mg / kg) or pantethine (30 mg / kg) or Compound 1 (also known as TTI-0102) (100 mg / kg) as described in Example 1. Concentrations are the mean of three rats, and error bars indicate standard deviations.

[0146] Fig.34A and Fig.34B . Plot the concentration-time curve of cysteamine in plasma after administration of 30 mg / kg, 60 mg / kg or 100 mg / kg of Compound 1 (also known as TTI-0102) to male Sprague-Dawley rats by gavage ( Fig.34A ), as described in Examples 11-13, and the pharmacokinetic parameters derived from each dose ( Fig.34B Abbreviations: Cmax = maximum cysteamine concentration; Tmax = time at which maximum cysteamine concentration occurs; AUC last = area under the drug concentration-time curve from time 0 to six hours; T1 / 2 = half-life of cysteamine in plasma; MRT last = mean residence time based on 6 hours of data.

[0147] Fig.35A and Fig.35BDepicts a bar graph showing the levels of cysteamine ( Fig.35A ) and pantetheine ( Fig.35B ) concentration. Gastrointestinal contents obtained from the stomach, proximal small intestine, distal small intestine, and cecum / colon were analyzed as described in Examples 11-13. Samples from all four intestinal segments were reduced with TCEP. Proximal and distal small intestinal contents were also analyzed without TCEP. The numbers above each bar indicate the value of the sample. The samples are aligned in the upper and lower figures to facilitate comparison of cysteamine and pantethine levels in the same sample.

[0148] Fig.36A . A synthetic scheme depicting the half-acylation of cystamine to produce compound 1 (cysteamine-pantetheine asymmetric disulfide). DCC is the abbreviation for the coupling reagent N,N'-dicyclohexylcarbodiimide. HOBt is the abbreviation for 1-hydroxybenzotriazole hydrate. DMF is the abbreviation for the solvent dimethylformamide.

[0149] Fig.36B . Scheme depicting the synthesis of Compound 1 via thiol-disulfide exchange. The reaction shown involving cysteamine (thiol) and pantetheine (disulfide) is one of two thiol-disulfide exchange reactions discussed in Example 14.

[0150] Fig.37 .Depict the proton NMR of TTI-0102 prepared by cystamine half-acylation ( 1 H NMR spectroscopy ( Fig.36A ). The structure of TTI-0102 is shown and used in 1 Peaks in the H NMR spectra are annotated by typing in lowercase letters. The table shows the values ​​of all peaks with their incremental values ​​(expressed in parts per million, or ppm) and peak heights.

[0151] Fig.38 .Describe in tabular form Fig.37 As shown in 1 The relationship between the predicted and observed proton peak heights in H NMR spectra, where protons Fig.37 are labeled identically in (a, b, c, d, e, f, g, h, i). DETAILED DESCRIPTION

[0152] The present invention provides compositions and methods that allow the in vivo production of cysteamine from precursor compounds (cysteamine precursors) in controlled amounts and at controlled locations in the gastrointestinal tract, as well as methods for treating cysteamine-sensitive symptoms, syndromes and diseases. The methods and compositions of the present invention may include any one of compounds 1-3 shown below, or a pharmaceutically acceptable salt thereof.

[0153]

[0154]

[0155] Compounds 1-3 may be administered alone, or in combination with a second active ingredient that is a cysteamine precursor, or in combination with an agent that modifies the release or uptake of cysteamine in a subject following administration of the compound, such as a reducing agent or pantetheinease inducer.

[0156] Cysteamine is a small, highly reactive thiol molecule (NH2-CH2-CH2-SH) that is present in all life forms from bacteria to humans. The IUPAC name for cysteamine is 2-aminoethanethiol. Other common names include thioethylamine, β-mercaptoethylamine, 2-mercaptoethylamine, decarboxylated cysteine, and thioethanolamine. In humans, cysteamine is produced by the enzyme pantetheinase, which cleaves pantetheine into cysteamine and pantothenic acid, also known as pantothenate or vitamin B5. Human pantetheinase is encoded by the Vanin 1 and Vanin 2 genes (abbreviated VNN1 and VNN2) and is widely expressed, including in the gastrointestinal tract. Therefore, dietary pantetheine, which is present in many foods (e.g., in nuts and dairy products), is cleaved in the gastrointestinal lumen to produce cysteamine and pantothenic acid, which are then absorbed. In particular, cysteamine can be transported through the gastrointestinal epithelium by organic cation transporters (OCTs), which are a family of transporters that include organic cation transporter 1 (OCT1), OCT2, and OCT3, which have been shown to transport cysteamine in intestinal epithelial cells. Based on its ability to be converted to cysteamine in the gastrointestinal tract, pantetheine is a cysteamine precursor. Cysteamine precursors represent a class of compounds that have advantages over cysteamine salts in terms of (i) tolerability and side effects, (ii) pharmacokinetics and dosing intervals, (iii) manufacturing, and (iv) product stability. More generally, administering cysteamine precursors that can generate cysteamine in vivo at different rates, and using formulation methods to deliver these precursors to selected sites in the gastrointestinal tract at selected times, can be adapted for treatment regimens by providing much better control of cysteamine pharmacokinetics, which has until now been a major obstacle to the widespread use of cysteamine and other thiols.

[0157] cysteamine precursor

[0158] Pantethine and its catabolites cysteamine and pantothenate are intermediate compounds in the biosynthesis of coenzyme A in plants and animals (for a diagram of the relevant metabolic and catabolic pathways, see Fig.11 ). Several compounds in the CoA biosynthetic pathway, such as 4-phosphopantetheine, dephospho-CoA, and CoA, can be catabolized in the human gastrointestinal tract to pantetheine, and then to cysteamine and pantothenate. Therefore, 4-phosphopantetheine, dephospho-CoA, and CoA are cysteamine precursors because they can be converted to cysteamine in the intestine. N-acetylcysteamine is also a cysteamine precursor and is deacetylated by intestinal or cellular deacetylases (e.g., deacetylases that convert N-acetylcysteine ​​to cysteine ​​in vivo).

[0159] Pantethine is a dimer of two pantetheine molecules connected by a disulfide bond. In other words, pantethine is an oxidized form of pantethine. The interconversion of pantethine and two pantetheines is not enzymatically mediated, and does not require ATP. On the contrary, the reaction is largely controlled by the redox environment in the intestine. In a reducing environment that tends to dominate in vivo, especially in cells, pantethine will dominate, and in a more oxidizing environment (such as the stomach), the balance will shift to pantethine. A small clinical study by Wittwer (Wittwer et al., Journal of Experimental Medicine (J. Exp. Med.) 76: 4 (1985)) showed that when administered orally, most of the pantethine is chemically reduced to pantethine in the human gastrointestinal tract, and then cleaved into cysteamine and pantothenate. Therefore, pantethine is a cysteamine precursor. Pantethine herein refers to the D-enantiomer.

[0160] The panthenyl moiety of pantethine contains a chiral carbon. Therefore, there are two enantiomeric forms of pantethine, traditionally referred to as D-pantethine and L-pantethine (also referred to as R-pantethine and S-pantethine). Only the D-enantiomer of pantethine can be cleaved by pantetheinease, and therefore only the D-enantiomer is qualified as a cysteamine precursor. The two enantiomers of pantethine can combine in four ways to form the disulfide pantethine: D-, D-; D, L; L-, D-; and L-, L-pantethine. Only D-, D-pantethine can be chemically reduced to two D-pantethines, and then cleaved to produce two cysteamines. Therefore, the D-, D-form of pantethine is strongly preferred, and the term pantethine used herein refers to the D-, D-enantiomer. The pantetheine-related compounds 4-phosphopantetheine, dephospho-CoA, and CoA must also be in the D-stereoisomeric configuration to produce D-pantetheine (and thereby cysteamine) when degraded in the intestine. Thus, "4-phosphopantetheine," "dephospho-CoA," and "CoA," and any analogs or derivatives thereof, are referred to herein as the D-enantiomer. None of pantetheine, 4-phosphopantetheine, dephospho-CoA, or CoA is absorbed by intestinal epithelial cells, but rather each compound must be catabolized to pantothenate and cysteamine to be absorbed (see Shibata et al., J. Nutr. 113:2107 (1983)).

[0161] Analogs or derivatives of pantetheine, 4-phosphopantetheine, dephospho-CoA or the D-stereoisomer of CoA that can be converted to the parent compound in the gastrointestinal tract (e.g., by natural enzymes or chemical processes) can also be used to form thiol or disulfide-type cysteamine precursors and are referred to herein as "suitable analogs or derivatives." For example, there are many physiological forms of CoA that are easily degraded to CoA in the intestine (e.g., acetyl-CoA, succinyl-CoA, malonyl-CoA, etc.). Any acetylated, alkylated, phosphorylated, lipidated or other analogs can be used as cysteamine precursors. Analogs of pantetheine, 4-phosphopantetheine, dephospho-CoA or CoA, as well as methods for their production, have been described in the literature (van Wyk et al., Chem Commun 4:398 (2007)).

[0162] In addition to itself, pantetheine can form disulfides with thiols, called pantetheine mixed disulfides, which constitute another class of cysteamine precursors. The thiol that reacts with pantetheine is preferably a naturally occurring thiol, or a non-natural thiol known to be safe in the human body based on a history of use in humans or animals. For example, mixed disulfides can be formed by reacting pantetheine with 4-phosphopantetheine, dephospho-coenzyme A or coenzyme A, compounds present in the human body and many foods. Such mixed disulfides produce two cysteines when reduced and degraded in the intestine. Pantetheine coupled to N-acetylcysteamine also produces two cysteines when reduced and degraded in the intestine. In certain embodiments, disulfide cysteamine precursors that can produce two cysteamines are preferred. Figure 18-21 Cysteamine yields for different classes of disulfide cysteamine precursors are shown. 4-Phosphopantetheine, dephospho-CoA, or analogs or derivatives of CoA (i.e., suitable analogs or derivatives) that can be converted to the parent compound in the gastrointestinal tract by chemical or enzymatic processes can also be coupled with pantetheine to form a pantetheine mixed disulfide cysteamine precursor, or they can be coupled to other thiols.

[0163] Pantethine mixed disulfides can also be formed by the reaction of pantethine with a thiol which itself is not degradable to cysteamine, such as L-cysteine, homocysteine, N-acetylcysteine, N-acetylcysteine ​​amide, N-acetylcysteine ​​ethyl ester, N-acetylcysteamine, L-cysteine ​​ethyl ester hydrochloride, L-cysteine ​​methyl ester hydrochloride, thiocysteine, allyl mercaptan, furfuryl mercaptan, benzyl mercaptan, thioterpineol, 3-mercaptopyruvic acid, cysteinylglycine, gamma-glutamylcysteine, gamma-glutamylcysteine ​​ethyl ester, glutathione, glutathione monoethyl ester, glutathione diethyl ester, mercaptoethylglucamide, thiosalicylic acid, thiocysteine, tiopronin or diethyldithiocarbamic acid. For Chemical Abstracts Service (CAS) registry numbers, molecular formulas, and molecular weights of exemplary thiol compounds that can react with pantethine to form pantethine mixed disulfides, see Fig.17 . Composed of pantetheine and any one of thiols 6-35 (for thiol numbering, see Fig.17 ) form disulfides which, after disulfide bond reduction and pantetheinase cleavage, yield one cysteamine. Although these second thiols are not convertible to cysteamine in the intestine, they may enhance cysteamine production by, for example, stimulating pantetheinase activity or participating in disulfide exchange with cysteamine-containing disulfides, or they may provide therapeutic benefits complementary to those provided by cysteamine (by, for example) acting as a reducing agent or by other mechanisms.

[0164] Dithiol compounds, such as dihydrolipoic acid (DHLA), meso-2,3-dimercaptosuccinic acid (DMSA), 2,3-dimercaptopropanesulfonic acid (DMPS), 2,3-dimercapto-1-propanol, bucillamine, or N,N'-bis(2-mercaptoethyl)isophthalamide, can also react with pantetheine to form pantetheine mixed disulfides with one free thiol group, or ternary compounds with two disulfide bonds linking two pantetheine molecules to the dithiol. The former mixed pantetheine disulfides produce one cysteamine upon disulfide bond reduction and pantetheinease cleavage, while the latter produce two cysteamines. See Table 1 for a table showing how cysteamine, pantetheine, 4-phosphopantetheine, dephospho-CoA, CoA, or N-acetylcysteamine can be combined with various dithiols to produce useful cysteamine precursors. Fig.21 Alternatively, two different thiols may be bonded to the dithiol to produce a cysteamine precursor, provided that one of the thiols is cysteamine, pantetheine, 4-phosphopantetheine, dephospho-CoA, CoA or N-acetylcysteamine, or a suitable analog or derivative thereof; i.e., a compound that is ultimately degraded to cysteamine in the gastrointestinal tract. Fig.21 Tables 2A and 2B in show some salient properties of such cysteamine precursors, including the range of molecular weights and cysteamine yields (i.e., the percentage of the cysteamine precursor that can be converted to cysteamine in vivo), and for selected examples, the number of in vivo degradation steps from the cysteamine precursor to cysteamine.

[0165] Similar to pantetheine, any of 4-phosphopantetheine, dephospho-CoA, CoA or N-acetylcysteamine, or suitable analogs or derivatives can (i) react with itself to form a homodimeric disulfide, or (ii) react with each other in various pairings to form mixed disulfides, or (iii) react with other thiols (which cannot be converted to cysteamine in vivo) to form mixed disulfides. All of these disulfides are cysteamine precursors. The first two classes can produce two cysteamines when reduced and degraded in the intestine, while the third class can only produce one cysteamine.

[0166] For example, Fig.17 Any of the thiols listed in can be combined with 4-phosphopantetheine (eg Fig.19 ), and dephosphorylation of coenzyme A ( Fig.19 ), and coenzyme A ( Fig. 20 ) or with N-acetylcysteamine ( Fig. 20 ) to form a mixed disulfide cysteamine precursor. Other naturally occurring thiols may also be used, as may non-natural thiols known to be safe in humans. Figure 18-21Schematically illustrated are some combinations of thiols and dithiols that can react to form the disulfide cysteamine precursors. Conversion of these compounds to cysteamine in the human gastrointestinal tract requires: (i) reduction of disulfide bonds to produce free thiols, (ii) in the case of disulfides containing 4-phosphopantetheine, dephospho-CoA, CoA or a suitable analog or derivative thereof, degradation by enzymes present in the intestine (e.g., phosphatases, diphosphatases, phosphodiesterases) to produce pantetheine, (iii) cleavage of pantetheine by pantetheinase. Disulfides containing N-acetylcysteamine must be reduced and deacetylated in the intestine, blood or tissues.

[0167] Cysteamine itself can also react with other thiols to form mixed disulfide cysteamine precursors. For example, cysteamine can react with pantetheine, 4-phosphopantetheine, dephospho-CoA, CoA, or N-acetylcysteamine, with analogs or derivatives of these five thiols that can be degraded to the parent compounds in the gastrointestinal tract, or with any of the thiols that are present in the gastrointestinal tract. Fig.17 List other thiols that react to form Figure 18-20 Two cysteamines can be linked to dithiols via two disulfide bonds to produce another type of disulfide cysteamine precursor ( Fig.21 ). Figure 8 The chemical structure of such a cysteamine precursor is shown: one dihydrolipoic acid is disulfide bonded to two cysteamines. Upon reduction of the disulfide bond, the two cysteines are released along with dihydrolipoic acid, which is a strong reducing agent and can complement the therapeutic properties of cysteamine in certain disease settings.

[0168] In summary, cysteamine precursors can be divided into three major categories: (i) thiols that can be degraded to cysteamine, (ii) mixed disulfides including cysteamine, including disulfides formed with dithiols, (ii) disulfides including pantetheine, and (iii) disulfides including 4-phosphopantetheine, dephospho-CoA or CoA or suitable analogs or derivatives. Each of the latter three categories can be further broken down based on the second thiol: (a) pantetheine or a suitable analog or derivative, (b) 4-phosphopantetheine, dephospho-CoA or CoA or a suitable analog or derivative, or (c) thiols that are not themselves cysteamine precursors (e.g., L-cysteine, homocysteine, N-acetylcysteine, N-acetylcysteine ​​amide, N-acetylcysteine ​​ethyl ester, N-acetylcysteamine, L-cysteine ​​ethyl ester hydrochloride, L-cysteine ​​methyl ester hydrochloride, thiocysteine, allyl mercaptan, furfurylthiol, benzyl mercaptan, 3-mercaptopyruvic acid, thioterpineol, glutathione, cysteinylglycine, gamma-glutamylcysteine, gamma-glutamylcysteine ​​ethyl ester, glutathione monoethyl ester, glutathione diethyl ester, mercaptoethyl glucamide, thiosalicylic acid, thiocysteine, tiopronin or diethyldithiocarbamic acid). Dithiol compounds, such as dihydrolipoic acid, meso-2,3-dimercaptosuccinic acid (DMSA), 2,3-dimercaptopropanesulfonic acid (DMPS), 2,3-dimercapto-1-propanol, bucillamine or N,N'-bis(2-mercaptoethyl)isophthalamide, can also be combined with cysteamine, pantetheine, 4-phosphopantetheine, dephospho-CoA or CoA or suitable analogs or derivatives to form disulfides.

[0169] Pharmacological properties of cysteamine precursors

[0170] The temporal and spatial patterns of in vivo cysteamine production from cysteamine precursors can vary greatly depending on the type of cysteamine precursor. Cysteamine precursors that require multiple chemical and enzymatic reactions to produce cysteamine will produce cysteamine later on average than those that require only one step. This property of cysteamine precursors can be used to design a variety of pharmaceutical compositions with different in vivo cysteamine production rates and durations. In addition, the pharmaceutical composition can be administered in combination and proportion to produce the desired pharmacological results. For example, in order to provide elevated plasma cysteamine levels shortly after drug administration, cysteamine mixed disulfides can be administered. The only step required to produce cysteamine from cysteamine mixed disulfides is disulfide bond reduction. Depending on the identification of the second thiol, a second cysteamine can be produced after one or more degradation steps. The second cysteamine can only be produced after disulfide bond reduction and another step, so it will definitely be produced later than the first cysteamine, thereby extending the time for cysteamine to be produced in the intestine and absorbed into the blood. Due to the fact that cysteamine free base and cysteamine salts (e.g. and ) have a very short half-life, this extended generation of cysteamine from cysteamine precursors in vivo represents a significant advance over current therapeutic agents.

[0171] In one approach, if the second thiol is pantetheine (i.e., cysteamine-pantetheine disulfide), then a pantetheine enzyme cleavage step is necessary to generate the second cysteamine. Pantetheine enzymes are typically located on the surface of enterocytes and are therefore in contact with only a portion of the intestinal contents at any one time, thereby extending the time over which cysteamine is generated. This combination of early and late cysteamine generation from one disulfide bonded molecule has several advantages: (i) cysteamine becomes available upon disulfide bond reduction, providing an early therapeutic benefit, (ii) cleavage of pantetheine occurs over time (pantetheine enzymes are expressed at varying levels throughout the gastrointestinal tract), extending the duration of the therapeutic benefit, (iii) prolonging the generation of cysteamine over time and space by disulfide bond reduction and pantetheine cleavage, reducing peak cysteamine concentrations that are closely associated with side effects, while also (iv) avoiding pantetheine enzymes or cysteine ​​absorption mechanisms, such as saturation of transport by OCT. In short, prolonged elevation of blood cysteamine levels provides patients with a more effective drug and a less toxic and more convenient form of administration.

[0172] Alternatively, if the second thiol is L-cysteine ​​(i.e., cysteamine-L-cysteine ​​disulfide), only one cysteamine is generated upon disulfide reduction, and there is no prolonged cysteamine generation. However, as described below, cysteamine-L-cysteine ​​disulfide can be formulated to be released in almost any part of the gastrointestinal tract, including the ileum or colon, where cysteamine precursors that can rapidly release cysteamine may be useful. In addition, cysteine ​​has also been shown to enhance the activity of pantetheinease and has beneficial effects in several disease models. Therefore, cysteamine-L-cysteine ​​disulfide may be a useful supplement to another cysteamine precursor, or may be useful in treating diseases that respond to both cysteamine and cysteine.

[0173] Disulfides containing thiols that require two or more catabolic reactions to produce cysteamine, such as 4-phosphopantetheine, dephospho-coenzyme A or coenzyme A, or suitable analogs or derivatives thereof, may be more efficiently degraded in the small intestine, where they are exposed to the digestive enzymes present in pancreatic juice, than in the stomach or large intestine. Disulfides prepared by reacting two such thiols with each other, or with a thiol other than cysteamine, will begin to produce cysteamine at a later time point and for a longer period of time than, for example, cysteamine-L-cysteine ​​disulfide. On average, 4-phosphopantetheine, dephospho-coenzyme A or coenzyme A, or suitable analogs, will produce cysteamine later than pantetheine, and the same is true for disulfides containing these compounds.

[0174] Cysteamine precursors, such as pantetheine and compounds that can be degraded to pantetheine in the intestine, and disulfides containing any of these compounds all produce pantothenate and cysteamine after cleavage by pantetheinease. Pantothenate or vitamin B5 is a water-soluble compound that is present in the diet and synthesized by intestinal bacteria. When pantothenate is administered in large doses, the excess is excreted in the urine. The review of the Folic Acid, Other B Vitamins and Choline Expert Panel of the Standing Committee of the Institute of Medicine of the United States on the Scientific Assessment of Dietary Reference Intake (National Academies Press (US), 1998) on pantothenate found that: "No reports of side effects of oral pantothenic acid in humans or animals have been found."

[0175] Mixture of Cysteamine Precursors

[0176] The methods and compositions of the present invention may include a mixture of cysteamine precursors to take advantage of their different pharmacological properties. In particular, individualized improvement of cysteamine plasma levels (or personalized for the needs of a given patient) can be achieved by using a mixture of cysteamine precursors. For example, the above-mentioned cysteamine-pantetheine mixed disulfide fixes the ratio of cysteamine to pantetheine at 1:1. However, cysteamine is rapidly absorbed and cleared from the body (elimination half-life: about 25 minutes), producing a sharp peak in blood levels, while pantetheine provides cysteamine (by pantetheinease cleavage) for several hours. Therefore, a dose of cysteamine-pantetheine mixed disulfide that produces therapeutic cysteamine levels (cysteamine released when the disulfide bonds are reduced) early may produce subtherapeutic cysteamine levels later because the cysteamine production from pantetheine is spread over a longer period of time. Therefore, a 1:1 ratio of cysteamine: pantetheine may not be an ideal choice for a particular patient or purpose. Adding more pantetheine to the dosage form will maintain blood cysteamine in the therapeutic concentration range for a longer period of time. To increase the ratio of pantetheine to cysteamine, for example, thiol pantetheine or disulfide pantetheine or another disulfide containing pantetheine can be co-formulated or co-administered with cysteamine-pantetheine mixed disulfide to achieve blood cysteamine levels in the therapeutic range for a longer period of time. The ratio of the two cysteamine precursors can be adjusted to obtain the desired pharmacokinetic parameters, such as maximizing the area under the cysteamine concentration-time curve (AUC), or minimizing the peak concentration (Cmax) of cysteamine, or maximizing the trough concentration (Cmin), or maintaining cysteamine blood levels above a threshold, or any combination of these parameters.

[0177] Cysteamine precursors, such as 4-phosphopantetheine, dephospho-CoA or CoA, and disulfides formed from these three compounds require more catabolic steps to produce cysteamine than pantetheine (which requires only one step). Therefore, the rate of cysteamine production from those cysteamine precursors is slower and longer on average than from pantetheine or certain pantetheine disulfides. Therefore, co-administration or co-formulation of 4-phosphopantetheine, dephospho-CoA or CoA or their disulfides with cysteamine-pantetheine and optionally pantetheine or pantethine provides another method for controlling the pharmacokinetics of cysteamine by selecting appropriate cysteamine precursors. In particular, the use of such cysteamine precursors can be used to further extend the time for cysteamine production in the gastrointestinal tract.

[0178] Contains 4-phosphopantetheine, dephosphorylated CoA, and CoA disulfide

[0179] Fig.11 The classical biosynthetic pathway of CoA, schematically shown in , involves five steps catalyzed by four enzymes (CoA synthase catalyzes the last two steps). The initial step - phosphorylation of pantothenate by pantothenate kinase - controls the flux through the pathway. Until recently, it was believed that the intermediate compounds in the CoA synthesis (or catabolism) pathway were not effectively absorbed in the gastrointestinal tract. Instead, only the catabolites of pantetheine (pantothenate and cysteamine) were absorbed in the intestine. Two important results of the understanding of the CoA pathway for cysteamine precursor therapy are that (i) the cysteamine precursor must be degraded in the intestine to cysteamine, which is then absorbed and transported to the site of therapeutic effect (e.g., liver, central nervous system), and (ii) cellular CoA synthesis must start with pantothenate (because other metabolic intermediates do not cross the cell membrane).

[0180] However, 4-phosphopantetheine effectively crosses cell membranes (Srinivasan et al., Nature Chemical Biology 11:784 (2015)). This observation has implications for the design and use of the cysteamine precursors described herein to treat a variety of diseases and conditions. First, it allows for treatment methods involving in situ production of cysteamine in multiple tissues and organs (as opposed to the intestine), including diseased tissues. In a second aspect, it enables the delivery of a CoA precursor (4-phosphopantetheine) to cells downstream of the initial synthesis step catalyzed by pantothenate kinase, which can be used to treat subjects with pantothenate kinase deficiency. Methods for treating these two types of diseases using cysteamine precursors are described below and illustrated with several examples.

[0181] In one approach, diseases of the kidney, liver, lung, and connective tissue, as well as infectious diseases, can be effectively treated because these organs (and others) contain pantetheinase expressed from the VNN1 or VNN2 genes. The method involves (i) administering to a patient a cysteamine precursor that can be degraded in the intestine to produce one or two molecules of 4-phosphopantetheine, some of which will (ii) be taken up by intestinal epithelial cells and enter the blood (where 4-phosphopantetheine is very stable) and then, through the circulation, (iii) pass through the diseased organ, where (iv) it can be degraded by phosphatases and pantetheinase to produce cysteamine at the site of the disease.

[0182] Advantages of this treatment approach may include (i) higher cysteamine concentrations at the disease site per equivalent dose than would be achieved with intestinal absorbed cysteamine, (ii) lower plasma cysteamine concentrations with resulting lower toxicity (since 4-phosphopantetheine is a circulating delivery vehicle), (iii) longer blood half-life than cysteamine (over 3 hours for 4-phosphopantetheine versus about 25 minutes for cysteamine), which extends dosing intervals and thereby increases patient convenience, and (iv) the ability to selectively target cysteamine to disease tissues in which pantetheinease overexpression is pathogenic, including, for example, metabolic diseases such as NASH (Sato W. et al., Hepatol Res. 34:256 (2006)) and certain inflammatory diseases (Naquet P. et al., Biochem Soc Trans. 42:1094 (2014)). Inflammation is often present at sites of infection, so selective cysteamine production at sites of infection is also possible and useful in settings where cysteamine has antimicrobial, antiviral, or antiparasitic effects. Thus, 4'-phosphopantetheine can be absorbed in the intestine, circulate in the blood, and then degraded to cysteamine in organs or diseased tissues that express pancreatic proteases, either constitutively, as in the kidney, or as a manifestation of active disease, as in inflammation.

[0183] 4-Phosphopantetheine-producing disulfide for kidney disease

[0184] As described above, pantetheine enzymes (encoded by the VNN1 and VNN2 genes) are expressed at high levels in the kidney. Therefore, some of the circulating 4-phosphopantetheine will be degraded in the kidney to produce cysteamine. The advantages of kidney-specific cysteamine production include higher tissue levels than would be available by gastrointestinal absorption of cysteamine, and fewer side effects associated with elevated blood levels of cysteamine (e.g., foul-smelling breath and sweat, nausea, vomiting, anorexia, and stomach pain). Kidney diseases that respond to cysteamine therapy include fibrotic diseases (e.g., glomerulonephritis) as well as metabolic diseases, including nephrotic cystinosis (in which renal failure is a major complication that can be delayed by cysteamine therapy for up to ten years).

[0185] Cystinuria is another inherited kidney disease that is associated with recurrent kidney stones (nephrolithiasis). On average, adult patients require surgery every 3 years for pain, infection, or other complications related to kidney stones, and the average patient undergoes 7 kidney stone surgeries by middle age. Patients with cystinuria are at increased risk for kidney loss requiring nephrectomy. A small but significant proportion of cases (1-3%) progress to end-stage renal disease and must be treated with dialysis or a kidney transplant.

[0186] Cystinuria is caused by mutations in one of two genes (SLC3A1 and SLC7A9) encoding the low-affinity cystine transporter rBAT, a heterodimer. Disease transmission is autosomal recessive; individuals who inherit two defective copies of either gene develop cystinuria.

[0187] In healthy human subjects, only 0.4% of cystine filtered through the glomerulus ends up in the urine; the other 99.6% is reabsorbed in the proximal tubule by rBAT (and to a lesser extent by another transporter). When rBAT is defective, high concentrations of cystine remain in the urine as it pools in the renal pelvis. Cystine can precipitate as stones, which can cause ureteral obstruction and severe pain. Kidney stones also increase the risk of infection. (Not all patients with cystinuria develop stones; the spectrum of the disease is very broad).

[0188] Initial treatment for stone-forming cystinuria patients is to drink 5 liters of fluid per day and alkalinize the urine to around pH 7.5, which increases the solubility of cystine. Second-line treatment is administration of thiol compounds, which can form mixed disulfides with cysteine. Mixed disulfides are more soluble than cystine and therefore remain dissolved in the urine. Thiopenicillamine and tiopronin have been used in this way, but most patients do not tolerate them well. α-Mercaptopropionylglycine is also approved by the US FDA for cystinuria, but about one-third of patients cannot tolerate it.

[0189] Orally administered cysteamine precursors, which can be degraded to 4-phosphopanamide in the intestine, are then absorbed, enter the circulation, and are ultimately degraded to pantetheine, and then degraded to cysteamine by pantetheinease in the kidney, are a class of useful compounds for the treatment of cystinuria. Cysteamine readily forms mixed disulfides with cysteine ​​by disulfide exchange with cystine, and cysteamine-cysteine ​​disulfide is more soluble in aqueous solutions (e.g., urine) than cysteine. Because this treatment method requires the formation of cysteamine in the kidneys, a lower dose of cysteamine precursor (only a small portion of which reaches the kidneys) will be required than the dose required for cysteamine formed in and absorbed from the intestines.

[0190] Other renal diseases suitable for cysteamine therapy can be treated using similar approaches, including fibrotic diseases associated with oxidative damage and genetic diseases, including those caused by mutations that change arginine codons to cysteine ​​codons. The blood supply to the kidneys is a major part of cardiac output, ensuring that the majority of absorbed 4-phosphopantetheine is delivered to the kidneys.

[0191] More generally, cysteamine precursors that can be degraded to 4-phosphopantetheine (including 4-phosphopantetheine disulfide) are useful for providing therapeutic doses of cysteamine to all organs that express significant levels of phosphatases and pantetheinases. For example, lung diseases associated with oxidative damage can be treated.

[0192] Suitable cysteamine precursors for use in these treatment methods include disulfides containing coenzyme A, dephospho-coenzyme A, and 4'-phosphopantetheine, each of which can be degraded to 4'-phosphopantetheine in the gastrointestinal tract by disulfide reduction (in the case of disulfides containing 4'-phosphopantetheine), or by disulfide reduction followed by enzymatic degradation (in the case of disulfides containing coenzyme A and dephospho-coenzyme A). In some embodiments, cysteamine precursors that provide two molecules of 4'-phosphopantetheine are superior to those that provide one molecule. For example, 4'-phosphopantetheine-dephospho-coenzyme A mixed disulfide, or homodimeric 4'-phosphopantetheine disulfide can provide more in situ cysteamine generation capacity than cysteine-4-phosphopantetheine mixed disulfide. Another class of useful cysteamine precursors includes dithiols linked to one or two thiols that can be degraded to 4'-phosphopantetheine. For example, dihydrolipoic acid is linked to one or two 4'-phosphopantetheine molecules via a disulfide bond.

[0193] More generally, any disulfide consisting of 4'-phosphopantetheine, dephospho-CoA or CoA, and another thiol, after reduction of the disulfide bond and (in the case of dephospho-CoA or CoA) partial degradation in the gastrointestinal tract, can be a source of 4'-phosphopantetheine. After transport across the gastrointestinal epithelium, and after reaching the circulation, 4'-phosphopantetheine may be degraded by serum phosphatases to panthenine (however, this is a slow reaction) and then by pantetheinases in the blood to cysteamine and pantothenate (a fast reaction), or 4'-phosphopantetheine may be degraded upon contact with tissues expressing phosphatases and pantetheinases. Phosphatases, including, for example, acid phosphatases encoded by the ACP1, ACP2, ACP5, and ACPT genes, and alkaline phosphatases encoded by the ALPI, ALPL, ALPP, and ALPPL2 genes, are (commonly) widely expressed. Tissues expressing the VNN1-encoded pantetheinase include the liver, kidney, heart, and gastrointestinal tract, while the VNN2-encoded pantetheinase is expressed in the kidney, bladder, pancreas, spleen, lung, hematopoietic system (e.g., bone marrow, lymph nodes, tonsils), connective tissue (smooth muscle, adipose tissue), and to a lesser extent, in the thyroid, adrenal glands, heart, and reproductive organs (testes, ovaries, fallopian tubes, endometrium). The VNN3 gene has been described as a pseudogene, but several reports have described differential VNN3 expression, suggesting that it has a functional role. VNN3 is widely expressed. Data on tissue and cell line expression of vanin family genes can be found in public databases, such as Protein Atlas (www.proteinatlas.org) and several publications (e.g. Jansen, PAM et al. Expression of the Vanin Gene Family in Normal and Inflamed Human Skin: Induction by Proinflammatory Cytokines. Investigative Dermatology 129:2167-2174, 2009).

[0194] Pantothenate kinase-associated neurodegeneration (PKAN)

[0195] A second therapeutic approach that can therapeutically use the disulfide cysteamine precursor that delivers 4-phosphopantetheine is illustrated by a disease called pantothenate kinase-associated neurodegeneration (PKAN). There is preclinical and clinical evidence that cysteamine has therapeutic effects in several neurodegenerative diseases, including Parkinson's disease, Huntington's disease, and neurodegeneration with brain iron accumulation (NBIA). NBIA refers to a group of rare, clinically heterogeneous diseases associated with progressive extrapyramidal signs, motor delays, and cognitive decline, among other symptoms. The age of onset ranges from infancy to late adulthood. Presenting symptoms vary widely, and the rate of progression varies. Therefore, the diagnosis is usually suggested by observing abnormal iron accumulation in the basal ganglia on a brain MRI scan. Cerebellar atrophy may also be present. NBIA is associated with mutations in any of 10 genes: PANK2, PLA2G6, C19orf12, FA2H, ATP13A2, WDR45, COASY, FTL, CP, and DCAF17. Except for mutations in the WDR45 gene located on chromosome X, NBIA is transmitted as an autosomal recessive disease.

[0196] The most common type of NBIA (30-50% of all cases) is pantothenate kinase-associated neurodegeneration (PKAN), which is caused by mutations in the gene encoding pantothenate kinase 2 (PANK2). Pantothenate kinase 2 is localized to the mitochondria and phosphorylates pantothenate to produce 4-phosphopanthenate, which is converted to 4-phosphopanthenoyl-cysteine, which is subsequently decarboxylated to 4-phosphopantheine (see Fig.11 ). Providing a source of 4'-phosphopantetheine, a metabolite downstream of the PANK2 catalytic step, overcomes the requirement for a functional PANK2 enzyme. Both CoA and dephospho-CoA can be degraded to 4'-phosphopantetheine in the gastrointestinal tract. Therefore, any disulfide composed of 4'-phosphopantetheine, dephospho-CoA, or CoA and another thiol can complement the deficiency of PANK2.

[0197] In certain embodiments, a compound containing 4'-phosphopantetheine, dephosphorylated CoA, or a disulfide of CoA can be administered to a patient suffering from PANK2 deficiency to improve disease symptoms. Specifically, Fig.19 (Tables 1C and 1D), Fig. 20 (Table 1E) and Fig.21 The disulfides shown in FIG. 5 (a subset of compounds including at least one 4′-phosphopantetheine, one dephospho-CoA, or one CoA; thiols 3, 4, and 5, respectively, according to the nomenclature in the figure).

[0198] The disulfide cysteamine precursors of the present application are particularly suitable for implementing the above-mentioned treatment methods. Disulfides provide an effective way to deliver 4'-phosphopantetheine (and ultimately cysteamine) because (i) disulfides are stable in air (i.e., stable to oxygen) and are therefore easier to formulate and store than thiols and can be stable for a long time, (ii) the thiol group is protected until the disulfide is reduced in the small intestine, close to the absorption site, and (iii) a second thiol with additive or complementary therapeutic properties can be delivered simultaneously. For example, in some embodiments, cysteamine-4-phosphopantetheine mixed disulfide, cysteamine-dephospho-CoA mixed disulfide and cysteamine-CoA mixed disulfide are useful therapeutic compounds.

[0199] N-Acetylcysteamine disulfide (Compound 3)

[0200] In certain embodiments, the cysteamine precursor is compound 3 or a pharmaceutically acceptable salt thereof. Homodimers of two N-acetylcysteamines are effective delivery vehicles for cysteamine, which can be used in two ways: they can be administered as a single agent, or in combination with one or more other cysteamine precursors. In both cases, the goal is to provide sustained blood N-acetylcysteamine and cysteamine levels within the therapeutic range (e.g., greater than 5 micromolar but less than 75 micromolar in plasma, or greater than 10 micromolar but less than 65 micromolar) for the longest possible time.

[0201] In those embodiments where compound 3 is administered as a single agent, it is preferably formulated in a manner that provides at least two release profiles: an early release profile and a late release profile. Early release formulations (also referred to as immediate release) begin to release compound 3 within ten minutes after oral administration. Late release formulations begin to release a considerable amount of compound 3 after about two to four hours. The two formulations are blended so that they can be taken together in a single dosage form. The ratio of the dose of compound 3 formulated for early release to the dose formulated for late release is at least 1:2, and can be within the range of up to 1:8 (e.g., 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8). In one embodiment, both early and late release dosage components are formulated into microbeads. Microbeads with two release profiles can be manufactured separately and then mixed together in a desired ratio to produce a dosage form (e.g., in a sachet). The method facilitates the manufacture of doses with different ratios of early and delayed release microbeads. Different ratios of the two types of microbeads can be used to individualize treatment for patients.

[0202] In some embodiments, compound 3 is formulated with three release profiles: early, intermediate and late. The early release component begins to release compound 3 within ten minutes after oral administration, the intermediate release component begins to release a considerable amount of compound 3 about two to four hours after the dose is taken, and the late preparation begins to release about 3 to 6 hours after taking. The three release components are blended so that they can be taken together in a single dosage form. The ratio of compound 3 in the three dosage components (early: intermediate: late) is at least 1:2:2. The compound 3 in the intermediate and late components can be independently varied between 2-8 times the amount in the early component, however, the late release component is at least equal to the intermediate release component (e.g., 1:2:8, 1:4:6, 1:4:4, 1:5:5, 1:6:8, etc.). In one embodiment, the early, intermediate and late release dosage components are all formulated into microbeads, which can be manufactured separately and then mixed together in a desired ratio (e.g., a ratio tailored for gastrointestinal tract and liver physiology) to produce a dosage form (e.g., in a sachet).

[0203] In certain embodiments, the late dosage component, or both the intermediate and late dosage components are formulated for prolonged residence time in the stomach (gastric retentive formulations). In other embodiments, the late or intermediate and late dosage components are both formulated for sustained release. In certain embodiments, the two-component or three-component dosage form is ingested with a meal, preferably a meal containing at least 500 calories, more preferably at least 700 calories. Preferably, the meal is nutritionally complex (e.g., contains several types of whole foods), and at least 25% of the calories are derived from fat.

[0204] In those embodiments where compound 3 is co-administered with at least one additional cysteamine precursor, it is formulated to provide a release profile that is complementary to the release profile of at least one other cysteamine precursor, so that the cysteamine precursors together provide a plasma cysteamine concentration within the therapeutic range that lasts as long as possible. In preferred embodiments, compound 3 provides cysteamine within the first 1 to 3 hours after administration, and at least one additional cysteamine precursor provides cysteamine within 3-6, 3-8, 4-10 or 3-12 hours, such as 12 hours, between doses. In such embodiments, compound 3 may be formulated for immediate release. In certain embodiments, at least one additional cysteamine precursor co-administered with compound 3 is compound 1 or a pharmaceutically acceptable salt thereof.

[0205] Enhancers for the production of cysteamine from cysteamine precursors

[0206] The methods and compositions of the present invention can utilize cysteamine production enhancers. Additional flexibility in controlling cysteamine blood levels can be achieved by combining a cysteamine precursor with an enhancer for the steps required to chemically and enzymatically decompose the cysteamine precursor into cysteamine in the intestine to absorb cysteamine into the blood and prevent rapid catabolism of cysteamine in the intestine, blood, or tissues. Specific enhancers exist for each of these steps. Thus, any cysteamine precursor described herein can be optionally co-formulated or co-administered or sequentially administered with an agent that enhances cysteamine production or intestinal absorption or slows cysteamine decomposition.

[0207] The first step in converting a disulfide cysteamine precursor to cysteamine is to reduce the disulfide to produce two thiols. The redox environment in the gastrointestinal tract may not contain sufficient reducing equivalents to quantitatively reduce the cysteamine precursor to its respective thiol, thereby limiting cysteamine production. For example, the concentrations of the reducing agents glutathione and cysteine ​​in gastric juice are very low or undetectable (see Nalini et al., Biol Int. 32:449 (1994)). Furthermore, in a small clinical study of high-dose pantethine, most of the pantethine was excreted unchanged in the feces, apparently reflecting incomplete disulfide bond reduction (see Wittwer et al., J. Exp. Med. 76:4 (1985)). To address this potential limitation, the reducing agent can be co-administered or co-formulated with the disulfide cysteamine precursor, or administered before or after the cysteamine precursor, so that it is available when and where it is needed. The reducing agent can promote disulfide bond reduction, releasing both thiols, or it can promote a thiol-disulfide exchange reaction, in which a thiol (A) and a disulfide (BC) react to produce a new disulfide (AB or AC) and a thiol (B or C), thereby releasing one of the thiols (e.g., cysteamine, pantethine, or a compound that can be degraded to cysteamine) from the original disulfide.

[0208] A variety of reducing agents can be used to promote disulfide reduction or thiol-disulfide exchange in the gastrointestinal tract. Reducing agents can directly reduce disulfide cysteamine precursors, or they can reduce other disulfides, such as glutathione disulfide, which in turn reduces disulfide cysteamine precursors or participates in thiol-disulfide exchange. In some embodiments, physiological compounds (i.e., substances normally found in the body) or food-derived compounds with reducing ability can be used to promote the reduction of disulfide cysteamine precursors, or promote thiol-disulfide exchange reactions. Physiological reducing agents, such as thiol glutathione or cysteine ​​(both present in the small intestine due to bile and enterocyte secretion), can be used, as can other compounds normally present in the body and in food, such as ascorbic acid (vitamin C), tocopherol (vitamin E) or dithiol dihydrolipoic acid, an effective reducing agent. Other widely available reducing agents can also be used, including thiols, such as N-acetylcysteine ​​and non-thiols, such as nicotinamide adenine dinucleotide (NADH), which can also be used. Fig.17 Any of the thiols listed in . Preferred reducing agents include those known to be safe at the doses required to cause changes in the local gastrointestinal redox environment. Up to several grams of reducing agent may be required per dosing period, for example 0.5-5 grams. Disulfide cysteamine precursors that may benefit from co-administration of reducing agents are shown in Fig.13 Specifically, compounds 1-3 may benefit from co-administration or appropriate timed subsequent administration of one or more reducing agents, as described herein. Two or more reducing agents may be combined. Preferably, the molecular weight of the reducing agent is less than 300 Daltons.

[0209] Adults produce 400 to over 1,000 milliliters (ml) of bile per day; the average volume has been estimated to be 750 ml (Boyer, Compr. Physiol. 3:32 (2013)). Bile is produced in the liver throughout the day. Some is stored in the gallbladder, while the remainder provides a steady, slow flow of bile, even in the fasting state (bile serves an excretory function as well as aiding digestion and fat absorption). Meals stimulate duodenal secretion of the peptide hormones secretin and cholecystokinin, and they stimulate bile production and gallbladder contraction, respectively. The concentration of thiols in bile is about 4 mM, consisting primarily of glutathione, but also includes gamma-glutamylcysteine, cysteinylglycine, and cysteine ​​(Eberle et al., J Biol. Chem. 256:2115 (1981); Abbott & Meister, J Biol. Chem. 258:6193 (1984))

[0210] Cysteine ​​and, to a lesser extent, glutathione are also secreted into the gastrointestinal lumen by intestinal epithelial cells to regulate the intraluminal redox potential. The concentration of thiol in the intestinal fluid from the rat jejunum has been directly measured, independent of the contribution of bile. The range for fasted rats is 60-200 μM, and the range for fed animals is 120-300 μM (Hagen et al., Am. J. Physiol. 259: G524 (1990); Dahm and Jones, Am. J. Physiol. 267: G292 (1994)). In addition, unlike bile secretion, the maintenance of lumen thiol levels is a dynamic process, so at least to some extent, the increase in cysteine ​​produced by intestinal epithelial cells can offset the increase in intestinal levels of oxidized molecules (such as disulfide cysteamine precursors) (Dahm and Jones, J. Nutr. 130: 2739 (2000)). The human small intestine secretes about 1.8 liters of fluid per day, and the colon secretes about 0.2 liters, for a total of about 2 liters. The concentration of thiols (mainly cysteine) in the secretions varies depending on the region of the gastrointestinal tract, the luminal redox potential, and the diet.

[0211] The total concentration of gastrointestinal thiols (bile and enterocyte derived) will affect the rate and extent of disulfide bond reduction and / or thiol-disulfide exchange necessary to convert cysteamine precursors to thiols, which is the necessary first step in their degradation to cysteamine. The amount of reducing equivalents available in the upper gastrointestinal tract after a meal can be estimated by making some assumptions. For example, if we assume that (i) 200 ml of bile is secreted within one hour after a large meal, followed by another 100 ml secreted over the next 2-3 hours, and (ii) the thiol concentration in bile is 4 mM, then the milliequivalents of thiol reducing power in bile are 0.3 L x 0.004 mol / L = 0.0012 moles of thiol (1.2 mmol). Further assume that the small intestinal enterocytes secrete an additional 400 ml within 4 hours after a meal, and that the thiol concentration is 200 μM, providing an additional 0.4 L x 0.0002 mol / L = 80 micromoles of luminal thiols. Combined with bile thiols, a total of approximately 1.28 mmol is available to reduce dietary disulfides and maintain intestinal redox potential. This is not an estimate of the upper limit of thiol secretion, which can be quite large, but rather a normal level of thiols in the small intestine several hours after a meal.

[0212] A 0.5 gram dose of cysteamine-(R)-pantetheine disulfide (MW: 353.52 g / L) contains approximately 1.41 mmol of disulfide bonds and can therefore in principle be converted to thiols (either by disulfide reduction or thiol-disulfide exchange) via endogenous levels of thiols (ignoring the need for luminal thiols for other physiological purposes).

[0213] More generally, doses of cysteamine precursors exceeding 1.25 mmoles may benefit from co-administration of an exogenous reducing agent. Many natural products commonly found in the diet can provide reducing power to facilitate cysteamine precursor reduction or thiol-disulfide bond exchange, including the major endogenous intestinal thiols cysteine ​​or glutathione. Cysteine ​​or glutathione analogs, such as N-acetylcysteine, N-acetylcysteine ​​ethyl ester or N-acetylcysteine ​​amide, may also be used. Ascorbic acid is another agent that can reduce disulfide bonds (Giustarini et al. Nitric Oxide 19:252 (2008)). The ascorbic acid dose required to provide the reducing power equivalent to, for example, 1 gram of the disulfide cysteamine precursor cysteamine-(R)-pantethioacetic acid disulfide may be calculated as follows:

[0214] The molecular weight of ascorbic acid (176.12 g / mol) is approximately half that of cysteamine-(R)-pantetheine disulfide (also known as Compound 1) (353.52 g / mol). Thus, 1 gram of ascorbic acid has a reducing equivalent that is equimolar to the number of disulfide bonds in a 2 gram dose of Compound 1. Although the U.S. Food and Nutrition Board recommends a daily intake of only 75 mg of vitamin C for women and 90 mg for men, many people take much higher doses, including 1 gram or more per day, apparently with few or no side effects.

[0215] Similar reasoning provides the amount of other reducing agents needed to match the dose of Compound 1 on a molar basis. For example, cysteine ​​(molecular weight: 121.15 Daltons) is approximately 34% of the mass of Compound 1; N-acetylcysteine ​​(molecular weight: 163.195 Daltons) is approximately 46% of the mass of Compound 1; alpha lipoic acid (molecular weight: 208.34 Daltons) is approximately 59% of the mass of Compound 1, and so on. Alpha lipoic acid and N-acetylcysteine ​​are widely available in 600 and 1,000 mg capsules and tablets, respectively, in vitamin stores and on the Internet, including sustained release formulations, indicating their non-regulated state. Similar calculations can be made for other disulfide cysteamine precursors based on their molecular weights.

[0216] Since bile is the major source of thiols and bile is continuously diluted along the length of the small and large intestines, the additional reducing power of the cysteamine precursor reduction is more useful in the jejunum, ileum, or colon than in the duodenum. Therefore, formulations designed to release reducing agents in the distal small and / or large intestine can be particularly useful supplements to the disulfide cysteamine precursor. Sustained release formulations of ascorbic acid and other reducing agents are commercially available. Alternatively, ascorbic acid can be co-formulated with the cysteamine precursor to ensure co-delivery of the two agents.

[0217] The electrochemical potentials (reduction strengths) associated with various bioreducing agents are known and provide guidance for their use, however the ability of these agents to reduce various disulfide cysteamine precursors is best determined empirically.

[0218] The kinetics of thiol-disulfide exchange reactions are strongly affected by pH (i.e., delayed by low pH). Such exchange reactions are another mechanism for disulfide bond reduction, for release of cysteamine from cysteamine mixed disulfides, or release of pantetheine from pantetheine disulfide, etc. To enhance the kinetics of thiol-disulfide exchange reactions, basic compounds can be co-administered or co-formulated with the disulfide cysteamine precursor so that it is available when and where it is needed. Physiological compounds present in high concentrations in pancreatic juice, such as bicarbonate, can be used to adjust the local gastrointestinal pH.

[0219] An essential step in converting many cysteamine precursors to cysteamine is the enzyme pantetheinase, which is encoded by the VNN1 and VNN2 genes in humans. Pantetheine and pantetheine disulfide, including pantethine, require this enzyme to produce cysteamine. Pantetheinase is also ultimately required for the production of cysteamine from compounds that can be converted to pantetheine in the gastrointestinal tract, such as 4-phosphopantetheine, dephospho-CoA, CoA, and suitable analogs and derivatives. Normal levels of pantetheinase in the gastrointestinal tract may not be sufficient to quantitatively cleave all pantetheine molecules provided by pharmacological doses. To address this limitation, compounds that induce pantetheinase expression can be co-administered or co-formulated with cysteamine precursors containing pantetheine or compounds that can be converted to pantetheine to increase the amount of pantetheinase in the gastrointestinal tract at the time and place of need (i.e., the time and place where pantetheine is present). Agents that induce pantetheinase expression include physiological substances, including certain food ingredients, and pharmacological agents, including FDA-approved drugs. Physiological inducers of VNN1 include a variety of substances that activate the transcription factor NF-E2-related factor-2 (more commonly abbreviated as Nrf2), peroxisome proliferator-activated receptor alpha (PPARα), and peroxisome proliferator-activated receptor gamma (PPARγ).

[0220] Factors that induce Nrf2 activation (via translocation to the nucleus) include natural products and certain drugs. For example, sulforaphane, an isothiocyanate present in cruciferous vegetables (e.g., broccoli, Brussels sprouts, cabbage, and cauliflower), induces VNN1 expression via Nrf2. Foods rich in sulforaphane (e.g., broccoli sprouts) can be used to induce pantetheine enzyme expression, or sulforaphane can be administered as a pure substance in a pharmaceutical composition. Certain food-borne thiols, including S-allylcysteine ​​and diallyl trisulfide (both present in onions, garlic, and garlic extracts) also induce Nfr2 and can be included in a diet administered with a cysteamine precursor. Alternatively, either compound can be obtained in pure form and administered in the form of a pharmaceutical composition. Lipids present in certain foods, including some polyunsaturated fatty acids, oxidized fats, omega-3 fatty acids, and the naturally occurring lipid octadecene ethanolamide (OEA), also induce Nrf2 and / or PPARα. Foods rich in oxidized fats include French fries and other fried foods, which can be co-administered with cysteamine precursors that require pantetheine enzyme cleavage to produce cysteamine. Omega-3 fatty acids are found in fish and are available in fish oil extracts and in pure form for use in pharmaceutical compositions.

[0221] Naturally occurring PPARα ligands include endogenous compounds such as eicosatetraenoic acid and eicosatetraenoic acid metabolites, including leukotriene B4,8-hydroxyeicosatetraenoic acid and certain members of the family. Pharmacology PPARα ligands include fibrates (e.g., bezafibrate, ciprofibrate, clinofibrate, clofibrate, fenofibrate, gemfibrozil), pirinixic acid (Wy14643) and di(2-ethylhexyl) phthalate (DEHP). Any natural or synthetic PPARα ligand can be co-formulated or co-administered with a cysteamine precursor that requires pantetheine enzyme cleavage to produce cysteamine. For a review of PPAR ligands, see Grygiel-Gorniak, B. Nutrition Journal 13:17 (2014).

[0222] Natural and synthetic PPARG agonists can also be used to stimulate Nrf2-mediated transcription of the pantetheine enzyme genes VNN1 and / or VNN2. Natural product PPARG agonists include eicosatetraenoic acid and metabolites, including 15-hydroxyeicosatetraenoic acid (15(S)-HETE, 15(R)-HETE, and 15(S)-HpETE), 9-hydroxyoctadecadienoic acid, 13-hydroxyoctadecadienoic acid, 15-deoxy-(δ)12,14-prostaglandin J2 and prostaglandin PGJ2, as well as honokiol, amorphoflavin 1, amorphoflavin B, and amorphastilbol. Other natural products activate both PPARG and PPARA, including genistein, biotin A, sargaquinoic acid, sargahydroquinoic acid, resveratrol, and amorphastilbol. Natural product PPARG agonists are described and reviewed in Wang et al., Biochemical Pharmacology 92:73 (2014). Pharmacological PPARγ agonists include thiazolidinediones (also known as glitazones, such as pioglitazone, rosiglitazone, lobeglitazone). Heme derived from red meat also induces VNN1 expression. PPARA or PPARG agonists that stimulate pantetheine expression can be co-administered or co-formulated with a cysteamine precursor containing pantetheine or a compound that can be degraded to pantetheine in the intestine. Two or more inducers of pantetheine expression can be combined to enhance expression or reduce the dose of any single agent.

[0223] Another important step in making cysteamine bioavailable throughout the body is absorption across the enterocytes. Cysteamine absorption from the intestinal lumen is mediated by transporters, and its native levels may not be sufficient to transport all the cysteamine in the intestinal lumen. Therefore, compounds that induce the expression of cysteamine transporters can be co-administered or co-formulated with cysteamine precursors to enhance cysteamine absorption. Cysteamine is transported across the intestinal epithelium by organic cation transporters 1, 2, and 3 (encoded by OCT1, OCT2, and OCT3 genes, also referred to as SLC22A1, SLC22A2, and SLC22A3 genes) and possibly by other transporters. Inducers of organic cation transporter expression include transcription factors PPARα and PPARγ, pregnane X receptors (PXR), retinoic acid receptors (RARs), and (in the case of OCT1) RXR receptors, as well as glucocorticoid receptors. Therefore, natural or synthetic ligands of these receptors can be used to increase OCT expression and thus enhance the absorption of cysteamine by enterocytes. Agents that stimulate cysteamine transporter expression can be co-administered or co-formulated with any type of cysteamine precursor.

[0224] The elimination half-life of cysteamine in humans (the time from Cmax to half Cmax after intravenous injection) is about 25 minutes. Some cysteamine doses are converted into a variety of disulfides, including mixed disulfides with free cysteine, with cysteinyl residues of proteins, and with glutathione. No pharmacological intervention can prevent this elimination mode, and in any case, the collection of cysteamine can still be used for further disulfide exchange. However, there is a cysteamine catabolic pathway that irreversibly converts cysteamine, effectively removing it from the body. The enzyme cysteamine dioxygenase oxidizes cysteamine to hypotaurine, which is an important factor in cysteamine elimination. Subsequently, hypotaurine is further oxidized to taurine. The co-administration of cysteamine precursors with one or both of these catabolites can slow down cysteamine catabolism by end-product inhibition. Therefore, in certain embodiments, cysteamine precursors are co-prepared, co-administered, or administered with hypotaurine and / or taurine in the best time sequence.

[0225] Fig.13 The classification of cysteamine precursors based on their thiol composition, the number of cysteamine molecules that can be produced, the metabolic steps required to produce cysteamine, potentially useful enhancers of cysteamine production in vivo, and the cysteamine release profile are shown. Fig.13 Compounds that alkalinize the intestinal contents and thus promote thiol-disulfide exchange and / or disulfide bond reduction ( Fig.13 ) is suitable for disulfide cysteamine precursors.

[0226] In summary, flexibility in controlling cysteamine blood levels can be achieved by co-formulating or co-administering (i) one or more cysteamine precursors with selected properties, (ii) one or more enhancers of in vivo cysteamine precursor breakdown and / or cysteamine absorption, (iii) one or more cysteamine catabolism inhibitors, using (iv) one or more types of formulations (e.g., immediate, delayed, sustained, gastroretentive, or colon targeted or a combination), and (v) a dosing regimen that enables optimal co-delivery of the cysteamine precursor and enhancer to the targeted segment of the gastrointestinal tract in amounts that can be effectively degraded and absorbed. The result of personalized application of these tools is sustained cysteamine blood levels within the therapeutic range for extended periods of time, resulting in superior pharmacological effects on the disease compared to existing compounds and formulations.

[0227] Pharmaceutical composition

[0228] The present invention provides compositions formulated to achieve therapeutically effective plasma concentrations of cysteamine over extended periods of time in order to: (i) reduce side effects associated with peak concentrations of cysteamine, (ii) reduce undertreatment caused by subtherapeutic trough concentrations of cysteamine and (iii) improve patient convenience by reducing daily doses and, therefore, improving compliance with treatment. The compounds and formulations of the present invention are also designed to (i) provide improved organoleptic properties compared to existing cysteamine formulations, (ii) reduce contact of free cysteamine with the gastric epithelium, which is a known source of gastrointestinal side effects, (ii) minimize the dose of cysteamine precursor required to achieve therapeutic cysteamine blood levels by matching the dose and delivery site with the relevant digestion and absorption processes in the gastrointestinal tract, which can be achieved by: (iii) optimizing cysteamine precursor breakdown and absorption by co-formulation or co-administration with enhancers of these processes.

[0229] For the compositions of the present invention, pharmaceutical excipients are included in all formulations to prevent the cysteamine precursor or its salt from being exposed to the oral cavity. Formulation methods for masking bitter or other unpleasant tastes include coatings, which can be applied in multiple layers. Flavors and dyes can also be used. Methods for producing pharmaceutical compositions with acceptable mouthfeel and / or taste are known in the art (e.g., see textbooks on pharmaceutical preparations cited elsewhere; patent literature also provides methods for preparing organoleptically acceptable pharmaceutical compositions (see, e.g., U.S. Patent Publication No. 20100062988).

[0230] Gastric retentive composition

[0231] The first composition provides a cysteamine precursor or a salt thereof in a gastric retentive formulation. A variety of gastric retentive technologies are known in the art, several of which have been successfully used in commercially available products. For a review, see, for example, Pahwa et al., Recent Patents in Drug Delivery and Formulation, 6:278 (2012); and Hou et al., Gastric retentive dosage forms: a review. Critical Reviews in Therapeutic Drug Carrier Systems 20:459 (2003).

[0232] Gastric retentive formulations provide sustained release of cysteamine precursors in the stomach. Depending on the type of cysteamine precursor, subsequent in vivo cysteamine production can begin in the stomach or in the small intestine, which is the most efficient tissue for absorbing cysteamine. Some cysteamine precursors can continue to be converted into cysteamine in the large intestine, even if released from the pharmaceutical composition in the stomach or small intestine. For example, a disulfide cysteamine precursor released in the stomach can be mainly maintained in an oxidized state in the acidic oxidative environment of the stomach, and then begins to release cysteamine after encountering a reducing agent (e.g., bile glutathione) in the small intestine. During 1-4 hours, preferably 1-6 hours, more preferably 1-8 hours, 1-10 hours or longer after ingestion, the gastric retentive composition will produce elevated blood cysteamine levels.

[0233] With the treatment of cysteamine bitartrate (see e.g. Compared with the recommendation of FDA Full Prescribing Information, the gastric retention preparation of cysteamine precursor should be administered with food, preferably with a meal containing sufficient calories and nutritional density to slow down gastric emptying. Nutrient-dense meals trigger osmotic pressure receptors and chemoreceptors in the small intestine (and to a lesser extent in the stomach), which have the effect of stimulating nerve and hormone signals, which reduces gastric motility and thus delays emptying. Delaying gastric emptying is a mechanism for prolonging the effect of gastric retention compositions. However, filling the stomach with a large amount of food or liquid helps to promote gastric motility and accelerate emptying, so nutritional density is a more important dietary characteristic than volume. Solid foods that must be ground into small particles in the gastric antrum and pylorus before being discharged into the duodenum can prolong gastric retention compared with liquid or semi-liquid foods. In liquid foods, high viscosity liquids can slow down gastric emptying relative to low viscosity liquids. Foods with high osmotic content trigger duodenal osmotic pressure receptors to transmit signals that slow down gastric emptying. Release of cysteamine precursors in the stomach (eg, from a gastro-retentive formulation) can increase the osmotic pressure of the gastric contents, thereby increasing the osmotic pressure of the duodenal contents.

[0234] In certain embodiments, disulfide cysteamine precursors are preferred for use in gastroretentive formulations because the acidic oxidative environment of the stomach tends to maintain the disulfide in its oxidized form, thereby limiting exposure of gastric epithelial cells to cysteamine, which is believed to be a cause of cysteamine toxicity. Upon entering the duodenum and mixing with bile containing high (millimolar) concentrations of glutathione, cysteine, and other reducing agents, the disulfide will be reduced, thereby generating a free thiol where it is exposed to pantetheinease and cysteamine transporter expressed on enterocytes.

[0235] The presence of fat in the small intestine is the most potent known inhibitor of gastric emptying and results in relaxation of the proximal stomach and contraction of the reduced pyloric region. Once the fat is absorbed in the small intestine and no longer triggers inhibitory signals to the stomach, gastric motility resumes its normal pattern. Therefore, gastroretentive formulations are ideally administered with a meal containing fatty foods. Protein-rich meals will also slow gastric emptying, but to a lesser extent, and carbohydrate-rich meals to an even lesser extent.

[0236] Gastric retentive compositions can also be administered with compounds that slow gastric emptying, including certain lipids, such as fatty acids with at least 12 carbon atoms, which stimulate enteroendocrine cells to release cholecystokinin and reduce gastric motility, while fatty acids with shorter carbon atoms are less effective. In some embodiments, food or meals can be supplemented with fatty acids or triglycerides containing fatty acids with 12 or longer carbon chains (e.g., oleic acid, myristic acid, triethanolamine myristic acid, fatty acid salts).

[0237] When fat and protein arrive in the duodenum, they stimulate the secretion of several intestinal hormones, including gastric hormones, cholecystokinin (CCK) and glucagon-like peptide 1 (GLP1). CCK slows down gastric emptying by binding to CCK1 receptor (abbreviated as CCK1R, formerly known as CCK-A receptor). In certain embodiments, orally active CCK agonists or mimetics, positive allosteric modulators of CCK1R, or agents that promote endogenous CCK release, or inhibit CCK degradation, or extend the effect of CCK by some combination of these or other mechanisms are administered together with gastric retention agents to slow down gastric emptying and extend the gastric retention of gastric retention compositions. CCK is a peptide that exists in several forms (e.g., CCK-8, CCK-53) within the range of 8 amino acids to 53 amino acids. Oral administration of peptides is ineffective because they are digested in the gastrointestinal tract. Small molecule CCK agonists have been developed and tested by several research groups. For example, SR-146,131 and related compounds were developed by scientists at Sanofi (US Pat. Nos. 5,731,340 and 6,380,230, incorporated herein by reference).

[0238] Certain protease inhibitors induce CCK production or release, or extend its half-life, or otherwise enhance its action, including food-derived mixtures and pure compounds. For example, the intake of protease inhibitor concentrates derived from potatoes is associated with elevated CCK levels, as is the intake of soy peptone and soy bean β-conglycinin. Camostate is a synthetic protease inhibitor with pleiotropic effects, including stimulating endogenous CCK release and thereby slowing gastric emptying. Camostate mesylate is a pharmaceutical salt widely used in humans. FOY-251 is an active metabolite of camostate. In some embodiments, agents that stimulate CCK production or release, or extend CCK half-life or otherwise enhance CCK action are co-formulated or co-administered with a gastric retention composition in an amount that slows gastric emptying. In some embodiments, camostat, FOY-251, or a prodrug, derivative, or active metabolite of camostat, or a pharmaceutically acceptable salt thereof, is co-formulated or co-administered with the gastroretentive composition in an amount between 50-300 mg / kg, or between 100-250 mg / kg.

[0239] Gastric emptying is also slowed by acidification of chyme. For example, citric acid and acetic acid have been shown to delay gastric emptying. In some embodiments, the food or meal includes a natural source of citric acid (e.g., fruit or juice from oranges, lemons, limes, grapefruits, or other citrus-rich fruits) or acetic acid (e.g., vinegar, pickles or other pickled vegetables) or lactic acid (e.g., sauerkraut or kimchi). In some embodiments, an acidic food or liquid in an amount sufficient to reduce the pH of gastric chyme to less than pH 4 or less than pH 3.5 is administered with the gastric retentive composition.

[0240] Glucagon-like peptide-1 (GLP1) is another gut hormone that is released by cells in the duodenum in response to food, particularly ingested fat, and affects gastric emptying. Several research groups have discovered orally administered GLP1 receptor agonists (e.g., Sloop et al., Diabetes 59:3099 (2010)). Positive allosteric modulators of the GLP1 receptor that are not agonists themselves but potentiate endogenous GLP1 are another class of GLP1R stimulators (e.g., Wootten et al., J. Pharmacol. Exp. Ther. 336:540 (2011); Eng et al., Drug Metabolism and Disposition 41:1470 (2013); see also U.S. Patent Publication Nos. 20060287242, 20070021346, 20070099835, 20130225488, and 20130178420, each of which is incorporated herein by reference). Compounds that positively regulate GLP-1 receptor signaling in the presence of endogenous GLP1 include quercetin, which works by binding to an allosteric site on the GLP-1 receptor and actively affecting receptor signaling when the endogenous ligand (GLP-1, a peptide that exists in several forms) binds. Some quercetin analogs are also positive regulators of endogenous GLP1. Quercetin is a flavonol found in many fruits, vegetables, leaves and grains. It is used as an ingredient in health products, beverages and foods. In some embodiments, a GLP-1 receptor agonist or positive enteric modifier of GLP-1 is co-formulated or co-administered with a gastric retention composition in an amount sufficient to delay gastric emptying. In some embodiments, the GLP-1 receptor agonist or positive enteric modifier is quercetin or an analog, derivative or active metabolite of quercetin. Certain small molecule drugs can also slow gastric emptying time and can be co-administered or co-formulated with a gastric retention composition.

[0241] Gastric emptying is also slowed by acidification of the chyme. For example, citric acid and acetic acid have been shown to delay gastric emptying. In some embodiments, the food or meal includes a natural source of citric acid (e.g., oranges, grapefruits, or other citrus-rich fruits) or acetic acid (e.g., vinegar, pickles or other pickled vegetables) or lactic acid (e.g., sauerkraut or kimchi). In some embodiments, the pH of the chyme is reduced to below 4 or below 3.5 by administering an acidic food or liquid with the gastroretentive composition.

[0242] U.S. Patent 8,741,885 describes a method for prolonging gastric retention of a gastroretentive pharmaceutical composition (e.g., a floating, swelling, or mucoadhesive composition) by combining the active pharmaceutical ingredient with an opioid. The purpose of the co-formulated opioid is to slow gastric emptying. Gastroparesis, or severely suppressed gastrointestinal motility, is a well-known and potentially serious complication of opioid therapy.

[0243] Sustained release composition

[0244] The second composition provides a cysteamine precursor or salt thereof in a non-gastric retentive sustained release formulation. Sustained release formulations are well known in the art: Wen, H. and Park, K. (eds.) Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice. Wiley, 2010; Augsburger, LL and Hoag, SW (eds.) Pharmaceutical Dosage Forms-Tablets, volume 3: Manufacture and Process Control. CRC Press, 2008. The sustained-release component can be a tablet, powder, or capsule filled with microparticles. Optionally, the size, composition (e.g., type or concentration of sustained-release polymer), or type or thickness of coating agent, or number and composition of layers (if coated with multilayer coating agent) of the particles can be varied so that the drug is released from a single particle at different rates or at different starting times, thereby providing overall drug release over an extended period of time compared to a formulation in which all particles are substantially the same. Sustained-release formulations can optionally be coated with pH-sensitive materials to prevent dissolution in the stomach (known as enteric coating). Microparticles in a single composition can vary in type or thickness of one or more coating agents. For example, the pH at which the coating dissolves may be very. The two or microparticles used in this mixed composition can be manufactured separately to strict specifications and then mixed in a certain ratio to achieve extended drug release in vivo.

[0245] Sustained release compositions can provide extended release of cysteamine precursors in the stomach and / or small intestine (if enteric coating, then not the former) and thus provide continuous in vivo cysteamine production. Sustained release formulations can be designed to release the drug for a period of time that is roughly equal to the sum of the average stomach and small intestine transit time, for example, if applied in a fasted state, 3-5 hours, or if applied with food or with a meal, 5-8 hours. Alternatively, sustained release formulations can be designed to release the drug for a period longer than the sum of the average stomach and small intestine transit time, so as to continue to release cysteamine precursors in the large intestine. In certain embodiments, when applied in a fasted state, this sustained release composition can release cysteamine precursors for 4-8 hours, or when applied with a meal, can release 6-10 hours or more.

[0246] The sustained release formulation can produce elevated blood cysteamine levels within 1-4 hours, preferably 1-6 hours, more preferably 1-8 hours, more preferably 1-10 hours or longer after ingestion. The sustained release formulation of cysteamine precursor can be administered with food or between meals, and optionally with an enhancer of cysteamine precursor degradation or cysteamine absorption. Food tends to inhibit the absorption of free cysteamine, especially fatty foods, and it is generally recommended to take cysteamine salts on an empty stomach, but a small amount of applesauce or similar food is allowed.

[0247] Mixed preparations

[0248] Some compositions must have ingredients of two types of formulations, one primarily directed to controlling the rate of drug release and the other primarily directed to controlling the anatomical site of drug release. For example, a gastric retentive formulation always contains the drug in a sustained release formulation; otherwise long-term gastric retention would be meaningless. However, there are methods of combining an immediate release component and a sustained release component in a single gastric retentive formulation. For example, the immediate release component can form an outer layer that dissolves rapidly or disintegrates rapidly in the stomach, leaving a core sustained release component that is retained in the stomach by one or more gastric retention mechanisms described herein. However, not all types of formulations can be effectively combined. For example, an enteric-coated gastric retentive formulation would be counterproductive because the gastric retentive formulation is designed to release the drug in the stomach - and gastric release would be blocked by a coating that resists dissolution in acidic media.

[0249] Compositions with different time or anatomical drug release profiles, when combined with a suitable cysteamine precursor, and optionally with an enhancer of cysteamine production or absorption, can provide blood cysteamine levels within the therapeutic range for 0.5-6 hours, more preferably 0.5-8 hours, and most preferably 0.5-12, 0.5-15 hours or longer. Examples of productive combinations of formulations are as follows, including mixed formulations with up to two drug release components, and individually formulated compositions that can be combined in various amounts and ratios to adjust the amount and timing of cysteamine production and absorption in vivo to meet the needs of individual patients.

[0250] The third composition provides a mixed formulation of a first enteric coating component formulated for delayed release of a cysteamine precursor or a salt thereof in the small intestine and a second component of enteric coated microparticles formulated for sustained release of a cysteamine precursor or a salt thereof throughout the small intestine and the proximal portion of the large intestine. The mixed formulation provides a first component to initially achieve elevated levels of cysteamine in the blood, while a second component maintains the cysteamine level in the blood over time.

[0251] A fourth composition provides a mixed formulation comprising (i) a sustained release gastric retentive formulation of a cysteamine precursor or a salt thereof, and (ii) an immediate release formulation of a cysteamine precursor or a salt thereof designed to release the drug in the stomach. The second component of the mixed formulation is on the outer surface of the composition and begins to dissolve immediately upon contact with the gastric contents. It first produces cysteamine, although not necessarily in the stomach. The first (gastric retentive) component provides a prolonged release of the cysteamine precursor in the stomach and subsequently produces cysteamine in vivo throughout the small intestine and, depending on the characteristics of the cysteamine precursor, into the large intestine. Production and absorption of cysteamine in vivo from the combination of the two components begins within 1 hour after administration of the mixed composition and continues for at least 5 hours, preferably for 8, 10, 12 or more hours within the therapeutic concentration range.

[0252] In the fifth composition, the first component is formulated for immediate release in the stomach and includes a cysteamine precursor, preferably a cysteamine mixed disulfide or pantetheine disulfide or a salt thereof, and the second component is formulated for sustained release of a cysteamine precursor or a salt thereof. The first component is on the outer surface of the composition so that the second component remains intact after the first component dissolves or disintegrates. The mixed formulation of this fifth composition can produce an initial increase in plasma cysteamine concentration from the immediate release component and maintain elevated cysteamine levels by the second (sustained release) component, wherein sustained in vivo cysteamine production is maintained for 6 hours, 8 hours, 10 hours or longer. The release of cysteamine precursors (or several different cysteamine precursors) along the gastrointestinal tract, from the stomach to the large intestine, allows the amount of cysteamine precursors to match the levels of pantetheinease and cysteamine transporters in all sections of the intestine, thereby maximizing cysteamine production and absorption. Continuous intestinal production and absorption of cysteamine avoids reliance on high Cmax to prolong exposure, thereby reducing cysteamine side effects associated with peak levels. Thus, mixed formulations of cysteamine precursors allow cysteamine to be applied to a wide variety of conditions that are sensitive to the effects of cysteamine.

[0253] In the sixth composition, the first component is formulated for immediate release in the stomach and includes a cysteamine precursor, preferably a cysteamine mixed disulfide or pantetheine disulfide or a salt thereof; the second component is formulated for releasing a cysteamine precursor or a salt thereof in the ileum and / or colon. The mixed formulation of this sixth composition can produce an initial increase in plasma cysteamine levels from the immediate release component and a second increase in plasma cysteamine levels from the iliac and colon targeting components roughly when the first peak rapidly declines. The second component can begin to release the cysteamine precursor 4 to 8 hours after administration, depending on whether it is administered with food. The controlled release of the cysteamine precursor (or a different cysteamine precursor) along the gastrointestinal tract, from the stomach to the large intestine, allows the amount of the cysteamine precursor to match the levels of pantetheinease and cysteamine transporter in all sections of the intestine to maximize cysteamine production and absorption.

[0254] Compound

[0255] The pharmaceutically acceptable compositions of the present invention include one or more cysteamine precursors or pharmaceutically acceptable salts thereof. The salts of the present invention may include, but are not limited to, alkali metal salts, such as sodium salts, potassium salts; alkaline earth metal salts, such as calcium salts, magnesium salts and barium salts; and organic base salts (such as amine base salts) and inorganic base salts. Exemplary salts are found in Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, Pa., 1985, page 1418, Berge et al., Journal of Pharmaceutical Sciences 66: 1 (1977), and Pharmaceutical Salts: Properties, Selection, and Use, (P. H. Stahl and C. G. Wermuth, eds.), Wiley-VCH, 2008, each of which is incorporated herein by reference in its entirety.

[0256] The compositions of the present invention may include a cysteamine precursor or salt thereof in a component of a gastroretentive or mixed formulation to achieve a plasma concentration of cysteamine within the therapeutic range within the first 4 hours after administration, preferably within the first 2 hours after administration, and most preferably within the first hour. The plasma concentration of cysteamine is preferably maintained within the therapeutic range for at least 5 hours, preferably 6 hours, more preferably 8 hours, 10 hours or longer. The formulation may include a thiol cysteamine precursor that can be enzymatically degraded to produce cysteamine, such as pantetheine, or a compound that can be degraded to pantetheine (and thus to cysteamine) in the gastrointestinal tract, such as 4-phosphopantetheine, dephospho-CoA or CoA, or a derivative or prodrug thereof that can be degraded to pantetheine (and then to cysteamine) in the gastrointestinal tract. Alternatively, the cysteamine precursor can be formed by reacting cysteamine or a compound that can be degraded to produce cysteamine with another thiol-containing organosulfur compound to form a disulfide compound. The disulfide cysteamine precursor or its salt can be formed by reacting cysteamine with a thiol cysteamine precursor, such as pantetheine, 4-phosphopantetheine, dephospho-CoA, CoA or N-acetylcysteamine, or by reacting cysteamine with other thiols, including N-acetylcysteine ​​(NAC), N-acetylcysteine ​​amide, N-acetylcysteine ​​ethyl ester, homocysteine, glutathione (GSH), Allyl mercaptan, furfurylthiol, benzyl mercaptan, thioterpineol (grapefruit mercaptan), 3-mercaptopyruvic acid, L-cysteine, L-cysteine ​​ethyl ester, L-cysteine ​​methyl ester, thiocysteine, cysteinylglycine, γ-glutamylcysteine, γ-glutamylcysteine ​​ethyl ester, glutathione monoethyl ester, glutathione diethyl ester, mercaptoethyl glucamide, thiosalicylic acid, tiopronin, or diethyldithiocarbamic acid. The thiol cysteamine precursor or cysteamine can also be reacted with a dithiol, such as dihydrolipoic acid, meso-2,3-dimercaptosuccinic acid (DMSA), 2,3-dimercaptopropanesulfonic acid (DMPS), 2,3-dimercapto-1-propanol (dimercaptopropanol), bucillamine, or N,N'-bis(2-mercaptoethyl)isophthalamide (BDTH2), to form a disulfide cysteamine precursor. For thiols that can be used to form disulfide cysteamine precursors, see Fig.17 , and see Schemes 18-21 for a table summarizing thiol pairs that can be linked to form disulfide cysteamine precursors. Other thiols suitable for forming cysteamine precursors are known in the art. For example, PCT Patent Publication No. WO 1993006832, which is incorporated herein by reference in its entirety, discloses Fig.17 Other suitable thiols not included in the above include N,N-dimethylcysteamine, thiocholine, aminopropylthiol, aminobutylthiol and aminopentylthiol, etc.

[0257] The disulfide formed can delay the release of cysteamine in the stomach and / or promote its in vivo production and absorption in the small intestine, depending on the characteristics of the cysteamine precursor used (eg, the number of degradation steps required to form cysteamine). Fig.13 A classification of cysteamine precursors is shown, and selected pharmacologically relevant properties are summarized. Figure 18-21 Information on the cysteamine yields of many disulfide cysteamine precursors is provided. The stomach is generally a more oxidizing and acidic environment than the small intestine. As the stomach contents enter the duodenum, they mix with pancreatic juice containing bicarbonate to neutralize gastric acid, and with bile, which contains millimolar concentrations of the physiological reducing agent glutathione, as well as related thiols including cysteine. Therefore, disulfides tend to remain oxidized in the stomach and are more likely to be reduced in the small intestine, or participate in disulfide exchange reactions with thiols. Disulfide exchange reactions are generally catalyzed by thiolate ions, which are much more nucleophilic than the thiol form; the formation of thiolate ions is unfavorable in the acidic environment of the stomach.

[0258] For example, the thiol cysteamine precursor pantetheine can form a homodimeric disulfide in which two pantetheines are covalently linked to form pantetheine (a disulfide cysteamine precursor). In some preferred embodiments, the cysteamine precursor provides more than one cysteamine, such as by providing, for example, a mixed cysteamine disulfide formed by linking cysteamine to pantetheine, 4-phosphopantetheine, dephospho-CoA or CoA, or by a corresponding mixed pantetheine disulfide formed by oxidizing pantetheine with 4-phosphopantetheine, dephospho-CoA or CoA, or a suitable prodrug or analog that can be converted to the parent compound in the gastrointestinal tract. Moreover, 4-phosphopantetheine can be disulfide bonded to dephospho-CoA or CoA, or dephospho-CoA can be disulfide bonded to CoA to prepare a cysteamine precursor capable of generating two cysteamines in vivo. Fig.13 The amount of cysteamine that can be produced in vivo from different classes of cysteamine precursors is shown. Figure 18-21 Specific disulfide cysteamine precursors are shown; those that generate two cysteamines in vivo are listed at the top of the table and the fractional yield of cysteamine per disulfide is also shown (in percent), as is the number of degradation steps required to generate cysteamine. In some embodiments, the reactive thiol group of cysteamine or the organosulfur can be modified to include substituents such as acetyl, ester, glutamyl, succinyl, phenylalanyl, polyethylene glycol (PEG) and / or folic acid.

[0259] In a preferred embodiment, the composition of the present invention may include pantetheine, a disulfide containing pantetheine, or a salt thereof in a component of a gastric retentive formulation and / or a component of a mixed formulation to maintain a high blood level of cysteamine for 5-10 hours or longer after administration. The composition may be a cysteamine precursor, which requires chemical reduction or enzymatic conversion of the parent compound to at least one cysteamine, thereby delaying the release of cysteamine. The formulation may include pantetheine, or a compound that can be degraded to pantetheine in the gastrointestinal tract (e.g., 4-phosphopantetheine, dephospho-coenzyme A, or coenzyme A; collectively referred to as a pantetheine precursor), wherein the thiol group of pantetheine or the pantetheine precursor reacts with the thiol group of another organic sulfur compound to form a disulfide compound. Since pantetheine enzymes are expressed at higher levels in the intestine than in the stomach, and the small intestinal lumen is a more reducing environment than the stomach, the pantetheine component of the disulfide cysteamine precursor can be converted to cysteamine in the small intestine and subsequently absorbed. For example, pantetheine can form a homodimeric disulfide, in which two pantetheines are covalently linked to form pantethine. The pantetheine-containing cysteamine precursor can also include a pantetheine mixed disulfide, in which a pantetheine thiol reacts with a thiol group to form a disulfide. In preferred embodiments, the pantetheine precursor provides more than one cysteamine, for example, via a mixed disulfide formed from cysteamine and pantetheine, which upon reduction and subsequent cleavage by pantetheinease produces 2 cysteamines and one pantothenic acid, or via a mixed disulfide pantetheine-CoA, which upon reduction and subsequent degradation and subsequent cleavage by pantetheinease produces 2 cysteamines, 2 pantothenic acids, and ADP. Figure 18-21 Other disulfide cysteamine precursors that produce two cysteamines when degraded in the intestine are shown in In some embodiments, the reactive thiol group of pantetheine or the organosulfur compound can be modified to include substituents such as acetyl, methyl ester, ethyl ester, glutamyl, succinyl, phenylalanyl, polyethylene glycol (PEG) and / or folic acid.

[0260] The distinction between cysteamine precursors that require pantetheine enzymatic cleavage to produce cysteamine and cysteamine precursors that require only chemical reduction to produce cysteamine (cysteamine mixed disulfides) is significant, as the kinetics of the conversion of the precursor compound to cysteamine is generally faster in the case of the second category, provided that a sufficiently reducing environment exists (or can be pharmacologically produced) in the intestine. A further distinction can be made between cysteamine precursors that require reduction, followed by pantetheine enzymatic cleavage (e.g., pantethine), and cysteamine precursors that require first reduction, followed by degradation to pantetheine, followed by pantetheine enzymatic cleavage (e.g., 4-phosphopantetheine, dephospho-CoA, or CoA containing disulfide bonds). The additional degradation step required for the latter class of disulfide cysteamine precursors slows down and prolongs the time for cysteamine production over a longer period of time.

[0261] The compounds of the present invention can be prepared by various methods known to those of ordinary skill in the art of chemical synthesis. Preparation of thiols, including cysteamine, pantetheine, 4-phosphopantetheine, dephospho-CoA or CoA and other thiols (see Fig.17 ) are well known in the art. Coenzyme A, pantethine, N-acetylcysteamine and glutathione are commercially available as dietary supplements. Fig.17 Most of the other thiols in are readily available from chemical companies.

[0262] Synthesis of cysteamine precursors

[0263] Compounds of the invention including thiol and disulfide cysteamine precursors can be prepared from readily available starting materials using methods and procedures known in the art, such as those described by Mandel et al., Organic Letters, 6:4801 (2004). Methods for making pantethine are described in U.S. Pat. Nos. 3,300,508 and 4,060,551, each of which is incorporated herein by reference. Methods for converting liquid pantethine to solid form are disclosed in Japanese Patent Publication Nos. JP-A-S50-88215 and JP-A-S55-38344. It should be understood that, unless otherwise stated, where typical or preferred process conditions (i.e., reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.) are given, other process conditions may also be used. Optimal reaction conditions may vary with the specific reactants or solvents used, but these conditions can be determined by one of ordinary skill in the art through routine optimization procedures.

[0264] In a preferred embodiment, the composition of the present invention includes one or more disulfide cysteamine precursors. Disulfides, which are oxidized forms of thiols, are easily formed from the constituent thiols without the need for expensive reagents or equipment. In addition, disulfides are not subject to oxidation, which may limit the long-term stability of thiol compounds exposed to air. Therefore, with respect to manufacturing, cost, storage cost, transportation, and patient convenience (i.e., long shelf life), the disulfide form of the cysteamine precursor is more preferred than the thiol form.

[0265] In some embodiments, a mixed disulfide cysteamine precursor is synthesized by linking two different thiols to form three reaction products: thiols A and B can be linked to form disulfides AA, AB, and BB. For example, disulfides formed by reacting cysteamine with pantetheine include: cysteamine-cysteamine (referred to as cystamine), cysteamine-pantetheine, and pantetheine-pantetheine (referred to as pantethine). All three compounds can be used to provide cysteamine, and in fact, the different steps involved in converting each compound to cysteamine can be pharmacologically beneficial by extending the period of time during which cysteamine is produced in vivo, either by disulfide bond reduction or by a combination of reduction and enzymatic degradation steps. Therefore, co-formulation of all three oxidation products without purification (except to remove unreacted thiols and / or undesirable impurities, such as solvents) can be pharmacologically useful. This is particularly true when each of the two reacting thiols is convertible to cysteamine (e.g., pantetheine, 4-phosphopantetheine, dephospho-CoA, CoA, N-acetylcysteine, or suitable analogs and prodrugs), or when cysteamine itself is reacted with a thiol that is convertible to cysteamine. Thus, in certain embodiments, each thiol is convertible to cysteamine (or one of them is cysteamine) by co-formulating all three disulfides formed by reacting two different thiols in a single composition. This method of synthesis and formulation does not require more complex synthetic steps, or post-synthesis purification steps required to separate the mixed disulfide from the two homodimeric disulfides simultaneously produced in the oxidation reaction. (Of course, unreacted thiols and other impurities must be removed prior to formulation of the pharmaceutical composition).

[0266] The advantages of preparing and co-formulating a mixture of three disulfides are not fully realized in the case of disulfide cysteamine precursors, which are prepared by reacting a thiol that is convertible to cysteamine with a second thiol that is not convertible to cysteamine. For example, the three disulfides formed by reacting pantetheine with N-acetylcysteine ​​(NAC) are: pantetheine-pantetheine (pantetheine), pantetheine-NAC, and NAC-NAC. The first two compounds are cysteamine precursors, while the third (NAC-NAC) is not. However, NAC-NAC may have beneficial pharmacological properties in modulating the intestinal redox environment, or beneficial medical properties due to providing two NAC molecules upon chemical reduction. Therefore, in certain embodiments, all three disulfide products formed by reacting cysteamine or a thiol that is convertible to cysteamine in vivo with a second thiol that is not convertible to cysteamine in vivo are co-formulated in a single composition.

[0267] When two different thiols are oxidized, the expected ratio of the reaction products depends on the molar ratio of the two thiols, the absolute concentration of the two thiols, the pH and / or the chemical environment around the thiol group of each thiol. If the ratio of thiol A to thiol B is 1:1, the expected molar ratio of the reaction products AA, BB, AB is about 1:1:2. (Deviations from the expected ratio may occur due to differences in the chemical bonds adjacent to the thiol, which may affect, for example, the kinetics of disulfide bond formation, which may be affected by the electronegativity of the atoms bonded to the thiol groups. Any deviations can be predicted or measured using methods known in the art). The ratio of the reaction products can be changed by changing the molar ratio of the two thiols. For example, in order to increase the ratio of AA and AB relative to BB, the molar concentration of thiol A can be increased relative to the molar concentration of thiol B. When two thiols are reacted, one of which is cysteamine or a compound that can be degraded to cysteamine (thiol A), and the other is a thiol that is not degradable to cysteamine (thiol B), the molar concentration of the first thiol can be increased relative to the molar concentration of the second thiol to increase the proportion of cysteamine precursors produced. For example, reacting thiols A and B in a 2:1 molar ratio increases the ratio of AA and AB (both cysteamine precursors) relative to BB (not a cysteamine precursor).

[0268] In certain embodiments, the oxidation of the two different thiols and / or the mixing of the reaction products can be enhanced by including a catalyst (reviewed in Musiejuk and Witt (2015)). For example, an oxidant such as hydrogen peroxide or dimethyl sulfoxide (DMSO), or a metal such as copper, manganese, or telluride, or iodine, diethyl azodicarboxylate (or related compounds), or dichlorodicyanoquinone (DDQ) can be added. Optimal performance of the catalyst can be achieved by empirically determining the optimal solvent system, catalyst concentration, and reaction conditions.

[0269] In other embodiments, asymmetric disulfides can be produced via a thiol-disulfide exchange reaction between a thiol and a symmetric disulfide. This type of reaction, such as the oxidation of two different thiols, provides a mixture of all possible products (symmetric and asymmetric disulfides). However, by providing a symmetric disulfide in molar excess over the thiol, the formation of asymmetric disulfides is favored, and may even be the main reaction product under optimized conditions. Examples 15 and 16 describe the synthesis of pantetheine-cysteamine disulfide via a sulfhydryl-disulfide exchange. The method is performed with cysteamine as the thiol and pantetheine as the disulfide, and with pantetheine as the thiol and cystamine as the disulfide. In a preferred embodiment of the thiol: disulfide exchange reaction, the molar ratio of thiol to disulfide (e.g., cysteamine: pantetheine) is 2:1 to 4:1, 2.5:1 to 3.5:1, 2.7:1 to 3.3:1. In certain embodiments, the solvent is methanol and the reaction time is 1-20 hours, or 1-12 hours, or 1-6 hours. In certain embodiments, the product of the thiol:disulfide exchange reaction (eg, TTI-0102) is subsequently precipitated (eg, as described in Example 17).

[0270] Alternatively, in another embodiment, the ratio of cysteamine precursors used in the pharmaceutical composition can be adjusted by combining the three reaction products of the mixed disulfide oxidation reaction with pure disulfides. For example, if thiol cysteamine (C) and pantethine (P) are oxidized in a 1:1 molar ratio, they will combine to form three products: CC, PP, and CP, in a ratio of about 1:1:2. Pure pantethine (PP) can be added to the mixture in any desired amount to prolong the in vivo cysteamine production properties of the mixture. Doubling the starting amount of pantethine will produce a ratio of 1:2:2. Adding four times the starting amount of pantethine will produce a ratio of 1:2:5.

[0271] It is also possible to combine two independently produced mixed disulfide reaction products to obtain a new ratio of cysteamine precursors. For example, if the cysteamine-pantetheine reaction products (CC, PP, and CP) are combined with equimolar amounts of the reaction products from the N-acetylcysteine ​​(NAC)-cysteamine (C) oxidation reaction (CC, NAC-NAC, and C-NAC in a ratio of 1:1:2), the mixture will contain five compounds, one of which, NAC-NAC, cannot be converted to cysteamine. The other four disulfides, PP, CC, CP, C-NAC, are present in a molar ratio of about 1:2:2:2. Optionally, pantetheine can be added to give a ratio of, for example, 2:2:2:2 (more simply expressed as 1:1:1:1), or in larger amounts to give a ratio of 1:1:1:5. Thus, the molar ratio of disulfides in a pharmaceutical composition can be controlled by various methods. In another example, the cysteamine-pantetheine reaction products (CC, PP, and CP) can be combined with equimolar amounts of the reaction products from the 4-phosphopantetheine (4P)-cysteamine (C) oxidation reaction (i.e., CC, 4P-4P, and C-4P in a 1:1:2 ratio) to produce a mixture of the five disulfides in a 1:1:1:2:2 ratio.

[0272] In summary, when one thiol is oxidized to prepare a cysteamine precursor disulfide, there is only one product (e.g., pantetheine + pantetheine = pantetheine). When two thiols are oxidized, there are three products, two or three of which are cysteamine precursors, depending on whether one or both thiols are degradable to cysteamine, or are cysteamine. By combining the products of these two types of reactions, it is easiest to prepare a mixture of cysteamine precursors. The mixture may include pure disulfides or three-component disulfide mixtures in various molar ratios. However, the heterodimeric cysteamine precursor may also be used in pure form after purification, or in combination with other homodimeric or heterodimeric cysteamine precursors.

[0273] Alternatively, by using more complex chemical methods, specific mixed disulfides (also called asymmetric disulfides) can be selectively synthesized (e.g., cysteamine and pantetheine can be combined to form essentially only the disulfide cysteamine-pantetheine). These methods use a variety of sulfur protecting groups and strategies for their removal. The most widely used methods require substitution of the sulfenyl derivative with a thiol or its derivative. Commonly used sulfenyl derivatives include: sulfenyl chloride, S-alkylthiosulfates and S-arylthiosulfates (Bunte salts), S-(alkylsulfanyl)isothioureas, benzothiazol-2-yl disulfides, benzotriazolyl sulfides, dithioperoxyesters, (alkylthio)dialkylsulfonium salts, 2-pyridyl disulfides and derivatives, N-alkyltetrazolyl disulfides, sulfenamides, sulfenyldimethylsulfonamides, sulfenylthiocyanates, 4-nitroarenesulfenylanilides, thiosulfinates and thiosulfonates, sulfanylthioamidines, thionitrites, sulfenylthiocarbonates, thioimides, thiophosphonium salts and 5,5-dimethyl-2-thio-1,3,2-dioxaphosphinane-2-yl disulfide. Other procedures involve: reaction of thiols with sulfinylbenzimidazoles, rhodium-catalyzed disulfide exchange, electrochemical methods, and the use of diethyl azodicarboxylate. These and other methods are reviewed by Musiejuk, M. and D. Witt. Organic Preparations and Procedures International 47:95 (2015). Thus, only moderate effort is required to prepare specific mixed (asymmetric) disulfides. Examples 1 and 2 provide synthetic procedures for mixed disulfides of the present invention.

[0274] In other embodiments, mixed disulfides can be synthesized from symmetric disulfides by preferentially coupling a substituent (e.g., acyl) to one end of a symmetric disulfide (i.e., half-acylation). For example, since cysteamine and pantetheine differ by a pantothenate moiety, the disulfide cystamine can be half-acylated by pantothenate to produce cysteamine-pantetheine disulfide. When the concentrations of the reactants are optimized and a coupling agent is added to promote acylation, this procedure can produce a yield of greater than 95%. Cystamine is an attractive starting point for the generation of asymmetric disulfides because it contains reactive amino groups at both ends. Example 14 describes the efficient synthesis of pantetheine-cysteamine disulfide via a reactive intermediate by half-acylation of cystamine with the substituent pantothenic acid. In certain embodiments, the molar ratio of acyl to disulfide is 1:2 to 1:4. In certain embodiments, the acylation reaction is promoted by adding N,N'-dicyclohexylcarbodiimide (DCC) at a DCC:acyl molar ratio of 3: 1 to 5: 1. In certain embodiments, the acylation reaction is promoted by adding 1-hydroxybenzotriazole (HOBt) at a HOBt:acyl molar ratio of 1: 1 to 1:3.

[0275] Stereochemistry

[0276] Some compounds of the invention exist in more than one enantiomeric form. In particular, pantetheine, 4-phosphopantetheine, dephospho-CoA, and CoA contain chiral carbons in the pantetheine moiety. Thus, each of these compounds can exist as a D- or L-enantiomer, or as a racemic mixture of the two in the case of the pantetheine group. However, human pantetheine enzymes (encoded by the VNN1 and VNN2 genes) are specific for D-pantetheine. (Bellussi et al., Physiological Chemistry and Physics 6:505 (1974)). Thus, only D-pantetheine (and not L-pantetheine) is a cysteamine precursor, and thus the present invention relates only to D-pantetheine, and only to the D-enantiomers of 4-phosphopantetheine, dephospho-CoA and CoA, and any analogs or prodrugs that can be converted to those compounds in the gastrointestinal tract. Likewise, all disulfide containing pantetheine, 4-phosphopantetheine, dephospho-CoA and CoA, or any suitable analogs or prodrugs, use only the D-enantiomer.

[0277] The L-enantiomers of amino acids and amino acid derivatives are preferred. Thus, "cysteine" herein refers to L-cysteine, homocysteine ​​refers to L-homocysteine, and cysteine ​​derivatives, such as N-acetylcysteine, N-acetylcysteine ​​amide, N-acetylcysteine ​​ethyl ester, cysteine ​​methyl ester, cysteine ​​ethyl ester, cysteinylglycine and gamma-glutamylcysteine ​​are all formed using the L-enantiomer of cysteine.

[0278] For dihydrolipoic acid, the R enantiomer is preferred because that is the enantiomer made in the human body. In general, for compounds that are normally found in the human body or in food, the naturally occurring enantiomer is preferred.

[0279] Salt forms and crystals

[0280] The pharmaceutical properties of any compound, including the cysteamine precursors of the present invention, can be improved by association with a counter ion or salt. Specific properties that can be improved include stability (e.g., less hygroscopic; less susceptible to oxidation; more tolerant to heat, humidity and pH extremes), better tendency to form crystals, ease of formulation (e.g., related to the properties of the solid form of the compound, such as a powder).

[0281] The potential of salt forms to improve the crystallization properties of compounds is particularly important because crystallization is a cheaper, faster and more scalable purification method than, for example, column chromatography. Methods for inducing precipitation of small molecules are known in the art (e.g., see Chen et al., Crystal Growth and Design, 11(4), 2011 for a review). Crystallization can be induced by cooling a saturated solution of the target compound, or by adding an antisolvent (a liquid in which the target compound is poorly soluble) to a solution of the compound (Mostafa et al. Chemical Engineering Science 63:5457-5467, 2008), or by introducing a surface that promotes crystal formation (e.g., scratched glass), or by adding seed crystals, or by adding compounds that will co-crystallize with the target compound (Korotkova and Karatchvil, Procedia Chemistry 10:473-476, 2014), including polymers (Edueng et al. Journal of Controlled Release 256:193-202, 2017). Industrial crystallization processes can be carried out in batch form or, increasingly, through continuous processes (Zhang et al. Engineering 3:354-364, 2017).

[0282] Crystallization can be used in one of two ways: the disulfide compound of interest can be selectively crystallized in the presence of impurities, the impurities remain in solution and can therefore be easily removed after crystallization, or one or more impurities can be crystallized while the compound of interest remains in solution. The two methods can be combined sequentially (one after the other).

[0283] Because cysteamine precursors will typically be administered in relatively large doses (in excess of 1 gram per day, and potentially up to ten grams for adults), any salt needs to be safe. Therefore, natural product salts that are present in the diet at significant levels and have pleasing organoleptic properties are preferred. Examples of such salts include, but are not limited to, acetates, citrates, and tartrates. The salt form of the cysteamine precursor that induces crystal formation may not overlap with the pharmaceutically preferred salt form, in which case the salt form may be specifically produced to aid crystallization, then redissolved in a solvent and the salt converted to the preferred pharmaceutical salt. Large salts that tend to promote crystal formation include benzoates and naphthoates (naphthoic acid).

[0284] Separation methods

[0285] Most of the synthetic routes outlined above are unable to produce mixed disulfides with greater than 99% purity (i.e., within the range required by drug regulatory agencies). The selectivity of crystallization may also not be sufficient to reduce drug impurities to acceptable levels. Therefore, a robust separation method may also be required. Therefore, in certain embodiments, any synthetic method can be combined with an effective scheme to separate the desired product (i.e., mixed disulfide cystamine precursor) from other compounds (including other disulfides) produced in the synthesis. In addition to crystallization, suitable separation methods include various chromatographic procedures, including resins that separate small molecules based on size, charge, hydrophobicity, affinity or other characteristics.

[0286] preparation

[0287] When used as a drug, a cysteamine precursor or a pharmaceutically acceptable salt, solvate or prodrug thereof can be administered in the form of a pharmaceutical composition. These compositions can be prepared in various ways well known in the pharmaceutical field, and can be made to release the drug in a specific section of the gastrointestinal tract at a controlled time by a variety of excipients and formulation techniques. For example, a formulation can be customized to address a specific disease, reach the blood cysteamine level required for achieving therapeutic efficacy, achieve the desired duration of drug action, and provide a group of compositions with different drug release characteristics, which can be administered in different combinations to take into account the patient-to-patient variation of cysteamine metabolism. Administration is mainly through the oral route, and can be supplemented by suppositories. Cysteamine precursors can also be co-formulated with agents that enhance the production or absorption of cysteamine in the body, including, for example, reducing agents, buffers, pantetheine enzyme inducers, or inducers for absorbing cysteamine by intestinal epithelial cells.

[0288] The pharmaceutical composition may contain one or more pharmaceutically acceptable carriers. In preparing the pharmaceutical composition for the method of the present invention, the cysteamine precursor, its pharmaceutically acceptable salt, solvate or prodrug is usually mixed with an excipient, diluted with an excipient or encapsulated in such a carrier in the form of, for example, a capsule, tablet, pouch, paper, vial or other container. The active component of the present invention can be administered alone or in a mixture in the presence of a pharmaceutically acceptable excipient or carrier. The excipient or carrier is selected based on the mode and route of administration, the gastrointestinal region targeted for drug release and the expected time curve of drug release. When the excipient is used as a diluent, it can be a solid, semisolid or liquid material (e.g., saline) that acts as a vehicle, carrier, matrix or other medium for the active ingredient. Therefore, the composition can be in the form of tablets, powders, granules, lozenges, pouches, cachets, elixirs, suspensions, emulsions, solutions, syrups, and soft and hard gelatin capsules. As known in the art, the type and amount of the excipient vary depending on the expected drug release characteristics. The resulting compositions may contain additional agents, for example preservatives or coatings.

[0289] Suitable pharmaceutical carriers and pharmaceutical necessities for pharmaceutical preparations are described in Remington: The Science and Practice of Pharmacy, 21st edition, Gennaro ed., Lippencott Williams & Wilkins (2005), a well-known reference text in the art, and USP / NF (United States Pharmacopeia and the National Formulary) or corresponding European or Japanese references. Examples of suitable excipients are lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium carbonate, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, cellulose derivatives, polyvinylpyrrolidone, poly(lactic-co-glycolic acid) (PLGA), cellulose, water, syrup, methylcellulose, vegetable oils, polyethylene glycol, hydrophobic inert bases, carbomer, hypromellose, gelucire 43 / 01, docusate sodium, and white wax. The formulation may additionally include: lubricants, such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives, such as methyl hydroxybenzoate and propyl hydroxybenzoate; sweeteners; and flavoring agents. Details of other exemplary excipients and their uses are described in Handbook of Pharmaceutical Excipients, 6th edition, Rowe et al., ed., Pharmaceutical Press (2009).

[0290] The pharmaceutical composition may include a cysteamine precursor salt, optionally co-formulated or co-administered with other agents that promote the degradation of the cysteamine precursor to cysteamine in vivo or enhance the intestinal absorption of cysteamine. The pharmaceutical composition may also include other therapeutic agents that supplement the pharmacological effects of cysteamine in the target disease. Exemplary enhancers of cysteamine production or absorption in vivo, as well as exemplary therapeutic agents that may be included in the compositions described herein, are provided herein.

[0291] The composition of the present invention may contain a single active ingredient (i.e., a single cysteamine precursor), or a combination of a first and a second active ingredient in a single unit dosage form, or a combination of a first, second, third, and optional fourth active ingredient and an optional fifth ingredient in a single unit dosage form. In a composition having two active ingredients, both ingredients may be cysteamine precursors or one ingredient may be an enhancer of in vivo cysteamine production (e.g., a reducing agent that promotes the reduction of disulfide cysteamine precursors, or an agent that induces increased expression of intestinal pantetheine enzymes) or an enhancer of intestinal absorption of cysteamine (e.g., an agent that induces increased expression of one or more organic cation transporters (e.g., OCT1, OCT2, or OCT3)). In a composition having three or four active ingredients, all ingredients may be cysteamine precursors, or one or two ingredients may be enhancers of in vivo cysteamine production and / or intestinal absorption. In a composition having two or more cysteamine precursors, the type of cysteamine precursor is selected to achieve in vivo cysteamine production over a sustained period of time. For example, a mixed disulfide cysteamine precursor that requires only disulfide bond reduction to produce one cysteamine and will therefore begin to produce cysteamine shortly after reaching a region of the gastrointestinal tract that has a redox environment conducive to disulfide bond reduction can be mixed with pantetheine, or with pantetheine disulfide, which requires disulfide bond reduction and pantetheine enzyme cleavage to produce cysteamine, and optionally also combined with a compound that can be degraded to pantetheine in the intestine or a disulfide containing such a compound, which requires an additional step to produce pantetheine and thus cysteamine. Compounds that can be degraded to pantetheine in the intestine include 4-phosphopantetheine, dephospho-coenzyme A, coenzyme A, and suitable analogs and derivatives. The time course of cysteamine production in vivo will vary depending on the number of degradation steps between the cysteamine precursor and cysteamine. In some embodiments, the composition containing multiple cysteamine precursors is formulated as a powder, granules, or liquid - a type of formulation that can accommodate large amounts of drug.

[0292] The pharmaceutical composition may also include one or more agents that enhance the performance of the formulation. For example, a gastroretentive composition may include a compound that slows gastric emptying, thereby extending the residence time of the composition in the stomach.

[0293] In a composition having two cysteamine precursor components, the first and second components may be present, for example, in a ratio of about 1:1.5 to about 1:4. In a composition having three cysteamine precursor components, the first, second and third components may be present, for example, in a ratio between about 1:1:2 to about 1:4:4. In a composition having four active components, the first to fourth active components may be present, for example, in a ratio of about 1:1:1:2 to about 1:2:5:5. In a composition having five active components, the first to fifth active components may be present, for example, in a ratio of about 1:1:2:2:2 to about 1:1:2:5:5:8.

[0294] In some embodiments, the composition comprising two or more cysteamine precursors includes one precursor selected for rapid in vivo cysteamine production (e.g., requiring only disulfide bond reduction) and a second precursor selected for intermediate or slower in vivo conversion to cysteamine, e.g., requiring chemical reduction and at least one enzymatic degradation step). In some embodiments, the pharmaceutical composition comprising two or more cysteamine precursors, at least one precursor is a cysteamine mixed disulfide that can generate cysteamine upon disulfide bond reduction. In further related embodiments, at least one additional component is a disulfide containing pantetheine or a compound that can be degraded to pantetheine in the gastrointestinal tract.

[0295] The composition may be formulated in solid unit dosage form (eg tablets or capsules), each dosage containing, for example, 50-800 mg of the active ingredient of the first component. For example, a dosage can contain from about 50 mg to about 800 mg, from about 50 mg to about 700 mg, from about 50 mg to about 600 mg, from about 50 mg to about 500 mg; from about 75 mg to about 800 mg, from about 75 mg to about 700 mg, from about 75 mg to about 600 mg, from about 75 mg to about 500 mg; from about 100 mg to about 800 mg, from about 100 mg to about 700 mg, from about 100 mg to about 600 mg, from about 100 mg to about 500 mg; from about 250 mg to about 800 mg, from about 250 mg to about 700 mg, from about 250 mg to about 600 mg, from about 250 mg to about 500 mg; from about 400 mg to about 800 mg, from about 400 mg to about 700 mg, from about 400 mg to about 600 mg; from about 450 mg to about 700 mg, from about 450 mg to about 600 mg of the active ingredient of the first component.

[0296] In alternative embodiments, the composition can be formulated as a liquid or powder unit dosage form, each dosage unit containing about 250 mg to about 10,000 mg of cysteamine precursor. For example, a dosage can contain about 250 mg to about 10,000 mg, about 250 mg to about 8,000 mg, about 250 mg to about 6,000 mg, about 250 mg to about 5,000 mg; about 500 mg to about 10,000 mg, about 500 mg to about 8,000 mg, about 500 mg to about 6,000 mg, about 500 mg to about 5,000 mg; about 750 mg to about 10,000 mg, about 750 mg to about 8,000 mg, about 750 mg to about 6,000 mg, about 750mg to about 5,000mg; about 1,250mg to about 10,000mg, about 1,250mg to about 8,000mg, about 1,250mg to about 6,000mg, about 1,250mg to about 5,000mg; about 2,000mg to about 10,000mg, about 2,000mg to about 8,000mg, about 2,000mg to about 6,000mg; about 2,000mg to about 5,000mg, about 3,000mg to about 6,000mg of the active ingredient of the first component.

[0297] In compositions having a first and a second cystamine precursor component, the amount of the second active component in the solid unit dosage form may vary, for example, 50-700 mg. For example, a dosage may contain from about 50 mg to about 700 mg, from about 50 mg to about 600 mg, from about 50 mg to about 500 mg, from about 50 mg to about 450 mg; from about 75 mg to about 700 mg, from about 75 mg to about 600 mg; from about 100 mg to about 700 mg; from about 100 mg to about 600 mg, from about 100 mg to about 500 mg, from about 100 mg to about 400 mg; from about 250 mg to about 700 mg, from about 250 mg to about 600 mg, from about 250 mg to about 500 mg, from about 250 mg to about 400 mg; from about 400 mg to about 700 mg, from about 400 mg to about 600 mg, from about 400 mg to about 500 mg, from about 450 mg to about 700 mg; from about 450 mg to about 600 mg, from about 450 mg to about 500 mg. In a composition having a cysteamine precursor as a first active ingredient and an in vivo cysteamine production enhancer as a second active ingredient, the amount of the second active ingredient in a unit dosage form may vary, for example, 0.1 mg to 400 mg.

[0298] In alternative embodiments including a first and a second cystamine precursor component, the amount of the second active component in the liquid or powder unit dosage form can vary, for example, from about 250 mg to about 6,000 mg. For example, a dosage may contain from about 250 mg to about 6,000 mg, from about 250 mg to about 5,000 mg, from about 250 mg to about 4,000 mg, from about 250 mg to about 3,000 mg, from about 250 mg to about 2,000 mg per dose; from about 500 mg to about 6,000 mg, from about 500 mg to about 5,000 mg, from about 500 mg to about 4,000 mg, from about 500 mg to about 3,000 mg; from about 750 mg to about 6,000 mg, from about 750 mg to about 5,000 mg, from about 750 mg to about about 1,250 mg to about 6,000 mg, about 1,250 mg to about 5,000 mg, about 1,250 mg to about 4,000 mg, about 1,250 mg to about 3,000 mg; about 2,000 mg to about 6,000 mg, about 2,000 mg to about 5,000 mg, about 2,000 mg to about 4,000 mg; about 2,000 mg to about 3,000 mg, about 2,500 mg to about 5,000 mg of the active ingredient of the second component.

[0299] In solid compositions having a third or third and fourth cysteamine precursor components, a unit dose may contain from about 50 mg to about 400 mg of each of the third (if present) and fourth active components. For example, a dose may contain from about 50 mg to about 400 mg, from about 50 mg to about 350 mg, from about 50 mg to about 300 mg, from about 50 mg to about 250 mg; from about 75 mg to about 400 mg, from about 75 mg to about 350 mg, from about 75 mg to about 300 mg, from about 75 mg to about 250 mg; from about 100 mg to about 400 mg, from about 100 mg to about 350 mg, from about 100 mg to about 300 mg, from about 100 mg to about 250 mg; from about 250 mg to about 400 mg, from about 250 mg to about 350 mg, or from about 250 mg to about 300 mg. In compositions having five active components, the unit doses of the five components may vary in the range of from about 50 mg to about 300 mg. In the composition having an in vivo cysteamine production enhancer as the fourth active ingredient and an optional third active ingredient, the amount of the fourth active ingredient and the optional third active ingredient in a unit dosage form may vary, for example, 0.1 mg to 400 mg.

[0300] In alternative embodiments including a third or third and fourth cysteamine precursor component in a liquid or powder unit dosage form, the unit dosage of the third active component and the optional fourth active component can vary, for example, from about 250 mg to about 4,000 mg. For example, the dosage can contain from about 250 mg to about 4,000 mg, from about 250 mg to about 3,000 mg, from about 250 mg to about 2,000 mg, from about 250 mg to about 1,000 mg, from about 500 mg to about 4,000 mg, from about 500 mg to about 3,000 mg, from about 500 mg to about 2,000 mg, from about 500 mg to about 1,000 mg; from about 750 mg to about 4,000 mg, from about 750 mg to about 3,000 mg, from about 750 mg to about 2,000 mg, from about 750 mg to about 1,000 mg; mg to about 1,000 mg; about 1,000 mg to about 4,000 mg, about 1,000 mg to about 3,000 mg, about 1,000 mg to about 2,000 mg, about 1,000 mg to about 1,500 mg; about 1,500 mg to about 4,000 mg, about 1,500 mg to about 3,000 mg, about 1,500 mg to about 2,000 mg; about 2,000 mg to about 4,000 mg, about 2,000 mg to about 3,000 mg of a third active ingredient, and optionally a fourth active ingredient.

[0301] The pharmaceutical compositions can be formulated so as to provide immediate, delayed, gastric retentive, sustained or colonic release (collectively referred to as controlled release) of the active ingredient after administration to the patient by employing procedures known in the art.

[0302] In order to prepare a solid composition (such as a tablet), one or more active ingredients (e.g., several cysteamine precursors) can be mixed with one or more pharmaceutical excipients to form a solid bulk formulation composition containing a uniform mixture of the compounds of the invention. When these bulk formulation compositions are referred to as uniform, the active ingredients are generally uniformly dispersed throughout the composition so that the composition can be easily subdivided into equivalent unit dosage forms, such as tablets, capsules, or microparticles. This solid bulk formulation is then subdivided into unit dosage forms of the above types.

[0303] Alternatively, two uniform batches of active ingredient mixed with one or more pharmaceutical excipients can be prepared, each using a different concentration of active ingredient. The first mixture can then be used to form a core, and the second mixture can be used to form a shell around the core to form a composition with variable drug release characteristics. If the high concentration batch is located in the core and the lower concentration batch is located in the shell, once the shell is substantially dissolved or eroded, the initial moderate drug release rate will be followed by a greater rate of drug release. In some embodiments, the pharmaceutical composition contains a higher concentration of active ingredient in the core than in the shell. The ratio of cysteamine precursor concentration in the core: shell can be, for example, in the range of about 1.5:1 to 4:1. The type or concentration of the excipient between the two batches can also be different in order to affect the drug release rate. In some embodiments, the polymer or other matrix forming component in the core is slower than the release of the active ingredient from the shell. In such embodiments, the higher concentration of cysteamine precursor in the core is partially or completely balanced by a slower drug release rate to extend the duration of cysteamine precursor release, and thus extend the duration of cysteamine production, intestinal absorption and blood level elevation in the body. One or more coatings may be applied to the core prior to application of the shell layer, and additional coatings may be applied to the shell to enable an efficient manufacturing process and / or to help provide desired pharmacological properties, including the timing and location of drug release in the gastrointestinal tract.

[0304] The pharmaceutical composition of the present invention includes those formulated for releasing a mixture of cysteamine precursors, which differ in the mechanism or quantity of the degradation steps leading to the production of cysteamine. Specifically, a mixture of two, three, four or five cysteamine precursors, each precursor being one, two, three or more chemical and / or enzymatic degradation steps away from the release of cysteamine. For example, one step may be disulfide bond reduction (in the case of cysteamine mixed disulfides) or pantetheine enzyme cleavage (in the case of pantetheine). Two steps may be disulfide bond reduction, followed by pantetheine enzyme cleavage (in the case of pantetheine disulfide), or phosphatase cleavage, followed by pantetheine enzyme cleavage (in the case of 4-phosphopantetheine). Three steps may be disulfide bond reduction before or after degradation to pantetheine (e.g., by phosphatase), followed by pantetheine enzyme cleavage (e.g., in the case of 4-phosphopantetheine disulfide). The four steps may be disulfide bond reduction followed by two degradation steps to pantetheine (e.g., removal of the adenine nucleotide moiety by an ectonucleotide diphosphatase followed by removal of the 4' phosphate by a phosphatase), followed by pantetheine enzymatic cleavage (e.g., in the case of CoA or dephosphorylated CoA disulfide). The purpose of combining cysteamine precursors with different chemical and / or enzymatic degradation pathways to cysteamine is to prolong the time that cysteamine is produced in and absorbed from the intestine and thus prolong the duration of therapeutically effective cysteamine blood levels. In some embodiments, the pharmaceutical compositions of the invention contain at least two cysteamine precursors, and in other embodiments, the pharmaceutical compositions contain three cysteamine precursors.

[0305] The pharmaceutical compositions of the present invention can be formulated for mixed release, meaning that one composition contains two drug release profiles. For example, an immediate release formulation can be combined with a sustained release formulation. (See, e.g., Fig.14 Composition F in (5). In such a composition, the first active ingredient can be formulated to begin immediate release between about 5 minutes and about 30 minutes after ingestion. For example, the first active ingredient can be released 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes or 45 minutes after ingestion of the composition. The first active ingredient is formulated so that a cysteamine plasma concentration within the therapeutic range is reached between about 15 minutes and 3 hours after ingestion, preferably between 30 minutes and 2 hours. For example, a therapeutic plasma cysteamine concentration can be reached 0.5 hours, 1 hour, 2 hours or 3 hours after ingestion of the composition. The type of cysteamine precursor used (e.g., thiol, cysteamine mixed disulfide, pantetheine disulfide, coenzyme A disulfide, N-acetylcysteamine disulfide, etc.) will affect the length of time to reach a therapeutic blood concentration of cysteamine, as well as the duration of maintaining a therapeutic blood concentration.

[0306] In compositions having two, three, and optionally four or five active ingredients (e.g., multiple cysteamine precursors and / or enhancers of the production and absorption of cysteamine in vivo), each of the second, third, and / or fourth, and / or fifth active ingredients is formulated for controlled release from the composition beginning between about 1 hour and about 8 hours after ingestion. Controlled release compositions may include delayed release and / or sustained release formulations. For example, the second, third, and / or fourth active ingredient may begin to release 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, or 8 hours after ingestion of the composition. The second, third, and / or fourth active ingredient is formulated so that the plasma concentration of cysteamine (which reflects the contribution of all active ingredients) begins to remain within the therapeutic range between about 30 minutes and 2 hours after ingestion and extends between about 6 and 10 hours after ingestion, more preferably between 8 and 12 hours, or longer. For example, after ingestion of the active component of the composition, plasma cysteamine concentrations may be maintained within the therapeutic range for 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 20 hours, or 24 hours. Depending on the age and size of the patient, the disease being treated, and the patient's cysteamine metabolism rate, two or more compositions may be required to deliver sufficient cysteamine precursor to achieve therapeutic blood levels within a few hours.

[0307] As an alternative or supplement to the pharmaceutical composition comprising a mixed formulation, in some embodiments, a composition consisting of a single type of formulation can be produced. That is, a time-based formulation, such as an immediate release or sustained release formulation, and an anatomically targeted formulation, such as a gastric retention, delayed release, and colon-directed formulation, can be prepared to be administered as a separate composition. The preparation of a collection of pharmaceutical compositions having different drug release characteristics (whether based on time or based on anatomy / physiology) has certain advantages. For example, such compositions can be administered to different patients in different combinations and ratios to reach blood cysteamine levels within the therapeutic range over an extended period of time. That is, the therapeutic regimen consisting of one, two, three or more compositions administered according to a specific schedule can be suitable for individual patients' cysteamine production, absorption, and metabolic capacity. Since it is known that these abilities vary between patients, a known limitation of existing cysteamine preparations is solved by a formulation containing multiple uniform compositions of different cysteamine precursors and different drug release characteristics, and the multiple uniform compositions can be combined in different ratios for different patients.

[0308] Preferably, the combination of two or more pharmaceutical compositions can maintain cysteamine blood levels within the therapeutic range for at least 2-8 hours after ingestion, more preferably 1-8 hours after ingestion, more preferably 2-10 hours and most preferably 1-10 hours, 1-12 hours, 1-14 hours or longer. Separately formulated pharmaceutical compositions containing different cysteamine precursors with different drug release profiles provide the dosing flexibility required for individualized dosing regimens to achieve therapeutically effective cysteamine blood concentrations over a long period of time.

[0309] There is ample evidence that gastric emptying time and colon transit time vary greatly in healthy individuals (up to two times or more). It is also known that the intestinal redox environment and pantetheine enzyme activity levels vary from individual to individual. These and other factors may explain the wide inter-individual variation in plasma cysteamine levels observed after cysteamine administration. For example, in a pharmacokinetic study of immediate release cysteamine bitartrate in healthy volunteers, the peak cysteamine blood level (Cmax) after a 600 mg oral dose was administered with a meal changed by more than 8 times, from 7 micromoles to 57.3 micromoles. (Dohil R. and P. Rioux, "Clinical Pharmacology of Drug Development (Drug Pharmacology in Drug Development)" 2: 178 (2013)). In the same study, the Cmax after 600 mg delayed release cysteamine bitartrate was administered with a meal changed by 12 times, from 2.1 μM to 25.4 μM. When cysteamine is administered to fasting patients, interpatient variation in cysteamine plasma levels is less extreme but still as high as fourfold. ), or even every 12 hours (as in It is difficult to avoid mealtimes completely when there is a lack of food.

[0310] Current cysteamine formulations and administration methods provide only one tool to address inter-subject variability: increase or decrease the dose. The cysteamine precursors, enhancers of in vivo cysteamine production and absorption, pharmaceutical formulation methods, and pharmaceutical administration methods of the present invention provide multiple tools to achieve therapeutic blood cysteamine levels by tailoring the compound, dosage form, and dosing regimen to the individual patient without causing unacceptable toxicity typically associated with high Cmax or inadequate therapeutic effects associated with blood levels chronically below the therapeutic threshold.

[0311] Another advantage of the separately formulated composition is that it can be administered at different times relative to the meal. This is a useful option because different classes of cysteamine precursors and different types of preparations interact differently with the meal. For example, gastric retention preparations should be administered with or shortly after a meal, preferably a nutrient-rich meal, to maximize the duration of gastric retention. In contrast, immediate release preparations containing mixed disulfides of cysteamine that can be rapidly converted to cysteamine by disulfide bond reduction should preferably not be administered with a large meal. Large meals interfere with the absorption of cysteamine in some individuals, but meals are compatible with certain cysteamine precursors that produce little cysteamine in the stomach, such as pantetheine disulfide, which tends to be converted to cysteamine in the small intestine.

[0312] The individualized dosing regimens possible with the compounds and formulations of the invention are particularly useful because, while extensive inter-individual variation in intestinal absorption of cysteamine has been well documented, it has also been well documented that intra-individual variation is modest by comparison. That is, a given subject will absorb and metabolize a dose of cysteamine substantially similarly when administered on multiple occasions under similar circumstances. Thus, once individualized to produce blood cysteamine levels within the therapeutic range for a particular patient, the dosing regimen should be relatively stable and produce predictable results over time.

[0313] Sustained release formulations can be designed using methods known in the art to release drugs over widely varying time periods. (Wen, H. and Park, K., eds., Oral Controlled Release Formulation Design and Drug Delivery: Theory and Practice, Wiley, 2010; Wells, JI and Rubinstein, MH, eds., Pharmaceutical Technology: Controlled Drug Release, Vols. I and II, Ellis and Horwood, 1991, and Gibson, M., ed., Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form, 2nd ed., Informa, 2009).

[0314] Fig.14 , 1516 provide examples of pharmaceutical compositions of the present invention, intended to illustrate aspects such as active ingredients (cysteamine precursor, enhancer of conversion of cysteamine precursor to cysteamine, and enhancer of intestinal absorption of cysteamine), dosage range (for all active components combined), formulation type (including mixed formulations), combination of composition and administration method (e.g., with food or with a meal). The active ingredients include a cysteamine precursor and an enhancer of in vivo cysteamine production and an enhancer of intestinal absorption of cysteamine.

[0315] Formulations for oral administration

[0316] Pharmaceutical compositions contemplated by the present invention include those formulated for oral administration ("oral dosage forms"). Oral dosage forms may be, for example, in the form of tablets, capsules, liquid solutions or suspensions, powders or liquids or solid crystals or particles containing a mixture of the active ingredient and a nontoxic pharmaceutically acceptable excipient. If formulated as a liquid, powder, crystal or particle, the dosage may be packaged in a manner that clearly delineates a unit dose. For example, the powder or granules or microparticles may be packaged in a sachet. The liquid may be packaged in a glass or plastic container.

[0317] Excipients are selected to provide acceptable organoleptic properties, control drug release characteristics, facilitate efficient manufacturing and ensure long-term stability of the pharmaceutical composition, as well as other considerations known to those skilled in the art of pharmacology, pharmacy and drug manufacturing. Excipients can be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose, starch (including potato starch), calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate or sodium phosphate); granulating and disintegrants (e.g., cellulose derivatives including microcrystalline cellulose, starch including potato starch, cross-linked sodium carboxymethyl cellulose, alginates or alginic acid); binders (e.g., sucrose, glucose, sorbitol, gum arabic, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, sodium carboxymethyl cellulose, methylcellulose, hydroxypropyl methylcellulose, ethylcellulose, polyvinyl pyrrolidone or polyethylene glycol); and lubricants, glidants and anti-adherents (e.g., magnesium stearate, zinc stearate, stearic acid, silicon dioxide, hydrogenated vegetable oils or talc). Other pharmaceutically acceptable excipients may be colorants, flavoring agents, plasticizers, humectants, preservatives, buffers, stabilizers, etc. Many of these excipients are sold in a variety of chemical forms by multiple excipient manufacturers, and / or may be used in different concentrations, and / or in different combinations with other excipients, with subsequent differences in performance characteristics. A particular excipient may fulfill more than one purpose in a formulation.

[0318] Formulations for oral administration may also be presented as chewable tablets, as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g. potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin), or as soft gelatin capsules in which the active ingredient is mixed with water or an oil medium (e.g. peanut oil, liquid paraffin or olive oil). Powders, granules and pellets may be prepared in a conventional manner using the ingredients mentioned above under tablets and capsules, using, for example, a mixer, fluidized bed equipment or spray drying equipment.

[0319] A useful preparation of one kind mainly controls the drug release rate (such as immediate release and sustained release preparations), although it has an important influence on the location of drug release. The second kind of useful preparation mainly controls the anatomical site of drug release (such as gastric retention preparations for drug release in the stomach, colon targeting preparations for the large intestine), although it has an impact on the release time. Enteric coating preparations have the following two important elements: it is designed to remain intact in the acidic stomach environment, and is usually dissolved in the more alkaline small intestine, which is a kind of anatomical targeting, but it is usually called delayed release preparations, highlighting the time control element. However, colon targeting preparations can also have enteric coatings to prevent dissolution in the stomach, highlighting the complex relationship between anatomical targeting and controlling drug release rate. In addition, there is a wide overlap between the excipients used in preparations based on time and anatomical or physiological targeting. These types of preparations can be combined in various ways to produce a variety of compositions with different drug release curves in time and space. These compositions can be combined in different amounts and ratios to individualize treatment plans to adapt to biochemical and physiological changes between patients, as well as changes in disease types, degrees and activity.

[0320] Gastric retentive preparations

[0321] Gastric retentive formulations can be used to release cysteamine precursors or salts thereof from the composition of the present invention in the stomach and control the release of the active ingredient of the composition in the stomach over an extended period of time. In other words, since the main point of gastric retentive formulations is that the gastric retention time is extended, the accompanying excipients should provide sustained release of the active ingredient over the entire period of time that the gastric retentive dosage form is expected to remain in the stomach and optionally for a longer period of time (including the time of passing through the small intestine and entering the colon). Gastric retention of the active ingredient of the present invention can be achieved by various mechanisms, such as mucoadhesion, floating, sedimentation, swelling and expansion, and / or by co-administration of pharmacological agents that delay gastric emptying. The excipients used in gastric retentive formulations and the size and shape of the pharmaceutical composition vary depending on the gastric retention mechanism.

[0322] Mucoadhesive / bioadhesive gastroretentive formulations

[0323] Mucoadhesion involves the adhesion of the polymer used in the formulation to the gastrointestinal mucus layer until it is spontaneously removed from the surface due to continued mucus production. Bioadhesion, sometimes used interchangeably with mucoadhesion, also includes the adhesion of polymers or other components of the pharmaceutical composition to molecules on the surface of gastrointestinal epithelial cells. The purpose of mucoadhesion and bioadhesion is to increase the time that the pharmaceutical composition is in close proximity to gastrointestinal epithelial cells, including cell types that are capable of cysteamine precursor cleavage (i.e., cells that express pantetheine enzymes on their surfaces), and cysteamine absorption and transport to the circulation (e.g., cells that express organic cation transporters). Mucoadhesive polymers can be used to formulate large dosage forms (such as tablets or capsules) and small dosage forms (such as microparticles or microspheres). Various physiological factors, such as peristalsis, mucin type, mucin turnover rate, gastrointestinal pH, fasting / fed state, and food type in the fed state affect the degree and persistence of mucoadhesion. The mechanism of mucoadhesion is believed to be through the formation of electrostatic and hydrogen bonds at the polymer-mucus boundary. Typically, mucoadhesion is achieved with a polymer that has an affinity for gastrointestinal mucus and is selected from synthetic or natural bioadhesive materials, such as polyacrylic acid, methacrylic acid and derivatives of both, polybrene, polylysine, polycarbophil, carbomer, alginates, polyglucosamine, cholestyramine, gums, lectins, polyethylene oxide, sucralfate, tragacanth, dextrins (e.g., hydroxypropyl β-cyclodextrin), polyethylene glycol (PEG), gliadin, cellulose and cellulose derivatives, such as hydroxypropyl methylcellulose (HPMC), or mixtures thereof. For example, cross-linked acrylic acid and methacrylic acid copolymers available under the trade names CARBOPOL (e.g., Carbopol 974P and 971P) and POLYCARBOPHIL have been used in mucoadhesive formulations. (Hombach J. and A. Bernkop-Schnürch. Handbook of Experimental Pharmacology 197: 251 (2010)). Other bioadhesive cationic polymers include acidic gelatin, polygalactosamine, polyamino acids (e.g., polylysine, polyornithine), polyquaternary compounds, prolamins, polyimines, diethylaminoethyldextran (DEAE), DEAE-imine, polyvinylpyridine, polythiodiethylaminomethylethylene (PTDAE), polyhistidine, DEAE-methacrylate, DEAE-acrylamide, polyparaaminostyrene, polyethylene oxide, Eudragit RL, Eudragit RS, GAFQUAT, polyamidoamines, cationic starch, DEAE-polyglucose, DEAE-cellulose and copolymerized methacrylates, including copolymers of HPMA, N-(2-hydroxypropyl)-methacrylamide (see, for example, U.S. Pat. No. 6,207,197).

[0324] Mucoadhesion is most effective when applied to small particles (eg, microparticles).Mucoadhesive formulations may be combined with one or more of the other gastroretentive formulation approaches described below, including floating formulations, swelling / swelling formulations, or any type of sustained release formulation.

[0325] Floating gastric retention preparations

[0326] Floating as a gastric retention mechanism is effective in formulations of active ingredients (e.g., cysteamine precursors) with a bulk density lower than that of gastric fluid and / or chyme (partially digested food in the stomach) in order to maintain buoyancy in the stomach. It is generally desirable that the density be less than 1 g / cm3, more preferably less than 0.9 g / cm3. Buoyancy can be achieved by (i) using low-density materials (including lipids), (ii) preforming one or more bubbles in the center of the composition, or (iii) using effervescent excipients to generate bubbles in vivo. The pharmaceutical composition of the latter type must be designed so that the gas generated by the effervescent excipient is retained in the composition and thereby contributes to its buoyancy. For example, the effervescent excipient can be embedded in a polymer matrix to capture the bubbles in the composition. The buoyant formulation of the latter type generally uses a matrix prepared from a swellable polymer or polysaccharide and an effervescent pair, such as sodium bicarbonate and citric acid or tartaric acid or a matrix containing a chamber for trapping air or liquid, which generates gas when in contact with liquid gastric contents at body temperature. Floating gastroretentive formulations have been extensively reviewed (eg, Kotreka, UK Critical Reviews in Therapeutic Drug Carrier Systems, 28:47 (2011)).

[0327] Floating drug compositions designed for gastric retention have been known in the art for some time. For example, U.S. Pat. Nos. 4,126,672, 4,140,755, and 4,167,558, each of which is incorporated herein by reference, describe a "hydrodynamically balanced" drug delivery system (HBS) in tablet form, whose density is less than that of gastric fluid (i.e., less than 1 gram per cubic centimeter). Thus, the composition floats on gastric fluid or chyme, thereby avoiding expulsion through the pylorus during muscular contractions of the stomach. The drug is released continuously from a cellulose-derived hydrophilic colloid, such as methylcellulose, hydroxyalkylcellulose (e.g., hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose), or sodium carboxymethylcellulose, which forms an impermeable barrier on the surface of the composition upon contact with gastric fluid, which barrier gradually erodes, slowly releasing the drug. In U.S. Pat. No. 4,140,755, incorporated herein by reference, a bilayer floating tablet is disclosed, having an outer layer formulated for immediate release and an inner layer formulated for sustained release.

[0328] Similar hydrodynamically balanced floating formulations for sustained delivery of L-dopa and decarboxylase inhibitors have also been described (see U.S. Pat. No. 4,424,235). Hydrophilic colloids such as gum arabic, tragacanth, locust bean gum, guar gum, acacia gum, agar, pectin, carrageenan, soluble and insoluble alginates, carboxypolymethylene, gelatin, casein, zein, and bentonite can be used to prepare the floating formulations of the present invention. The floating formulation may include up to about 60% of a fatty substance or a mixture of fatty substances selected from beeswax, cetyl alcohol, stearyl alcohol, glyceryl monostearate, hydrogenated castor oil, and hydrogenated cottonseed oil (the density of fats and oils is lower than that of gastric fluid). The floating formulation can promote sustained release of cysteamine precursors and provide higher plasma cysteamine levels for a longer period of time. The prolonged higher plasma cysteamine levels allow for less frequent dosing.

[0329] The floating composition of the present invention may contain a gas generating agent. Methods of formulating floating compositions using gas generating compounds are known in the art. For example, floating microcapsules containing sodium bicarbonate are described in U.S. Pat. No. 4,106,120. Similar floating particles based on gas generation are described in U.S. Pat. No. 4,844,905. Floating capsules have been described in U.S. Pat. No. 5,198,229.

[0330] The floating composition may optionally contain an acid source and a carbonate or bicarbonate agent that generates gas, which together act as an effervescent pair to generate carbon dioxide gas, which provides buoyancy for the formulation. When the mixture is in contact with water or when the alkaline component is in contact with an acidic liquid (e.g., gastric juice), the effervescent pair consisting of a soluble organic acid and an alkali metal carbonate forms carbon dioxide. Typical examples of the acid used include citric acid, tartaric acid, malic acid, fumaric acid, or adipic acid. Typical examples of the gas-generating alkali used include sodium bicarbonate, sodium carbonate, sodium glycine carbonate, sodium sesquicarbonate, potassium carbonate, potassium bicarbonate, calcium carbonate, calcium bicarbonate, ammonium bicarbonate, sodium bisulfite, sodium metabisulfite, etc. The gas generator interacts with the acid source triggered by contact with water or contact with hydrochloric acid in gastric juice to generate carbon dioxide or sulfur dioxide, which is trapped in the matrix of the composition and improves its floating characteristics. In one embodiment, the gas generator is sodium bicarbonate and the acid source is citric acid.

[0331] The dynamics of floating are important because if the composition is not lighter than gastric juice and / or chyme shortly after reaching the stomach, it will likely be rapidly discharged through the pylorus. Some compositions have a lower density than gastric juice and chyme when ingested, such as compositions containing preformed bubbles, or compositions containing low-density materials (such as lipids). For those floating compositions (i.e., effervescent formulations) that must reach a density lower than gastric juice and / or chyme after reaching the stomach, it is preferred to reach a density lower than 1 gram / cubic centimeter within 30 minutes, more preferably within 15 minutes, and most preferably within ten minutes after contact with gastric juice. The duration of floating is also important and should be matched to the duration of drug release. That is, if the composition is designed to release the drug within 6 hours, it should also be able to float for 6 hours. Preferably, the floating composition maintains a density less than 1 for at least 5 hours, more preferably 7.5 hours, more preferably 10 hours or more.

[0332] Large doses of cysteamine precursors (e.g., 2-10 grams) may be required to effectively treat some cysteamine-sensitive diseases, and / or to achieve adequate blood levels in tall adult subjects. Because the amount of any active agent that can be included in a standard dosage form (e.g., tablet, capsule) is limited by the patient's ability to swallow a large composition, and further because the administration of multiple tablets or capsules may be inconvenient or unpleasant (or impossible for patients with dysphagia), alternative dosage forms that do not limit the amount of active agent in a unit dosage form are useful. Powders, granules, and liquids are examples of non-size-limited dosage forms that can still be delivered in unit doses by suitable packaging, such as in a sachet or vial. In some embodiments of the present invention, the floating gastric retention composition of the present invention is administered in liquid form. In another embodiment, the liquid composition includes alginate. In other embodiments, the active pharmaceutical ingredient is delivered in the form of a powder or granules that can be sprinkled on food.

[0333] A liquid gastric retention floating drug delivery system utilizes alginate as an excipient. Alginate is a linear block polysaccharide copolymer made of β-D-mannuronic acid and α-L-guluronic acid residues linked by 1,4 glycosidic bonds. It is used for a variety of purposes in pharmaceutical compositions, including as a sustained release polymer (see Murata et al., Eur J Pharm Biopharm 50:221 (2000)). Gaviscon is a brand name for a floating liquid alginate formulation containing an antacid. It has been used to treat gastroesophageal reflux for decades, so the safety of chronic alginate intake has been well established. Alginate floating formulations with small molecule drugs have been described (see Katayama et al., Biol Pharm Bull. 22:55 (1999); and Itoh et al., Drug Dev Ind Pharm. 36:449 (2010)). Floating formulations that form a layer on the surface of the gastric contents are sometimes referred to as raft-forming formulations. Raft-forming floating / gelled sustained release compositions have been described by Prajapati et al., J Control Release 168:151 (2013); and Nagarwal et al., Curr Drug Deliv. 5:282 (2008).

[0334] The U.S. Patent No. 4,717,713, which is incorporated herein by reference, discloses a liquid (drinkable) preparation, which forms a semisolid gel-like matrix in the stomach when in contact with the gastric contents, thereby realizing the controlled release of the drug from the gelatinous matrix. Disclosed is a gel-forming vehicle, including xanthan gum, sodium alginate, complex coacervation pairs, such as gelatin or other polymers and carrageenan, and thermogel methylcellulose, all or part of which can be combined in various ratios to affect the dissolution and / or diffusion rate of the suspended pharmaceutical active agent. Other excipients used include carbonate compounds, such as calcium carbonate, which effectively float the gel as a gelling accelerator and as a gas generating agent. Xyloglucan and gellan gum can also be used as gelling agents, or a combination of gelling agents.

[0335] Liquid (drinkable) floating formulations may include microparticles, which may be provided as a liquid suspension (concentrate or ready-to-use) or as a powder that can be added to a liquid (e.g., water, juice or other beverage). Floating gastric retentive compositions may also be delivered in powder form for sprinkling on or otherwise mixing with food.

[0336] Floating gastric retention formulations may include mucoadhesive polymers or other mucoadhesive components (see U.S. Pat. Nos. 6,207,197 and 8,778,396, incorporated herein by reference), and polymers such as polyethylene oxide, polyvinyl alcohol, sodium alginate, ethylcellulose, poly(lactic)-co-glycolic acid (PLGA), polylactic acid, polymethacrylate, polycaprolactone, polyesters, polyacrylic acid, and polyamides may be used.

[0337] Swelling and expanding gastric retentive compositions

[0338] Swelling and expansion are gastric retention mechanisms in which, upon contact with gastric fluid, the composition swells to a degree that prevents it from leaving the stomach through the pylorus. As a result, the composition is retained in the stomach for a long time, for example until the surface of the composition is eroded to reduce its diameter to less than the diameter of the pylorus, or until the food is substantially emptied from the stomach, at which time strong muscle contractions (sometimes referred to as "housekeeper waves") sweep through the stomach, clearing its contents. When the composition exceeds a diameter of about 14-16 mm in the swollen or expanded state, the composition is excluded from passing through the pyloric sphincter. Preferably, the diameter of the composition exceeds 16-18 mm. Swelling can be combined with flotation, which keeps the formulation away from the pylorus, especially in the fed state.

[0339] The concept of a formulation that swells upon contact with gastric fluid and is thus retained in the stomach has been known since the 1960s. U.S. Pat. No. 3,574,820 discloses a tablet that swells upon contact with gastric fluid to a size that prevents it from passing through the pylorus and is thus retained in the stomach. Similarly, U.S. Pat. No. 5,007,790 describes a tablet or capsule composed of a hydrophilic, water-swellable, cross-linked polymer that swells rapidly to promote gastric retention while allowing drug molecules mixed with the polymer to dissolve slowly.

[0340] U.S. Patent Publication No. 20030104053, incorporated herein by reference, discloses a unit dosage tablet for delivering a drug wherein the active ingredient is dispersed in a solid single matrix formed by a combination of poly(ethylene oxide) and hydroxypropyl methylcellulose. This combination is said to provide unique benefits in terms of release rate control and reproducibility while allowing the tablet to swell to achieve gastric retention and the tablet to gradually disintegrate to clear the tablet from the gastrointestinal tract after drug release occurs. U.S. Patent No. 6,340,475, also assigned to DepoMed (incorporated herein by reference), highlights a unit oral dosage form of an active ingredient produced by incorporating the active ingredient into a polymer matrix composed of a hydrophilic polymer that swells upon absorbing water to a size large enough to facilitate retention of the dosage form in the stomach during a fed mode. The polymer matrix is ​​formed from a polymer selected from the group consisting of poly(ethylene oxide), cellulose, cross-linked polyacrylic acid, xanthan gum, and alkyl-substituted celluloses such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, and microcrystalline cellulose.

[0341] In addition, DepoMed researchers have developed a gum-based swelling gastric retention system. U.S. Patent No. 6,635,280, incorporated herein by reference, discloses a controlled release oral dosage form for a highly water-soluble drug, comprising one or more polymers forming a solid polymer matrix that swells to a size large enough to facilitate retention of the dosage form in the stomach during the feeding mode when water is absorbed. The polymer matrix can be formed by a polymer selected from the following: poly(ethylene oxide), cellulose, alkyl-substituted cellulose, cross-linked polyacrylic acid, and xanthan gum. U.S. Patent No. 6,488,962, incorporated herein by reference, discloses an optimal tablet shape that prevents passage through the pylorus while maintaining ease of swallowing. Tablets are prepared using water-swellable polymers, including cellulosic polymers and their derivatives, polysaccharides and their derivatives, polyalkylene oxides, polyethylene glycols, polyglucosamines, poly(vinyl alcohol), xanthan gum, maleic anhydride copolymers, poly(vinyl pyrrolidone), starch and starch-based polymers, maltodextrin, poly(2-ethyl-2-oxazoline), poly(ethyleneimine), polyurethane hydrogels, cross-linked polyacrylic acid and its derivatives, and copolymers of the polymers listed above, including block copolymers and graft polymers.

[0342] U.S. Patent No. 6,723,340, incorporated herein by reference, discloses an optimal polymer mixture for preparing a swelling gastric retention composition. The mixture provides optimal control of swelling and drug release parameters as well as control of dissolution / erosion parameters to ensure that the composition enters the small intestine after substantially complete drug release. A preferred polymer mixture includes a combination of poly(ethylene oxide) and hydroxypropyl methylcellulose. A preferred molecular weight range and viscosity range are provided for the polymer mixture.

[0343] The methods described in the above patent publications have been used to formulate four US FDA-approved swelling gastric retentive formulations described in various publications (e.g., reviewed in: Berner et al., Expert Opin Drug Deliv. 3:541 (2006)).

[0344] U.S. Patent Publication No. 20080220060, incorporated herein by reference, discloses a gastric retention formulation comprising an active substance granulated with a mixture of a weak gelling agent, a strong gelling agent, and a gas generating agent. Herein, the strong gelling agent is selected from the group consisting of methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose without low-substituted hydroxypropyl cellulose, hydroxyethyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, xanthan gum, guar gum, carrageenan, locust bean gum, sodium alginate, agar, gelatin, modified starch, copolymers of carboxyvinyl polymers, copolymers of acrylates, copolymers of ethylene oxide and propylene oxide, and mixtures thereof. The patent also describes a manufacturing method. U.S. Patent No. 7,674,480 discloses a swelling gastric retention formulation method using a mixture including a super disintegrant, tannic acid, and one or more hydrogels to provide very rapid swelling. U.S. Patent Publication No. 20040219186, incorporated herein by reference, provides an expandable gastric retention device comprising a gel formed from a polysaccharide based on xanthan gum or locust bean gum or a combination thereof. U.S. Patent Publication No. 20060177497, incorporated herein by reference, discloses an oral controlled release dosage form based on gellan gum as a platform technology for gastric retention. The dosage form also comprises a hydrophilic polymer, such as guar gum, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, xanthan gum.

[0345] U.S. Patent No. 6,660,300 discloses a biphasic swelling gastric retention formulation technology suitable for delivering water-soluble drugs, wherein swelling and drug release are achieved through separate compartments of the composition: an inner solid particulate phase comprising a drug and one or more hydrophilic polymers, one or more hydrophobic polymers and / or one or more hydrophobic materials, such as waxes, fatty alcohols and / or fatty acid esters. One or more hydrophobic polymers and / or one or more hydrophobic materials (such as waxes, fatty alcohols and / or fatty acid esters) are used to form an outer solid continuous phase (in which particles of the drug-containing inner phase are embedded). Tablets and capsules are disclosed.

[0346] Other excipients suitable for use in the swollen or expandable matrix formulation include (i) a water-swellable polymer matrix and (ii) a hydrophilic polymer selected from the group consisting of polyalkylene oxides, particularly poly(ethylene oxide), polyethylene glycol and poly(ethylene oxide)-poly(propylene oxide) copolymers; cellulosic polymers; acrylic and methacrylic acid polymers, copolymers and esters thereof, preferably copolymers of acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate and other acrylate species thereof with each other or with aminoethyl acrylate; maleic anhydride copolymers; polymaleic acid; poly(acrylamides), such as polyacrylamide itself, poly(methacrylamide), poly(dimethylacrylamide) and poly(N-isopropylacrylamide); poly(enols), such as poly(vinyl alcohol); poly(N-vinyl lactams), such as poly(vinyl pyrrolidone); ), poly(N-vinyl caprolactam) and copolymers thereof; polyols such as glycerol, polyglycerols (especially highly branched polyglycerols), propylene glycol and 1,3-propylene glycol, which are substituted with one or more polyalkylene oxides, such as mono-, di- and tri-polyoxyethylated glycerols, mono- and di-polyoxyethylated propylene glycols, and mono- and di-polyoxyethylated 1,3-propylene glycol; polyoxyethylated sorbitol and polyoxyethylated glucose; polyoxazolines, including poly(methyloxazoline) and poly(ethyloxazoline); polyvinylamine; polyvinyl acetate, including polyvinyl acetate itself and ethylene-vinyl acetate copolymers, polyvinyl acetate phthalate, and the like, polyimines, such as polyethyleneimine; starch and starch-based polymers; polyurethane hydrogels; polyglucosamine; polysaccharide gums; zein; and shellac, ammoniated shellac, shellac-acetyl alcohol and shellac n-butyl stearate. The gastroretentive formulations may also include any combination of floating formulations, mucoadhesive formulations, swellable matrix formulations, shape-deforming formulations, and / or magnetic formulations.

[0347] In some embodiments, the pharmaceutical composition of the invention is a gastroretentive composition that is retained in the stomach due to swelling to a size that inhibits passage through the pylorus. In further embodiments, the gastroretentive composition is retained in the stomach by both swelling and flotation mechanisms.

[0348] Expanded and deformed gastric retentive preparations

[0349] Also described are pharmaceutical compositions that expand, decompress or otherwise change size and / or shape when in contact with liquid gastric contents, and are suitable delivery vehicles for the compounds and formulations of the present invention. Such compositions employ principles similar to swelling / expansion gastric retention formulations, because they change the shape in the stomach to a size and / or geometry that is not easily permitted to pass through the pylorus. Methods and materials for preparing expanded, stretched or otherwise deformed gastric retention compositions are known in the art. For example, U.S. Patent No. 3,844,285 describes a variety of such devices for veterinary use in ruminants, but the basic principles are also applicable to human gastric retention formulations. U.S. Patent No. 4,207,890 describes a controlled release drug delivery system, which consists of a "collapsed, expandable, non-porous polymeric envelope of a medicament containing an effective amount of expansion agent inside", which swells and expands when in contact with gastric fluid, and is therefore retained in the stomach in an expanded state. The composition is administered in a disintegrated form in a capsule. Unfolding and deforming gastroretentive compositions have been reviewed (eg, Klausner et al., Journal of Controlled Release 90: 143 (2003)).

[0350] An exemplary unfolded gastric retention technology called the "Accordion Pill" is being developed by IntecPharma (Jerusalem, Israel). Various shapes of multi-layered planar structures, at least one of which contains a drug, are folded into an accordion or stepped shape and packaged in a capsule, as described in Kagan, L. Journal of Controlled Release 113:208 (2006). Other features of the accordion pill and related technology are disclosed in U.S. Pat. No. 6,685,962, which is incorporated herein by reference, including preferred pharmaceutical excipients for its construction. The capsule dissolves upon contact with gastric contents, releasing the folded composition, which rapidly unfolds and is then retained in the stomach for up to 12 hours when administered with a regular meal.

[0351] Other gastric retention technologies include superporous hydrogels and ion exchange resin systems. Superporous hydrogels swell rapidly (within one minute of contact with liquid) due to rapid water absorption through many interconnected pores. The composition can swell to 100 times or more of its original size, but still maintain sufficient mechanical strength to withstand the gastric contraction forces caused by co-formulation with hydrophilic polymers such as cross-linked sodium carboxymethylcellulose (e.g., trade name: Ac-Di-Sol). Ion exchange resin beads can be loaded with negatively charged drugs and floated using gas generators (e.g., bicarbonate, which reacts with chloride ions in gastric fluid to produce carbon dioxide gas). The beads are encapsulated in a semipermeable membrane that captures gas, resulting in long-term floating of the beads.

[0352] Gastric retentive formulations may also include any combination of mucoadhesive, floating, raft-forming, swelling, unfolding / deformation, superporous hydrogel, or ion exchange resin formulations. Such combinations are known to those skilled in the art. For example, U.S. Pat. No. 8,778,396 ("Multiple Unit Gastrointestinal Dosage Forms Comprising Microparticles"), which is incorporated herein by reference in its entirety, describes a mucoadhesive floating gastric retentive formulation composed of a combination of microparticles.

[0353] The compositions of the present invention may include, but are not limited to, hydrophilic polymers having swelling and / or mucoadhesive properties to further promote gastric retention. Hydrophilic polymers having swelling and / or mucoadhesive properties are suitable for incorporation into the compositions of the present invention, including, but are not limited to, polyalkylene oxides; cellulosic polymers; acrylic and methacrylic acid polymers and their esters, maleic anhydride polymers; polymaleic acid; poly(acrylamide); poly(enol); poly(N-vinyl lactam); polyols; polyoxyethylated sugars; polyoxazolines; polyvinylamines; polyvinyl acetates; polyimines; starch and starch-based polymers; polyurethane hydrogels; polyglucosamine; polysaccharide gums; zein; shellac-based polymers; polyethylene oxide, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, methyl cellulose, polyacrylic acid, maltodextrin, pregelatinized starch, and polyvinyl alcohol, copolymers and mixtures thereof.

[0354] The release of the active ingredient from the composition can be achieved by using suitable retardants, including excipients well known in the pharmaceutical art due to their release retardant properties. Examples of such release retardants include, but are not limited to, polymeric release retardants, non-polymeric release retardants, or any combination thereof.

[0355] Polymeric release retardants useful for the purposes of the present invention include, but are not limited to, cellulose derivatives; polyols; sugars, gums and derivatives thereof; vinyl derivatives, polymers, copolymers or mixtures thereof; maleic acid copolymers; polyalkylene oxides or copolymers thereof; acrylic acid polymers and acrylic acid derivatives; or any combination thereof. Cellulose derivatives include, but are not limited to, ethylcellulose, methylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), hydroxyethylcellulose, hydroxymethylcellulose, hydroxyethylmethylcellulose, carboxymethylcellulose (CMC) or combinations thereof. Polyols include, but are not limited to, polyethylene glycol (PEG) or polypropylene glycol; or any combination thereof. Sugars, gums and derivatives thereof include, but are not limited to, dextrin, polydextrin, polydextrose, pectin and pectin derivatives, alginic acid, sodium alginate, starch, hydroxypropyl starch, guar gum, locust bean gum, xanthan gum, locust gum, tragacanth gum, carrageenan, gum arabic, gum arabic, fenugreek fiber or gellan gum, etc.; or any combination thereof. Vinyl derivatives, polymers, copolymers or mixtures thereof include (but are not limited to) polyvinyl acetate, polyvinyl alcohol, a mixture of polyvinyl acetate (8 parts w / w) and polyvinyl pyrrolidone (2 parts w / w) (Kollidon SR), vinyl pyrrolidone copolymers, vinyl acetate copolymers, polyvinyl pyrrolidone (PVP); or combinations thereof. Polyalkylene oxides or copolymers thereof include (but are not limited to) polyethylene oxide, polypropylene oxide, poly(oxyethylene)-poly(oxypropylene) block copolymers (poloxamers) or combinations thereof. Maleic acid copolymers include (but are not limited to) vinyl acetate maleic anhydride copolymers, butyl acrylate styrene maleic anhydride copolymers, etc. or any combination thereof. Acrylic acid polymers and acrylic acid derivatives include (but are not limited to) carbomer, methacrylic acid, polymethacrylic acid, polyacrylates, polymethacrylates, etc. or combinations thereof. Polymethacrylates include, but are not limited to, a) copolymers formed from monomers selected from methacrylic acid, methacrylates, acrylic acid and acrylates, c) copolymers formed from monomers selected from ethyl acrylate, methyl methacrylate and trimethylammonioethyl methacrylate chloride, etc., or any combination thereof. Non-polymeric release retardants useful for the purposes of the present invention include, but are not limited to, fats, oils, waxes, fatty acids, fatty acid esters, long chain monohydric alcohols and esters thereof, or combinations thereof.In one embodiment, non-polymeric release retardants used in the present invention include, but are not limited to, Cutina (hydrogenated castor oil), Hydrobase (hydrogenated soybean oil), Castorwax (hydrogenated castor oil), Croduret (hydrogenated castor oil), Carbowax, Compritol (glyceryl behenate), Sterotex (hydrogenated cottonseed oil), Lubritab (hydrogenated cottonseed oil), Apifil (sallow), Akofine (hydrogenated cottonseed oil), Softtisan (hydrogenated palm oil), Hydrocote (hydrogenated soybean oil), Corona (lanolin), Gelucire (polyethylene glycol laurate), Precirol (glyceryl palmitostearate), Emulcire (cetyl alcohol), Plurol diisostearique (polyglyceryl diisostearate) and Geleol (glyceryl stearate), and mixtures thereof.

[0356] The gastroretentive composition of the present invention may be in the form of, for example, but not limited to, a monolithic or multilayer dosage form or an embedded system. In one embodiment of the present invention, the gastroretentive composition is in the form of a bilayer or trilayer solid dosage form. In an illustrative embodiment, a solid pharmaceutical composition in the form of an expanded bilayer system for oral administration is suitable for delivering an active pharmaceutical ingredient from the first layer immediately upon reaching the gastrointestinal tract and delivering another pharmaceutical agent, which may be the same or different from the second layer, in a modified manner within a specific time period. The second layer may be formulated to swell in the composition, thereby prolonging the retention of the composition in the stomach.

[0357] In another illustrative embodiment, a solid pharmaceutical composition for oral administration contains two layers: one layer contains the active ingredient and a suitable release retardant, and the other layer contains a swellable agent in combination with other excipients. In another embodiment of the invention, a solid pharmaceutical composition for oral administration contains an embedding system, which is a dedicated dosage form, comprising a first tablet containing the active ingredient, which is placed inside a second tablet containing excipients that ensure gastric retention. In this system, the tablet containing the active ingredient is small and is covered on all sides except at least one side with a blend of excipients, which contain a swellable polymer or a floating system or both, which ensure gastric retention.

[0358] In another embodiment of the invention, the dosage form may be optionally coated. The surface coating may be used for sensory purposes (particularly thiols or disulfides with odor or unpleasant taste), for drug labeling purposes (e.g., color coding systems for dosage forms), for aesthetic purposes, for stabilizing the dimensions of compressed dosage forms, or for delaying drug release. The surface coating may be any conventional coating suitable for enteral use. Any conventional technique for conventional ingredients may be used for coating. The surface coating may be obtained, for example, using a fast dissolving film using conventional polymers, such as, but not limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose, polyvinyl alcohol, polymethacrylate, etc. Coating excipients and methods of using them are well known in the art. See, for example, McGinity, James W. and Linda A. Felton, Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms, 3rd edition, Informa Healthcare, 2008.

[0359] In addition, in another embodiment of the present invention, the composition is in the form of multi-particulates, including but not limited to pellets, microspheres, microcapsules, microbeads, microparticles or nanoparticles, which have extended transit in the intestine to effectively deliver active agents that require longer retention time in the intestine. The multi-particulate system can be (i) bioadhesive or mucoadhesive, thereby delaying gastrointestinal transit, or (ii) can float on the top of the gastric contents, optionally forming a gel-like layer, or (iii) can be coated with a pH-sensitive outer layer or a layer that dissolves in the weakly acidic environment of the small intestine, or in the neutral to slightly alkaline environment of the ileum (usually the intestinal segment with the highest pH), or (iv) can be formed using a drug containing a polymer that is not digested by human enzymes, but can be digested by enzymes produced by intestinal bacteria, resulting in drug release in the distal ileum and colon. In one embodiment, the composition of the present invention in the form of multi-particulates is gastro-retentive. Such multi-particulate systems can be prepared by methods including but not limited to granulation, granulation, spray drying, spray congealing, etc.

[0360] Suitable polymer release control agents can be used in the present composition. In one embodiment, the polymer release control agent is pH independent or pH dependent or any combination thereof. In another embodiment, the polymer release control agent used in the present composition can be swelling or non-swelling. In another embodiment, the polymer release control agent that can be used in the present composition includes (but is not limited to) cellulose derivatives, sugars or polysaccharides, poly (ethylene oxide)-poly (propylene oxide) block copolymers (poloxamers), vinyl derivatives or their polymers or copolymers, polyalkylene oxides and their derivatives, maleic acid copolymers, acrylic acid derivatives, etc. or any combination thereof.

[0361] Controlled release compositions for oral use can be constructed to release active drugs by controlling the dissolution and / or diffusion of active drug substances. Any of many strategies can be adopted to obtain controlled release, and thereby optimize plasma concentration relative to the time curve. In an example, controlled release is obtained by appropriately selecting various formulation parameters and ingredients, including, for example, various types of controlled release compositions and coatings. Therefore, the drug is formulated into a pharmaceutical composition together with a suitable excipient, and the pharmaceutical composition releases the drug in a controlled manner after administration. Examples include single or multiple unit tablets or capsule compositions, oil solutions, liquids, suspensions, emulsions, microcapsules, microspheres, nanoparticles, powders and particles. In certain embodiments, the composition includes biodegradable pH and / or temperature-sensitive polymer coatings.

[0362] Dissolution or diffusion controlled release can be achieved by tablets, capsules, pills or granular preparations of suitable coated compounds, or by incorporating compounds into suitable matrixes. Controlled release coatings may include one or more of the above-mentioned coating materials and / or such as shellac, beeswax, sugar wax, castor wax, carnauba wax, stearyl alcohol, glyceryl monostearate, glyceryl distearate, glyceryl palmitostearate, ethylcellulose, acrylic resin, dl-polylactic acid, cellulose acetate butyrate, polyvinyl chloride, polyvinyl acetate, vinyl pyrrolidone, polyethylene, polymethacrylate, methyl methacrylate, 2-hydroxymethylacrylate, methacrylate hydrogel, 1,3-butylene glycol, ethylene glycol methacrylate and / or polyethylene glycol. In controlled release matrix preparations, matrix materials may also include such as hydrated methylcellulose, carnauba wax and stearyl alcohol, carbopol 934, silicone, tristearin, methyl acrylate-methyl methacrylate, polyvinyl chloride, polyethylene and / or halogenated fluorocarbons.

[0363] Alternatively, certain cysteamine precursors or enhancers of cysteamine production or absorption in the body can be formulated and administered as medical foods. Medical foods are regulated by the U.S. FDA as foods, not drugs. Methods for formulating medical foods are known in the art. See, for example, U.S. Patent Publication No. 20100261791, which describes methods for preparing and administering active compounds in foods or beverages. Nutracia is a medical food company headquartered in the Netherlands with more than 250 patent applications and patents describing methods for combining pharmacologically active agents with foods or beverages.

[0364] Coating

[0365] Pharmaceutical compositions formulated for oral delivery, such as tablets or capsules of the present invention, may be coated or otherwise mixed to provide a dosage form having a delayed or extended release advantage. The coating may be adapted to release the active drug substance in a predetermined pattern (e.g., to achieve a controlled release formulation), or it may be adapted to release the active drug substance only after passing through the stomach, such as by using an enteric coating (e.g., pH-sensitive polymers ("pH-controlled release"); polymers with slow or pH-dependent swelling, dissolution or erosion rates ("time-controlled release"); polymers that are degraded by enzymes ("enzyme-controlled release" or "biodegradable release"); and polymers that form a firm layer that is destroyed by increased pressure ("pressure-controlled release")). Exemplary enteric coatings that can be used for the pharmaceutical compositions described herein include sugar coatings, film coatings (e.g., based on hydroxypropylmethylcellulose, methylcellulose, methylhydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, acrylate copolymers, polyethylene glycol and / or polyvinylpyrrolidone), or coatings based on methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, polyvinyl acetate phthalate, shellac and / or ethylcellulose. In addition, time-delay materials such as glyceryl monostearate or glyceryl distearate can be used.

[0366] For example, a tablet or capsule may comprise an inner dosage and an outer dosage component, the latter being in the form of a coating on the former. The two components may be separated by an enteric layer, which serves to resist disintegration in the stomach and allow the inner component to pass intact into the duodenum or to be delayed in release.

[0367] When enteric coatings are used, ideally, a large amount of the drug is released in the lower gastrointestinal tract. Alternatively, a leaky enteric coating can be used to provide a release profile between immediate release and delayed release formulations. For example, U.S. Patent Application 20080020041A1 discloses a pharmaceutical formulation coated with an enteric material that releases at least a portion of the active ingredient when in contact with gastric fluid and the remainder when in contact with intestinal fluid.

[0368] In addition to the coating that affects delayed release or extended release, the solid tablet composition may include a coating that is suitable for protecting the composition from undesirable chemical changes (e.g., chemical degradation before the release of the active drug substance). The coating may be applied to the solid dosage form in a similar manner as described in Encyclopedia of Pharmaceutical Technology, Vol. 5 and 6, Swarbrick and Boyland, 2000.

[0369] For controlled release formulations, the active ingredient of the composition can be targeted for release in the small intestine. The formulation may contain an enteric coating so that the composition is resistant to the low pH environment found in the stomach, but sensitive to the higher pH environment of the small intestine. In order to control the release of the active ingredient in the small intestine, a multi-granular formulation can be used to prevent the simultaneous release of the active ingredient. The multi-granular composition can include a plurality of separate enteric coated cores, which include a hydrophobic phase containing a cysteamine precursor or its salt dispersed in a microcrystalline cellulose-based gel, and a hydrophilic phase containing a hydrogel. Microcrystalline cellulose (MCC) is used as a release-controlling polymer for a cysteamine precursor or its salt, preventing dose dumping and stabilizing a cysteamine precursor or its salt when the core dissolves or erodes in the intestine. Two or more multi-granular compositions that are different in terms of excipients in the core or coating layer can be combined in a pharmaceutical composition (e.g., capsule, powder, or liquid) to release the active ingredient (e.g., cysteamine precursor) over a longer period of time. Alternatively, the same effect can be achieved by using different concentrations of excipients in two or more batches of microparticles, and then combining the microparticles from the different batches in a selected ratio (eg, 1:1) to achieve a targeted drug release profile.

[0370] The composition may include a plurality of separate enteric coated cores containing from about 15% w / w to about 70% w / w cysteamine precursor or a salt thereof, from about 25% w / w to about 75% w / w microcrystalline cellulose, and from about 2% w / w to about 15% w / w methylcellulose, wherein the % w / w is the % w / w of the enteric coated cores.

[0371] In some cases, it may be advantageous to include a continuous protein subcoating layer covering each core and separating each core from its respective enteric coating, because the protein subcoating layer further enhances the stability of the cysteamine precursor or its salt. The continuous protein subcoating is suitable for preventing the cysteamine precursor or its salt from mixing with the enteric coating. Some preferred protein subcoatings have the following properties: the subcoating may include a gelatin film adhered to the core and / or the subcoating may contain a dried protein gel.

[0372] In certain embodiments, the enteric coated core releases no more than about 20% of the cysteamine precursor or salt thereof within about 2 hours of exposure to a 0.1 N HCl solution, and subsequently releases no less than about 85% of the cysteamine precursor or salt thereof within about 8 hours of exposure to a substantially neutral pH environment.

[0373] Preferably, the enteric coated core is spherical and does not exceed 3 mm in diameter.

[0374] In order to prevent adhesion of the composition administered alone in the stomach, the composition of the present invention can be coated with an antiadhesive. Antiadhesives can also be used to prevent microparticles from adhering to each other. For example, the composition can be coated with a thin outermost layer of microcrystalline cellulose powder. Alternatively, adhesion can be prevented by coating with a polymer that is insoluble in gastric juice but permeable and swellable. For example, it has been shown that 30% polyacrylate dispersions (e.g., Eudragit NE30D, Evonik Industries) can prevent floating microtablets from adhering in the stomach (see Rouge et al., European Journal of Pharmaceutics and Biopharmaceutics 43:165 (1997)).

[0375] Commercial forms of the listed excipients for enteric coatings include, for example, various brands of polymethacrylates (a chemically isomeric group of compounds including aminomethacrylate copolymers, ammoniummethacrylate copolymers, ethylacrylate copolymer dispersions, methylmethacrylate copolymer dispersions, methacrylic acid copolymers, and methacrylic acid copolymer dispersions) sold as product lines by companies including, but not limited to, Ashland, BASF Fine Chemicals (Kollicoat product line), ColorCon (Acryl-EZE product line), Eastman Chemical (Eastacryl product line), and Evonik Industries (Eudragit product line).

[0376] Formulations for ileal and colonic drug release

[0377] In some embodiments, ileum and / or colon targeted formulations can be used to deliver cysteamine precursors to the distal ileum and colon. (The term "colon targeted" is used herein to refer to both ileum targeted and colon targeted formulations; any composition that initially releases drug in the ileum may also release drug in the colon, and some drug released in the ileum may reach the colon). The drug delivery advantages of colon targeted compositions include long-term contact with the large intestinal epithelium and the presence of colonic bacteria that can be used for site-specific delivery.

[0378] From a pharmacokinetic point of view, colonic absorption of cysteamine is ideal because, due to its extremely short half-life, cysteamine must be continuously produced (and absorbed) in the gastrointestinal tract to maintain blood levels within the therapeutic range. The ingested pharmaceutical composition (if not a gastric retention composition) can reach the colon three to five hours after ingestion (on average, in most subjects), if ingested under fasting conditions, or six to ten hours after ingestion of food (on average, in most subjects). The only way to maintain blood cysteamine levels within the therapeutic range after the dosage form reaches the colon is to ensure that cysteamine is produced and absorbed in the colon. Some cysteamine precursors released in the small intestine can enter the colon intact and degrade into cysteamine in the colon. However, in order to provide stable cysteamine production in the colon, cysteamine precursors should be formulated to be released in the colon (or ileum), where they can be degraded into cysteamine and absorbed. The colon-targeted composition is not intended to be used alone as a therapy for cysteamine-sensitive diseases, but rather to supplement preparations for other areas of the gastrointestinal tract.

[0379] Two approaches to colon-targeted delivery have been extensively developed and are described below.

[0380] The first approach involves utilizing enzymes produced in the colon by enteric bacteria. Enteric bacteria can digest various polymers that are difficult for human enzymes to digest, which are present in saliva, gastric juice, intestinal juice, or pancreatic juice. A pharmaceutical composition containing such a polymer cannot be digested - and therefore the active ingredient mixed with the polymer cannot escape - until it encounters enzymes produced by enteric bacteria in the terminal ileum (where bacterial density begins to increase) or in the colon (where there may be 1,000,000,000,000 bacteria per milliliter of colonic content).

[0381] Cysteamine precursors and / or other active ingredients (e.g., enhancers of in vivo cysteamine production or absorption) can be mixed with polymers that delay drug release and can only be digested by enzymes produced by enteric bacteria (in the human gastrointestinal tract). Polymers for colon-targeted drug delivery based on selective degradation by enteric bacteria include polydextrose hydrogels (Hovgaard, L. and H. Brondsted, J. Controlled ReI. 36:159 (1995)), cross-linked chondroitin (Rubinstein et al., Pharm. Res. 9:276 (1992)), and hydrogels containing azo aromatic moieties (Brondsted, H. and J. Kopoecek, Pharm. Res. 9:1540 (1992); and Yeh et al., J. Controlled ReI. 36:109 (1995)).

[0382] The drug is covalently linked to the carrier to form a stable precursor in the stomach and small intestine, and releases the drug in the large intestine after enzymatic cleavage by the intestinal microflora; examples of these precursors include azo conjugates, cyclodextrin conjugates, glycoside conjugates, glucuronate conjugates, polydextrose conjugates, polypeptides, and polymer conjugates. The basic principle is that the covalent bond connecting the drug to the carrier must be indigestible by human enzymes but digestible by intestinal bacterial enzymes.

[0383] The second approach involves taking advantage of the high pH of the ileum relative to the rest of the gastrointestinal tract. In healthy subjects, the pH in the gastrointestinal tract increases from the duodenum (about 5.5 to 6.6 from proximal to distal duodenum) to the terminal ileum (about pH 7-7.5), then decreases in the cecum (about pH 6.4), and then increases again from the right to the left side of the colon, with a final value of about pH 7.

[0384] The composition can be coated with a pH-sensitive polymer that dissolves only at a neutral to slightly alkaline pH (e.g., above pH 6.5, above pH 6.8, or above pH 7). Underneath the pH-sensitive coating is a sustained release formulation from which the drug is slowly released by diffusion, erosion, or a combination. This approach is described in U.S. Pat. No. 5,900,252, which is incorporated herein by reference.

[0385] Colon targeting methods based on enterobacteria and pH can be combined. See, for example, Naeem et al., Colloids SurfB Biointerfaces S0927 (2014). The study describes coated nanoparticles formed using bacterially digestible polymers. Another technique for combining pH and bacterial enzyme digestion to deliver drug-containing liquid-filled capsules to the colon is described in U.S. Patent Publication No. 20070243253, which discloses a formulation using a polymer including starch, amylose, amylopectin, polyglucosamine, chondroitin sulfate, cyclodextrin, polydextrose, pullulan, carrageenan, scleroglucan, chitin, colloidal glucan and fructan, and a pH-sensitive coating that dissolves at a pH above about pH 5 or higher.

[0386] Other approaches to colon-targeted drug delivery employ: (i) time-release systems, in which once the multilayer formulation passes through the stomach, the outer layers begin to dissolve and, depending on the thickness and composition of the coating, the drug is released after a lag time of 3-5 hours, which is about the transit time of the small intestine; (ii) redox-sensitive polymers, in which a combination of azo polymers and disulfide polymers provide drug release in response to the low redox potential of the colon; (iii) bioadhesive polymers that selectively adhere to colonic mucus, slowing the transport of the dosage form to allow drug release; and / or (iv) osmotic controlled drug delivery, in which the drug is released through a semipermeable membrane due to osmotic pressure.

[0387] David R. Friend's book "Oral Colon-Specific Drug Delivery" (CRC Press, 1992) provides and summarizes earlier colon targeting methods (many of which are still useful), such as polydextrose-based delivery systems, glycoside / glycosidase-based delivery, azo bond prodrugs, hydroxypropyl methacrylamide copolymers, and other colon delivery matrices. Colon-targeted drug delivery has recently been reviewed by, for example, Bansal et al., Polim Med. 44: 109 (2014). Recent methods include the use of novel polymers that can be digested by enzymes produced only by intestinal bacteria, including natural polymers found in various plants, as well as microbeads, nanoparticles, and other microparticles.

[0388] Treatment

[0389] The present invention relates to novel compositions and methods suitable for treating cysteamine sensitive diseases and conditions. Treatment requires oral administration of a cysteamine precursor that can be converted to cysteamine in the gastrointestinal tract. An important class of cysteamine precursors are mixed disulfides, which provide two thiols after reduction in vivo. Both thiols can be converted to cysteamine in vivo, or only one. Cysteamine precursors in which both thiols can be converted to cysteamine are a preferred class of therapeutic agents for diseases including cystinosis, cystic fibrosis, malaria, and viral and bacterial infections. Non-limiting examples of such mixed disulfides include cysteamine-pantetheine and cysteamine-4-phosphopantetheine.

[0390] For some other diseases, a second thiol that is not convertible to cysteamine can be selected to supplement or enhance the therapeutic effect of cysteamine. In certain embodiments, the mixed disulfide cysteamine precursor for treating neurodegenerative and neuropsychiatric diseases includes a second thiol from the following group: N-acetylcysteine, cysteine ​​methyl ester, cysteine ​​ethyl ester, gamma-glutamylcysteine, gamma-glutamylcysteine ​​ethyl ester, homocysteine, cysteine ​​and dihydrolipoic acid.

[0391] Combinations of mixed disulfide cysteamine precursors provide further flexibility in addres...

Claims

1. Use of a pharmaceutical composition comprising N-acetylcysteine-pantetheine disulfide or cysteamine-N-acetylcysteine ​​disulfide, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a cysteamine-sensitive disorder in an individual, wherein the medicament comprises 50 to 150 milligrams per kilogram of body weight (mg / kg) of N-acetylcysteine-pantetheine disulfide or cysteamine-N-acetylcysteine ​​disulfide, or a pharmaceutically acceptable salt thereof, wherein the medicament is formulated to be administered once or more daily to a subject. The subject is administered orally, and wherein the cysteamine-sensitive disorder is selected from cystinosis; neurodegenerative diseases; neurodevelopmental diseases; neuropsychiatric diseases; mitochondrial diseases; fibrotic diseases of the kidney, liver or lung; parasitic infections; sickle cell anemia; cancer; ischemic diseases, including ischemic heart disease or stroke; chronic obstructive pulmonary disease (COPD); cystic fibrosis (CF); bacterial infections; viral infections; non-alcoholic steatohepatitis (NASH); alcoholic steatohepatitis; and non-alcoholic fatty liver disease (NAFLD).

2. The use according to claim 1, wherein the medicament is not formulated for administration within 2 hours of administration of a reducing agent to the individual.

3. The use according to claim 1, wherein the medicament is formulated for administration to the individual once, twice or three times daily.

4. The use according to claim 1, wherein the dosage is 2000-8000 mg of N-acetylcysteine-pantetheine disulfide or cysteamine-N-acetylcysteine ​​disulfide, or a pharmaceutically acceptable salt thereof.

5. The use according to claim 1, wherein the drug is formulated for immediate release.

6. The use according to claim 1, wherein the drug is (i) formulated as a powder and the dosage form is a sachet, or (ii) formulated as a tablet or capsule, or (iii) formulated as a liquid solution or suspension.

7. Use according to any one of claims 1 to 6, wherein the cysteamine-sensitive disorder is a neurodegenerative disease selected from Huntington's disease, neurodegenerative disorders with brain iron accumulation, Parkinson's disease and Alzheimer's disease.

8. The use according to any one of claims 1 to 6, wherein the cysteamine-sensitive disorder is a neurodevelopmental disease selected from Rett syndrome and other MECP2 mutation-associated disorders.

9. Use according to any one of claims 1 to 6, wherein the cysteamine-sensitive disorder is a mitochondrial disease selected from Leigh's syndrome, MELAS, MERFF and Friedreich's ataxia.

10. The use according to any one of claims 1 to 6, wherein the cysteamine-sensitive disorder is a fibrotic disease selected from Alport's disease, focal segmental glomerulosclerosis (FSGS), alcoholic steatohepatitis (ASH) and pulmonary fibrosis.

11. The use according to any one of claims 1 to 6, wherein the cysteamine-sensitive disorder is a bacterial infection or a viral infection.